As filed with the Securities and Exchange Commission on December 9, 2009

Registration No. 333-162700

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

AMENDMENT NO. 1

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

ALDAGEN, INC.

(Exact name of registrant as specified in its charter)

Delaware

2836

56-2185054

(State or other jurisdiction of

incorporation or organization)

(Primary Standard Industrial

Classification Code Number)

(I.R.S. Employer

Identification Number)

2810 Meridian Parkway, Suite 148

Durham, NC 27713

(919) 484-2571

(Address, including zip code, and telephone number, including

area code, of registrant’s principal executive offices)

W. Thomas Amick

Chief Executive Officer

2810 Meridian Parkway, Suite 148

Durham, NC 27713

(919) 484-2571

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Brent B. Siler, Esq.

Darren K. DeStefano, Esq.

Brian F. Leaf, Esq.

Cooley Godward Kronish LLP

One Freedom Square, Reston Town Center

11951 Freedom Drive

Reston, VA 20190-5656

(703) 456-8000

David E. Redlick, Esq.

Stuart R. Nayman, Esq.

Wilmer Cutler Pickering Hale and Dorr LLP

399 Park Avenue

New York, NY 10022

(212) 230-8800

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ¨

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 under the Securities Exchange Act of 1934. (Check one):


Large Accelerated Filer ¨		Accelerated Filer ¨		Non-accelerated Filer x		Smaller Reporting Company ¨

The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any state where the offer or sale is not permitted.

Subject to completion, dated December 9, 2009

Prospectus

shares

LOGO

Common stock

We are offering shares of our common stock. This is our initial public offering and no public market exists for our shares. We anticipate that the initial public offering price will be between $ and $ per share.

We have applied to have our common stock listed on The NASDAQ Global Market under the symbol “ALDH.”

Investing in the common stock involves risks. See “Risk Factors” beginning on page 9.

Price $ per share


	Price to public	Underwriting discounts and commissions	Proceeds to company before expenses

Per share	$	$	$
Total	$	$	$

We have granted the underwriters a 30-day option to purchase up to an additional shares of common stock to cover over-allotments, if any.

The Securities and Exchange Commission and state securities regulators have not approved or disapproved these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The underwriters expect to deliver the shares of common stock to purchasers on , 2009.


Cowen and Company		Wells Fargo Securities

Needham & Company, LLC

Boenning & Scattergood, Inc.

The date of this prospectus is , 2009.

TABLE OF CONTENTS


		Page
Prospectus Summary		1

Risk Factors		9

Special Note Regarding Forward-Looking Statements		34

Use of Proceeds		36

Dividend Policy		36

Capitalization		37

Dilution		39

Selected Financial Data		41

Management’s Discussion and Analysis of Financial Condition and Results of Operations		43

Business		60

Management		93

Executive Compensation		99

Certain Relationships and Related Party Transactions		114

Principal Stockholders		118

Description of Capital Stock		122

Shares Eligible for Future Sale		127

Underwriting		130

Legal Matters		136

Experts		136

Where You Can Find Additional Information		136

Index to Financial Statements		F-1

You should rely only on the information contained in this prospectus and any related free writing prospectus we may authorize to be delivered to you. We have not, and the underwriters have not, authorized any person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. Neither this prospectus nor any related free writing prospectus is an offer to sell, nor are they seeking an offer to buy, these securities in any state where the offer or solicitation is not permitted. The information contained in this prospectus is complete and accurate as of the date on the front cover of this prospectus, but information may have changed since that date.

PROSPECTUS SUMMARY

The items in the following summary are described in more detail later in this prospectus. This summary does not contain all of the information you should consider. Before investing in our common stock, you should read the entire prospectus carefully, including the “Risk Factors” beginning on page 9 and the financial statements and related notes beginning on page F-1. Unless the context indicates otherwise, as used in this prospectus, the terms “Aldagen,” “our company,” “we,” “us” and “our” refer to Aldagen, Inc.

Overview

We are a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. Our most advanced product candidates are ALD-101, ALD-301 and ALD-201. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving engraftment following umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. In addition, based on the results of our Phase 1/2 clinical trial of ALD-301, we intend to commence a pivotal Phase 3 clinical trial of ALD-301 in 2010 to evaluate its efficacy in treating critical limb ischemia. We have received a special protocol assessment, or SPA, concurrence letter from the FDA for the design of this trial, which means that the FDA has determined that the design and planned analyses of the trial sufficiently address the trial’s objectives and that the trial is adequately designed to provide the necessary data that, depending on the outcome, could support an application for marketing approval. We have also completed a Phase 1 clinical trial of ALD-201 for the treatment of ischemic heart failure. We are also developing additional product candidates for the improvement of engraftment following cord blood transplants used to treat leukemias, for the treatment of inherited metabolic diseases and for the post-acute treatment of ischemic stroke.

Our product candidates consist of specific populations of adult stem cells that we isolate using our proprietary technology. Stem cells are cells within the human body that have the potential to develop, or differentiate, into other types of cells with individual characteristics and specific functions. Stem cells found in blood, tissues or organs are referred to as adult stem cells. In preclinical studies, adult stem cells expressing high levels of an enzyme known as aldehyde dehydrogenase, or ALDH, exhibited a variety of activities that we believe may promote the regeneration of multiple types of cells and tissues. These studies were conducted at numerous research institutions and academic centers, including Washington University in St. Louis, Duke University and the Terry Fox Laboratory of the British Columbia Cancer Agency in Vancouver. We have developed a proprietary technology that allows us to isolate adult stem cells that express high levels of ALDH, which we refer to as ALDH-bright, or ALDH^br, cells. We believe that the ALDH^br stem cell populations we produce may have a variety of therapeutic uses.

Our Most Advanced Product Candidates

We are developing ALD-101 to improve engraftment following umbilical cord blood transplants. We are developing ALD-301 to treat critical limb ischemia and ALD-201 to treat ischemic heart failure.

ALD-101 to Improve Engraftment Following Cord Blood Transplants Used to Treat Pediatric Inherited Metabolic Diseases

In March 2008, we began a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving engraftment following cord blood transplants used to treat a group of progressive, degenerative and often fatal inherited metabolic diseases in children. These diseases develop because blood-forming stem cells in the patient’s bone marrow do not make a particular enzyme. In many cases, the only treatment available to these patients is a transplant of blood-forming stem cells that can make the enzyme. Such blood-forming stem cells are found in cord blood. ALD-101 is the population of ALDH^br stem cells we produce from a portion of a cord blood

unit using our proprietary technology. ALD-101 is infused into the patient shortly after the transplant of the remaining portion of the cord blood unit. In October 2008, we received orphan drug designation from the FDA for ALD-101 for improving engraftment times in patients with inherited metabolic diseases undergoing cord blood transplants.

During a cord blood transplant, a patient’s own blood-forming stem cells are intentionally destroyed, and the patient is infused with cord blood containing normal blood stem cells that make the missing enzyme. Eventually these stem cells repopulate the patient’s bone marrow with blood-forming cells and the number of circulating blood cells returns to normal. This process is called engraftment. The speed of engraftment is measured by how long it takes to restore normal levels of platelets, which are cell fragments that circulate in the blood and promote blood clotting, and neutrophils, which are white blood cells that protect against infections. During the period between transplant and engraftment, while blood cell levels are depressed, there is significant risk of life-threatening infections, bleeding and transfusion related reactions. We believe that a reduction in engraftment times could reduce these risks associated with cord blood transplants and decrease the cost of the related hospital stay and post-hospitalization costs.

In a 24-patient Phase 1 clinical trial, we observed a reduction in the time to platelet and neutrophil engraftment in patients receiving ALD-101 following their cord blood transplant, as compared to similar patients who had received a cord blood transplant without ALD-101 in an earlier independent clinical trial. Our pivotal Phase 3 clinical trial of ALD-101 is designed to further evaluate its ability to accelerate engraftment following cord blood transplants in pediatric patients with inherited metabolic diseases. We expect to complete enrollment of this trial in the first quarter of 2011 and to receive the efficacy results of the trial in the second quarter of 2011.

ALD-301 to Treat Critical Limb Ischemia

In 2008, we completed a 21-patient Phase 1/2 clinical trial of ALD-301 to assess its safety and potential efficacy as a treatment for advanced critical limb ischemia in patients with no treatment options for restoring blood supply to the affected limb, or revascularization. Critical limb ischemia is a condition characterized by significant impairment of blood flow to the legs and feet caused by a blockage of the arteries. Patients with severe cases of critical limb ischemia may experience persistent pain in their lower extremities and may also suffer from severe tissue damage in the affected area. There are no drugs currently approved by the United States Food and Drug Administration, or FDA, for the treatment of this condition. For advanced critical limb ischemia patients with no other therapeutic options for improving blood flow, amputation of the affected limb is often the only available clinical option.

ALD-301 is the population of ALDH^br stem cells we produce using our proprietary technology to sort a specified quantity of bone marrow collected from the patient receiving the therapy. ALD-301 is injected into the patient’s leg muscle. In our Phase 1/2 clinical trial, ALD-301 was well-tolerated, and we believe that the trial data provided initial evidence of improved blood flow and improved clinical status within the ALD-301 treatment group. For example, at 24 weeks following the injection, ten of the 11 patients in the ALD-301 treatment group were alive and had not required amputation of their affected limbs. Typically, up to 35% of critical limb ischemia patients with no revascularization options require an amputation within six months. In August 2009, we received an SPA concurrence letter from the FDA for the design of a pivotal Phase 3 clinical trial of ALD-301 for the treatment of critical limb ischemia. We plan to commence enrollment of the pivotal trial in 2010.

ALD-201 to Treat Ischemic Heart Failure

Investigators have completed a 20-patient Phase 1 clinical trial of ALD-201 to assess its safety and potential efficacy as a treatment for ischemic heart failure. Ischemic heart failure is caused by an obstruction of the arteries feeding blood to the heart tissue. The resulting damage to the heart muscle reduces the heart’s ability to pump

blood efficiently to the rest of the body. Once ischemic heart failure patients have exhausted all potential options for restoring blood supply to the heart, their only other option is a heart transplant, if they are eligible for one.

ALD-201 is the population of ALDH^br stem cells we produce using our proprietary technology to sort a specified quantity of bone marrow collected from the patient receiving the therapy. ALD-201 is injected directly into the patient’s heart muscle. This procedure is currently performed using a specialized catheter. In the recently completed Phase 1 clinical trial, ALD-201 was well-tolerated, and we believe that the trial data provided initial evidence of improved blood flow and improved clinical status within the ALD-201 treatment group.

Other Product Candidates

We are also developing ALD-151 to improve engraftment following cord blood transplants used to treat leukemia, ALD-601 to treat inherited metabolic diseases through in utero stem cell transplantation and ALD-401 for the post-acute treatment of ischemic stroke. We are currently enrolling patients in a Phase 1 clinical trial of ALD-151. Investigators have received clearance from the FDA to begin a Phase 1 clinical trial of ALD-601. ALD-401 is currently in preclinical development.

Our ALDH^br Technology

Our proprietary technology represents a novel approach to isolating adult stem cells for therapy. We believe that the ALDH^br stem cell populations produced using our technology have several potential advantages, including:

•

our ALDH^br cell populations may have a variety of therapeutic uses;

•

our ALDH^br cell populations include a diverse, or heterogeneous, mix of stem cell types, which we believe may promote tissue repair in a variety of ways;

•

our technology produces stem cell populations that are well characterized, meaning that each population produced has a high level of purity and a consistent set of physical and chemical characteristics; and

•

our technology allows for the rapid production of the ALDH^br cell populations and their administration to the patient without requiring time-consuming manipulation, such as cell culturing or expansion of the size of the cell populations.

Our Business Strategy

Our goal is to become a fully integrated biopharmaceutical company focused on the development, manufacturing and commercialization of regenerative cell therapies that address disease areas with significant unmet medical needs and commercial potential. To achieve this goal, we are pursuing the following strategies:

•

continue clinical development of our most advanced product candidates;

•

commercialize our cord blood transplant product candidates with an internal sales force;

•

selectively pursue strategic collaborations for the development and commercialization of some of our product candidates;

•

expand and enhance our manufacturing capabilities; and

•

develop new product candidates to target additional indications based on our technology.

Risks Related to our Business and to our Ability to Realize the Advantages of our ALDH^br Technology

Our business, and our ability to realize the advantages of our ALDH^br technology, are subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully

in the “Risk Factors” section of this prospectus immediately following this prospectus summary. For example, we expect to continue to incur substantial losses for the foreseeable future, and we may never achieve or maintain profitability. We may not receive necessary regulatory approvals for any of our product candidates and may not generate sufficient revenues to continue our business operations. The FDA has raised specific concerns about our use of a historical control as part of the pivotal Phase 3 clinical trial of ALD-101, and we may be required to conduct additional clinical trials at our expense in order to address the FDA’s concerns before we can obtain regulatory approval for this product candidate. We may need substantial additional funding and may be unable to raise capital when needed. Clinical trials of our product candidates may fail to demonstrate safety and efficacy to the FDA’s satisfaction or may not otherwise produce positive results. Our product candidates are based on novel stem cell technologies that are inherently risky, and they may not be understood or accepted by the marketplace. We have only limited experience manufacturing our product candidates and we may not be able to manufacture our product candidates efficiently or in quantities sufficient for commercial sale. Our patent position might not adequately protect our product candidates or any future products, which could allow others to compete against us more directly. We face substantial competition in our industry, which may result in others discovering, developing or commercializing products before or more successfully than we do.

Corporate Information

We were incorporated in Delaware in March 2000 under the name StemCo Biomedical, Inc. In November 2005, we changed our corporate name to Aldagen, Inc. Our principal executive office is located at 2810 Meridian Parkway, Suite 148, Durham, North Carolina 27713. Our telephone number is (919) 484-2571. Our website address is www.aldagen.com. Information contained in, or accessible through, our website does not constitute a part of, and is not incorporated into, this prospectus.

We use Aldagen^®, ALDEFLUOR^®, ALDECOUNT^® and the Aldagen logo as trademarks and service marks in the United States. All other trademarks or trade names referred to in this prospectus are the property of their respective owners.

The Offering

Common stock offered by us

Common stock to be outstanding after this offering

Over-allotment option

Use of proceeds

We estimate that the net proceeds from our sale of shares of common stock in this offering will be approximately $ million, or approximately $ million if the underwriters exercise their over-allotment option in full, based upon an assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We currently expect to use the net proceeds from this offering as follows:

•

approximately $ million to initiate and conduct a pivotal Phase 3 clinical trial of ALD-301;

•

approximately $ million to fund our development and commercialization activities for ALD-101; and

•

the balance for other general corporate purposes and working capital.

These estimates are subject to change. See “Use of Proceeds.”

Proposed NASDAQ Global Market symbol

ALDH

The number of shares of our common stock that will be outstanding immediately after this offering is based on 3,619,747 shares of common stock outstanding as of September 30, 2009, and excludes:

•

6,655,463 shares of our common stock issuable upon the exercise of stock options outstanding under our 2000 stock option plan as of September 30, 2009, at a weighted-average exercise price of $0.32 per share;

•

1,809,791 shares of our common stock issuable upon the exercise of outstanding warrants as of September 30, 2009, at a weighted-average exercise price of $0.77 per share; and

•

shares of our common stock to be reserved for future issuance under our equity incentive plans following this offering.

Except as otherwise indicated herein, all information in this prospectus, including the number of shares that will be outstanding after this offering, assumes or gives effect to:

•

a -for- reverse stock split of our common stock that we expect to complete prior to the closing of this offering;

•

the issuance of 26,285 shares of Series B convertible preferred stock upon the exercise of warrants that would otherwise expire immediately prior to the closing of this offering;

•

the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 59,288,071 shares of our common stock, which will occur automatically upon the closing of this offering;

•

the issuance of an aggregate of shares of our common stock upon the conversion of all outstanding principal and accrued interest on convertible promissory notes in the aggregate principal amount of $7.3 million, which we issued in October 2009 and refer to as the October convertible bridge notes, and which convert automatically upon the closing of this offering, and upon the net exercise of warrants we issued in connection with the October convertible bridge notes, which expire upon the closing of this offering, assuming the initial public offering price in this offering is $ per share, the midpoint of the range set forth on the cover page of this prospectus, and assuming that this offering is closed on , 2009; and

•

no exercise of the underwriters’ over-allotment option.

Summary Financial Data

The following tables summarize our financial data. We have derived the following summary of our statement of operations data for the years ended December 31, 2006, 2007 and 2008 from our audited financial statements appearing later in this prospectus. We have derived the following summary of our statement of operations data for the nine months ended September 30, 2009 and 2008 and for the period from March 3, 2000 (inception) through September 30, 2009, and balance sheet data as of September 30, 2009 from our unaudited financial statements appearing later in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the future and our results for any interim period are not necessarily indicative of the results that may be expected for a full fiscal year. You should read the summary of our financial data set forth below together with our financial statements and the related notes to those statements, as well as “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing later in this prospectus.

Note 3 to our financial statements explains the method we used to compute basic and diluted net loss per share allocable to common stockholders and pro forma basic and diluted net loss per share.

We have presented the summary balance sheet data as of September 30, 2009:

•

on an actual basis;

•

on a pro forma basis to give effect to:

•

our issuance of the October convertible bridge notes and our receipt of $7.3 million in net proceeds from that issuance;

•

our issuance of 26,285 shares of our Series B convertible preferred stock prior to the closing of this offering upon the exercise for cash of warrants that would otherwise expire upon the closing of this offering and our receipt of an aggregate of $26,285 in proceeds from those exercises;

•

the conversion of all then outstanding shares of our convertible preferred stock, including the Series B convertible preferred stock we expect to issue upon the exercise of warrants prior to the closing of this offering, into an aggregate of 59,288,071 shares of our common stock, which will occur automatically upon the closing of this offering;

•

the conversion of outstanding principal and accrued interest on the October convertible bridge notes and the issuance of an aggregate of shares of our common stock upon such conversion and upon the net exercise of warrants we issued in connection with the October convertible bridge notes, assuming the initial public offering price in this offering is $ per share, the midpoint of the range set forth on the cover page of this prospectus, and assuming that this offering is closed on , 2009; and

•

the reclassification of the preferred stock warrant liability to additional paid-in capital upon conversion of warrants to purchase convertible preferred stock into warrants to purchase common stock; and

•

on a pro forma as adjusted basis to give further effect to our sale of shares of common stock in this offering at an assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

Each $1.00 increase or decrease in the assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, would increase or decrease each of cash and cash equivalents, working capital, total assets and total stockholders’ equity on a pro forma as adjusted basis by approximately $ , assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. Each $1.00 increase in the assumed initial public offering price of $ per share would decrease the aggregate number of shares issued upon the conversion of the October convertible bridge notes and upon net exercise of the related warrants by shares, and each $1.00 decrease in the assumed initial public offering price per share would increase the aggregate number of shares by the same amount. Every additional month after , 2009 that lapses before the closing of this offering would

increase the aggregate number of shares issued upon the conversion of the October convertible bridge notes and upon net exercise of the related warrants by shares. The pro forma and pro forma as adjusted information presented in the summary balance sheet data is illustrative only and will change based on the actual initial public offering price, the date of closing and other terms of this offering determined at pricing.


	Year Ended December 31,									Nine Months Ended September 30,						Period from March 3, 2000 (inception) through September 30, 2009
	2006			2007			2008			2008			2009
	(In thousands, except share and per share data)
Statement of Operations Data:
Revenues	$	105		$	211		$	179		$	166		$	337		$	1,144
Operating expenses:
Cost of product sales		46			75			76			62			130			387
Research and development		3,239			4,842			6,142			4,510			4,254			31,955
Selling, general and administrative		1,058			1,761			4,052			3,665			1,831			14,055

Total operating expenses		4,343			6,678			10,270			8,237			6,215			46,397

Loss from operations		(4,238	)		(6,467	)		(10,091	)		(8,071	)		(5,878	)		(45,253	)
Total other expense		(1,538	)		(234	)		(97	)		(25	)		(834	)		(4,784	)
Income tax benefit		—			—			8			—			—			8
Cumulative effect of change in accounting principle		—			—			—			—			—			(1,470	)

Net loss		(5,776	)		(6,701	)		(10,180	)		(8,096	)		(6,712	)		(51,499	)
Accretion of redeemable convertible preferred stock		(1,223	)		(2,120	)		(3,588	)		(2,579	)		(2,994	)		(13,964	)
Gain on exchange of redeemable convertible preferred stock and beneficial conversion feature		14,518			—			—			—			—			14,390

Net income (loss) attributable to common stockholders		7,519			(8,821	)		(13,768	)		(10,675	)		(9,706	)	$	(51,073	)

Income allocable to preferred stockholders		(5,621	)		—			—			—			—

Net income (loss) allocable to common stockholders	$	1,898		$	(8,821	)	$	(13,768	)	$	(10,675	)	$	(9,706	)

Basic net income (loss) per share allocable to common stockholders	$	0.56		$	(2.53	)	$	(3.80	)	$	(2.95	)	$	(2.68	)

Diluted net income (loss) per share allocable to common stockholders	$	0.32		$	(2.53	)	$	(3.80	)	$	(2.95	)	$	(2.68	)

Shares used to compute basic net income (loss) per share allocable to common stockholders		3,411,000			3,487,396			3,619,747			3,619,747			3,619,747

Shares used to compute diluted net income (loss) per share allocable to common stockholders		5,918,171			3,487,396			3,619,747			3,619,747			3,619,747

Pro forma net loss per share—basic and diluted							$	(0.22	)				$	(0.15	)

Pro forma weighted-average shares outstanding—basic and diluted								62,877,255						62,877,255


	As of September 30, 2009
	Actual			Pro forma	Pro forma as adjusted
	(In thousands)
Balance Sheet Data:
Cash and cash equivalents	$	8,786		$	$
Working capital		5,264
Total assets		10,517
Preferred stock warrant liability		1,614
Notes payable, including current portion		2,693
Redeemable convertible preferred stock		53,198
Additional paid-in capital		—
Deficit accumulated during the development stage		(48,050	)
Total stockholders’ (deficit) equity		(48,046	)

RISK FACTORS

Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information included in this prospectus, before you decide to purchase shares of our common stock. If any of the following risks actually occurs, they may harm our business, prospects, financial condition and operating results. As a result, the trading price of our common stock could decline and you could lose part or all of your investment.

Risks Related To Our Business

We have incurred significant losses since our inception. We expect to continue to incur losses for the foreseeable future and may never achieve or maintain profitability.

We have incurred losses in each year since our inception and expect to continue to experience losses over the next several years. Our net loss was $6.7 million for the nine months ended September 30, 2009 and $10.2 million for the year ended December 31, 2008. As of September 30, 2009, we had a deficit accumulated during the development stage of $48.0 million. To date, we have financed our operations primarily through a combination of privately placed convertible preferred stock sales, convertible promissory notes, bank financing, capital lease agreements for the purchase of equipment and, during 2002 and 2003, research and development grants from governmental authorities. Our losses have resulted principally from costs incurred in our research and development programs and from our general and administrative expenses. We have devoted substantially all of our time, money and efforts to the research and development of our product candidates. We have not completed development of any of our product candidates. ALDEFLUOR and ALDECOUNT are our only commercially available products, and they are available only for research or diagnostic use. We have not received a significant amount of revenue from sales of ALDEFLUOR and ALDECOUNT, and we do not anticipate significant sales from these products in the future. Because of the numerous risks associated with drug development, we are unable to predict whether our development efforts will be successful.

We expect to continue to incur significant operating expenses and anticipate that our expenses and losses will increase in the foreseeable future as we seek to:

•

complete our pivotal Phase 3 clinical trial of ALD-101;

•

initiate our pivotal Phase 3 clinical trial of ALD-301;

•

initiate later-stage clinical trials of ALD-201;

•

complete our ongoing Phase 1 clinical trial of ALD-151 and initiate additional clinical trials if supported by the results of the ongoing trial;

•

initiate clinical programs for ALD-401 and ALD-601;

•

gain regulatory approvals for our product candidates that successfully complete clinical trials;

•

expand our manufacturing capabilities and capacity;

•

maintain, expand and protect our intellectual property portfolio;

•

establish a sales and marketing infrastructure to commercialize selected products for which we may obtain regulatory approval;

•

hire additional clinical, quality control, scientific and management personnel; and

•

add operational, financial, accounting, facilities engineering and information systems personnel, consistent with expanding our operations and our status as a public company.

To become and remain profitable, we must succeed in developing and eventually commercializing products with significant market potential. This will require us to be successful in a range of challenging activities, including successfully completing preclinical testing and clinical trials of our product candidates, obtaining

regulatory approval for our product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of many of these activities. We may never succeed in these activities and may never generate revenues that are significant or large enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the market price of our common stock and could impair our ability to raise capital, expand our business or continue our operations. A decline in the market price of our common stock could also cause you to lose all or a part of your investment.

We may need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts.

We are a development stage company and, with the exception of ALDEFLUOR and ALDECOUNT, have no commercial products. All of our product candidates are still being developed and will require significant additional clinical development and additional investment before they can be commercialized. We anticipate that our most advanced product candidates, ALD-101, ALD-301 and ALD-201, will not be commercially available for several years, if at all.

We expect that our research and development expenses will continue to increase in connection with our ongoing activities, particularly as we continue our pivotal Phase 3 clinical trial of ALD-101, commence our pivotal Phase 3 clinical trial of ALD-301, commence additional clinical trials of ALD-151 if the ongoing Phase 1 clinical trial of this product candidate yields promising results, and initiate clinical trials of ALD-401 and ALD-601. We anticipate that we will need to enter into a collaboration agreement with a third party to conduct and fund our planned later-stage clinical trials of ALD-201. If we are not able to enter into a collaboration agreement on terms that are acceptable to us, we will need to raise additional capital to fund these trials or delay or abandon the trials. In addition, subject to obtaining regulatory approval of any of our product candidates, we expect to incur significant commercialization expenses for product sales and marketing. We currently believe that our cash and cash equivalents, together with the net proceeds of this offering and interest income on these balances, will be sufficient to meet our anticipated cash requirements for at least the next 24 months. However, we cannot assure you that our plans will not change or that changed circumstances will not result in the depletion of our capital resources more rapidly than we currently anticipate. Accordingly, we may need substantial additional funding and may be unable to raise capital when needed or on attractive terms, which would force us to delay, reduce or eliminate our research and development programs or commercialization efforts.

Our future capital requirements will depend on many factors, including:

•

the scope, progress and results of our research and preclinical development programs;

•

the scope, progress, results, costs, timing and outcomes of the clinical trials of our product candidates, including larger, later-stage clinical trials for ALD-201 for which we intend to enter into a collaboration agreement with a third party to conduct and fund these trials;

•

the timing of and the costs involved in obtaining regulatory approvals for our product candidates, a process which could be particularly lengthy or complex given the FDA’s limited experience with marketing approval for therapeutics using adult stem cells;

•

the costs of operating, expanding and enhancing our manufacturing facilities and capabilities to support our clinical activities and, if our product candidates are approved, our commercialization activities;

•

the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and liabilities;

•

revenues received from sales of our product candidates, if approved by the FDA;

•

the costs of additional general and administrative personnel, including accounting and finance, legal and human resources employees, as a result of becoming a public company; and

•

the costs of developing our anticipated internal sales, marketing and distribution capabilities.

As a result of these factors, we may need or choose to seek additional funding following this offering. We would likely seek such funding through public or private financings or some combination of the two. We might also seek funding through collaborative arrangements if we determine them to be necessary or appropriate. Additional funding may not be available to us on acceptable terms, or at all. If we obtain capital through collaborative arrangements, these arrangements could require us to relinquish rights to our technology or product candidates and could result in our receiving only a portion of the revenues associated with the partnered product. If we raise capital through the sale of equity, or securities convertible into equity, it would result in dilution to our then existing stockholders. If we raise additional capital through the incurrence of indebtedness, we would likely become subject to covenants restricting our business activities, and holders of debt instruments would have rights and privileges senior to those of our equity investors. In addition, servicing the interest and principal repayment obligations under debt facilities could divert funds that would otherwise be available to support research and development, clinical or commercialization activities.

If we are unable to obtain adequate financing on a timely basis, we may be required to delay, reduce or eliminate one or more of our product development programs.

Our operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.

Our operations to date have primarily been limited to organizing and staffing our company, developing and securing our technology and undertaking or funding preclinical studies and clinical trials of our product candidates. We have not yet demonstrated our ability to successfully complete large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product to the satisfaction of the FDA, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, it may be difficult for you to make any predictions about our future success or viability.

If we are not able to retain and recruit qualified management and scientific personnel, we may fail in developing or commercializing our technologies and product candidates.

Our future success depends to a significant extent on the skills, experience and efforts of our scientific and management teams, including W. Thomas Amick, our chief executive officer, Edward Field, our president and chief operating officer, Dr. Andrew Balber, our chief scientific officer, David Carberry, our chief financial officer, and Dr. James Hinson, our chief medical officer. The loss of any or all of these individuals could harm our business and might significantly delay or prevent the achievement of research, development or business objectives. We have entered into an employment agreement with Mr. Amick with an undefined term, a consulting agreement with Dr. Hinson and offer letters with our other executives. The existence of an employment agreement, a consulting agreement or an offer letter does not, however, guarantee retention of these executives, and we may not be able to retain those individuals for the duration of or beyond the end of their respective terms. We do not maintain “key person” insurance on any of our management personnel.

Mr. Amick, our chief executive officer, was recently named as the interim chief executive officer of Discovery Laboratories, Inc., a public biotechnology company, to serve on a part-time basis. Mr. Amick has served as chairman of the board of directors of Discovery Laboratories since 2007. Mr. Amick has informed us that he does not believe that the new interim position will involve a significant increase in his time commitment or obligations beyond those in his existing role as chairman of the board. However, it is possible that his responsibilities at Discovery Laboratories might require that he spend less time managing our company.

Under our consulting agreement with Dr. Hinson, he is obligated to devote at least 30 hours per week to our company. While serving as our chief medical officer, Dr. Hinson may consult for other companies that do not compete with us. We cannot assure you that Dr. Hinson’s time commitment to us will be sufficient to perform the duties of our chief medical officer.

Recruiting and retaining qualified scientific and clinical personnel and, if our products are approved, sales and marketing personnel, will also be critical to our success. We may not be able to attract and retain these

personnel on acceptable terms, given the competition among numerous pharmaceutical and biotechnology companies for similarly skilled personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on outside advisors and key clinical investigators who assist us in formulating our research and development and clinical strategy. A loss of any of these advisors or investigators could compromise our ability to pursue our strategy.

Risks Related to the Development of Our Product Candidates

If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

Before obtaining regulatory approval for the sale of our product candidates, we must conduct, at our own expense, extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including:

•

regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;

•

clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs that we expect to be promising;

•

the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;

•

our third party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner or at all;

•

we might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;

•

regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;

•

the cost of clinical trials of our product candidates may be greater than we anticipate;

•

the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and

•

our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators to halt or terminate the trials.

For example, the FDA placed a clinical hold on the Phase 1 clinical trial of ALD-201 in March 2008 after a patient experienced a ventricular arrhythmia during the injection procedure. The arrhythmia stabilized and the procedure continued without further incident. Because this patient had a history of arrhythmia, the FDA expressed concerns that patients enrolled in this trial who are at risk for ventricular arrhythmia would be at higher risk for adverse events resulting from catheter manipulation or injections into their heart muscle. Even though the investigators concluded that the arrhythmia was unrelated to our product candidate, the FDA requested an expansion of the exclusion criteria for the trial. The clinical trial protocol for ALD-201 was modified to address the FDA’s concerns, and the FDA removed the clinical hold in April 2008. Two other serious adverse events occurred during the Phase 1 clinical trial of ALD-201. One patient suffered an acute myocardial infarction, or

heart attack, that did not occur near the time of the procedure and was determined by the investigator to be unrelated to treatment. Another patient in the ALD-201 clinical trial experienced a ventricular tachycardia, or accelerated heartbeat originating from the patient’s ventricle. The ventricular tachycardia occurred during, and was considered to be related to, the NOGA mapping procedure. The Phase 1 clinical trial of ALD-201 was completed as planned. However, there can be no assurance that similar cardiac events will not occur in future clinical trials of ALD-201, particularly in light of the poor heart function of patients with no further revascularization options who will be the target of these future clinical trials.

In our Phase 1/2 clinical trial of ALD-301, one patient experienced severe hypotension 10 days after treatment and another patient suffered an ischemic stroke nine days after treatment. In both cases, however, the clinical investigator determined the adverse events to be unrelated to treatment with ALD-301, and the trial proceeded and was completed as planned. We cannot assure you, however, that similar incidents will not occur in future clinical trials that could give rise to safety concerns relating to our product candidates.

If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, or if there are safety concerns, we may:

•

be delayed in obtaining marketing approval for our product candidates;

•

not be able to obtain marketing approval;

•

obtain approval for indications that are not as broad as intended;

•

have the product removed from the market after obtaining marketing approval;

•

be subject to additional post-marketing testing requirements; or

•

be subject to restrictions on how the product is distributed or used.

Our product development costs will also increase if we experience delays in testing or approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to commercialize our product candidates and may harm our business and results of operations.

If the FDA concludes that our use of a historical control as the comparator for the pivotal Phase 3 clinical trial of ALD-101 is not adequate, regulatory approval of ALD-101 could be prevented or delayed, which would negatively affect our business.

In March 2008, we began enrolling patients in a pivotal Phase 3 clinical trial of ALD-101 in pediatric patients receiving cord blood transplants for the treatment of inherited metabolic diseases. If this trial is successful, we intend to submit a biologics license application, or BLA, to the FDA seeking marketing approval for ALD-101.

We plan to compare the results of our pivotal Phase 3 clinical trial of ALD-101 to results from a historical control group of patients who received cord blood transplants for the same inherited metabolic diseases during the Cord Blood Transplantation, or COBLT, trial. Although the FDA has informed us that it will take into consideration the small number of patients with inherited metabolic diseases available for evaluation in a clinical trial, it has expressed major reservations regarding the use of a historical control for this trial and has recommended that we seriously consider conducting a clinical trial with a concurrent control arm or a case-match historical control trial rather than using the historical control of the COBLT trial. A case-match historical control trial would involve seeking specific cases in historical databases that match a variety of clinical characteristics similar to those of each patient being studied in our trial that could serve as the control comparator for our trial.

Moreover, the FDA has noted that the acceptability of the COBLT trial as a historical control in particular is unclear as a basis for approval. The FDA has stated that time to engraftment in the COBLT trial was longer than in other published studies and they asked us to comment on this discrepancy. This concern raises the possibility that the FDA may view a comparison of our results to the COBLT trial as overstating the potential efficacy of ALD-101. In our response to the FDA, we reviewed the published studies they cited and concluded that, in each case, either the study was not comparable to the COBLT trial or there were unrelated reasons for the shorter engraftment times. However, the FDA may ultimately disagree with our view.

If we complete our pivotal Phase 3 clinical trial of ALD-101 using this historical control, the FDA may conclude that this study design is not adequate to approve ALD-101 for commercialization and may require us to conduct additional clinical trials of ALD-101 using a concurrent control or case-match historical control group. This could significantly increase the cost and time required to complete our trials involving ALD-101 and would substantially delay, or could prevent, any potential marketing approval for ALD-101.

Our ability to secure FDA approval to commercialize ALD-101 depends upon cord blood banks applying for and receiving approval from the FDA to sell cord blood units to treat inherited metabolic diseases.

We are developing ALD-101 to be used as a supplement to cord blood transplants in patients with inherited metabolic diseases. The FDA has informed us that cord blood units must be licensed in order for us to obtain approval of ALD-101 as a supplement to cord blood transplants. In October 2009, the FDA issued final guidance to cord blood banks outlining the BLA requirements for cord blood intended to treat, among other conditions, Hurler syndrome, Krabbe disease and adrenoleukodystrophy, which are three of the inherited metabolic diseases included in our pivotal Phase 3 clinical trial of ALD-101. To our knowledge, no cord blood banks have filed a BLA under the FDA guidance, although we expect that banks will soon begin to seek such licenses. We cannot predict whether or when the FDA will approve any filed BLAs, or for which indications such BLAs may be approved. Absent licensure for the indications included in our pivotal Phase 3 clinical trial of ALD-101, we may not be able to commercialize ALD-101, which would delay and diminish our ability to generate product revenues.

Development of our product candidates is subject to significant uncertainty because each is derived from source material that is inherently variable.

The number of ALDH^br cells in bone marrow varies from patient to patient. Furthermore, although the minimum number of ALDH^br cells in a banked cord blood unit is controlled by screening standards, there are differences in the number of ALDH^br cells that can be produced from each cord blood unit. This inherent variability may adversely affect our ability to manufacture our products in two ways. First, each cord blood unit or bone marrow collection that we receive and process will yield a different number of ALDH^br cells. As a result, we may not be able to consistently produce a product with a sufficient number of ALDH^br cells for every patient. Accordingly, we may not be able to treat all patients effectively, or we will have to find other ways to increase the yield of ALDH^br cells. If we have to change our manufacturing methods, we may have to perform additional clinical trials. Second, variability in the source material for our product candidates, such as cord blood or bone marrow, may cause variability in the composition of other cells besides the ALDH^br cells in our product candidates. Such variability in composition or purity could adversely affect our ability to establish acceptable release specifications and the development and regulatory approval process for our product candidates may be delayed.

The results of preclinical studies may not correlate with the results of human clinical trials. In addition, early stage clinical trial results do not ensure success in later stage clinical trials, and interim trial results are not necessarily predictive of final trial results.

To date, we have not completed the development of any products through regulatory approval. While we and others have analyzed the potential of our product candidates in preclinical studies with animals, the potential efficacy of ALD-101, ALD-301 and ALD-201 have only been evaluated in Phase 1 or Phase 1/2 clinical trials.

The safety or potential efficacy of each of our other clinical-stage product candidates has not been evaluated in a completed Phase 1 clinical trial. The results of preclinical studies evaluating our product candidates in animals may not be predictive of results in clinical trials involving humans, and the outcomes of preclinical studies in animals and early clinical trials may not be predictive of the success of later clinical trials. The final safety and efficacy data from our pivotal Phase 3 clinical trials of ALD-101 and ALD-301 may be less favorable than the data observed in the Phase 1 clinical trial of ALD-101 and the Phase 1/2 clinical trial of ALD-301, which were based on smaller numbers of patients. In addition, the determination of statistical significance of our pivotal Phase 3 clinical trial of ALD-101 will require the application of more rigorous statistical procedures than we used to determine statistical significance in the Phase 1 clinical trial of ALD-101. Furthermore, interim results of a clinical trial, such as those contemplated by the protocol for our pivotal Phase 3 trial of ALD-301, do not necessarily predict final results. We cannot assure you that the clinical trials of any of our product candidates will ultimately be successful. New information regarding the safety and efficacy of our product candidates that may be less favorable than the data observed to date may arise from our continuing analysis of the data.

We may experience delays in enrolling patients in clinical trials of our product candidates, which could delay or prevent the receipt of necessary regulatory approvals.

We may not be able to initiate or continue clinical trials of our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or other regulatory authorities. We may also be unable to engage a sufficient number of clinical trial sites to conduct our trials. For example, we have experienced delays in enrollment in our pivotal Phase 3 clinical trial of ALD-101 as a result of the small number of patients with the inherited metabolic disorders included in this trial and the small number of centers that treat these patients. We have experienced similar delays in enrolling patients in our Phase 1 clinical trial for ALD-151. The challenge of enrolling patients will become more difficult if we are required by the FDA or a similar regulatory agency outside the United States to conduct a trial on a larger population than we currently anticipate. In that event, we might be required to seek patients to participate in our trials from Europe or other foreign jurisdictions, which could raise regulatory uncertainties and increase our clinical trial costs.

We and our investigators may also face challenges in convincing patients to participate in our clinical trials due to the novelty of our stem cell-based therapies. Some patients may have concerns regarding stem cells that may negatively affect their perception of our therapies and their decision to enroll in our trials. Moreover, because of the rare nature of the disorders targeted by ALD-601, there may be difficulty enrolling patients in the planned Phase 1 clinical trial of this product candidate. Furthermore, patients suffering from diseases within our target indications, particularly for the trials of our cardiovascular product candidates, may enroll in competing clinical trials, which could negatively affect our ability to complete enrollment of our trials. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, and our inability to enroll a sufficient number of patients for any of our current or future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.

We are subject to numerous risks associated with seeking regulatory approval of ALD-201 pursuant to a protocol that requires the use of a medical device that has not received, and may never receive, regulatory approval in the United States. The catheter system we intend to use in connection with the development of ALD-201 is owned by an unaffiliated third party.

Investigators recently completed a clinical trial of ALD-201 under a protocol that required participating clinical investigators to deliver ALD-201 or a placebo, as the case may be, to enrolled patients using a specialized NOGA^®XP Cardiac Navigation System, which we refer to as the NOGA system, and a MyoStar™ injection catheter. The NOGA system and the MyoStar catheter have been developed by Biosense Webster Inc., a subsidiary of Johnson & Johnson. The NOGA system, which is a medical device cleared by the FDA under the 510(k) premarket notification process, is commercially available in the United States. The MyoStar catheter is currently cleared for use only in the context of clinical trials in the United States being conducted under an investigational new drug application, or IND. The commercial deployment of ALD-201 is likely to be dependent

upon the MyoStar catheter or another catheter system securing regulatory approval for use with ALD-201. Notwithstanding our investment of considerable resources in the development and testing of ALD-201 using the MyoStar catheter, the MyoStar catheter may never receive the regulatory approvals that would allow for its commercial use in combination with ALD-201 in the United States.

We are not affiliated with Biosense Webster Inc. or any other Johnson & Johnson company. We currently have no right to control the development, clinical testing or refinement of the MyoStar catheter. Biosense Webster currently has the right to make decisions without consulting with us or considering our views. These decisions could directly or indirectly compromise our ability to secure regulatory approval of ALD-201. These decisions include:

•

the terms and conditions under which the NOGA system and the MyoStar catheter will be made available for use to trial investigators, or at all;

•

the terms and conditions under which the diagnostic consoles that are part of the NOGA system will be made available for use to trial investigators, if at all;

•

the modification of the MyoStar catheter or any of its components and its protocol for use as a result of information obtained during trials;

•

the license or sale of intellectual property relating to the NOGA system or the MyoStar catheter to a third party, potentially including our competitors;

•

the use of the NOGA system or the MyoStar catheter or any of their components, in conjunction with clinical therapies other than ours;

•

the suspension or abandonment of other clinical trials involving the MyoStar catheter; and

•

the suspension or abandonment of efforts to obtain FDA approval or clearance.

The unavailability of the NOGA system or the MyoStar catheter, for any reason, would have a material adverse effect on our ALD-201 product development and commercialization efforts as we would be unable to recover the time and money expended prior to such determination of unavailability. Although there are other available catheter systems in the marketplace, we have not evaluated their costs or safety and effectiveness, or whether ALD-201 would be compatible with such catheter systems. Moreover, such catheters may never receive regulatory approvals that would allow for their commercial use in a combination product with ALD-201.

We rely on research institutions and treatment centers to conduct and oversee our clinical trials and, in some cases, to maintain regulatory files for our product candidates. If we are not able to secure and maintain agreements with suitable research institutions or treatment centers on acceptable terms to conduct or oversee our clinical trials, or if these institutions do not perform as required, we may not be able to obtain regulatory approval for, or commercialize, our product candidates.

The IND for the Phase 1 clinical trial of ALD-201 is held by a third-party research institution, the Texas Heart Institute, rather than by us. The IND under which the Phase 1 clinical trial of ALD-101 was conducted and the Phase 1 clinical trial of ALD-151 is proceeding is held by Duke University, or Duke, as is the IND for the planned Phase 1 clinical trial of ALD-601. As a result, we may have limited or no control over interactions with the FDA regarding trials conducted under these INDs. In the clinical trials for which a research institution holds the IND, we rely on the institution to conduct these clinical trials and correspond with the FDA. We expect, however, that the more advanced clinical trials, if any, of these product candidates would be conducted under an IND that would be held by us. For our pivotal Phase 3 clinical trial of ALD-101 and our planned pivotal Phase 3 clinical trial of ALD-301, we hold the IND and rely on additional entities, such as treatment centers or medical practices, to conduct our clinical trials. For example, our Phase 3 clinical trial of ALD-101 is being conducted at three sites across the United States, and we anticipate expanding this trial to as many as 10 sites. We also expect to enroll patients in our pivotal Phase 3 clinical trial of ALD-301 at numerous trial sites across the United States.

Our reliance upon research institutions, hospitals and clinics provides us with less control over the timing and cost of clinical trials and the ability to recruit subjects. If we are unable to enter into and maintain agreements with these entities on acceptable terms, or if any engagement is terminated, we may be unable to enroll patients on a timely basis or otherwise conduct our clinical trials in the manner we anticipate.

In addition, there is no guarantee that these entities or any other third parties upon which we rely for administration and conduct of clinical trials of our product candidates will devote adequate time and resources to the clinical trials or perform as required by contract or in accordance with regulatory requirements. If these third parties fail to meet expected deadlines, fail to adhere to the clinical protocols or fail to act in accordance with regulatory requirements, or if they otherwise perform in a substandard manner, clinical trials of our product candidates may be extended, delayed or terminated, and as a result we may not be able to commercialize our product candidates.

If the potential of our product candidates to address the indications we are pursuing is not realized and we are unable to demonstrate in clinical trials that our product candidates are safe and effective for those indications, the value of our technology and our development programs could be significantly reduced.

We are currently exploring the potential of our product candidates to address their targeted indications. We have not proven in clinical trials that our product candidates will be safe and effective for the indications for which we intend to seek approval. Our product candidates are susceptible to various risks, including undesirable and unintended side effects, inadequate therapeutic efficacy or other characteristics that may prevent or limit their marketing approval or commercial use. We have not treated a sufficient number of patients to allow us to evaluate the most frequent or most serious adverse events that could occur with our product candidates. Any undesirable side effects that might be caused by our product candidates could interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications. We could also be required to change the manner in which a product candidate must be administered, which could require us to conduct additional clinical trials. If the potential of our product candidates is not realized, whether as a result of unintended consequences or otherwise, the value of our technology and our development programs could be significantly reduced.

Risks Related to the Commercialization of Our Product Candidates

Our product candidates are based on novel stem cell technologies that are inherently risky and may not be understood or accepted by the marketplace.

We are subject to the risks of failure inherent in the development and commercialization of therapeutic products based on new technologies. The novel nature of our therapeutics based on adult stem cells creates significant challenges with regards to product development and optimization, manufacturing, government regulation, third-party reimbursement and market acceptance. For example, the FDA has relatively limited experience approving and regulating therapies based on adult stem cells.

Even if we successfully develop and obtain regulatory approval for our product candidates, the market may not understand or accept them, which could adversely affect our future sales. We are developing product candidates that are new treatments. Our future success depends, in part, upon a small number of practitioners who serve as key industry thought leaders. If these parties have or develop a negative perception of our company or our product candidates, our potential for commercial success could be harmed.

The degree of market acceptance of any of our product candidates will depend on a number of factors, including:

•

the clinical safety and effectiveness of our product candidates, the availability of alternative treatments and the perceived advantages of our product candidates over alternative treatments;

•

the relative convenience and ease of administration of our product candidates;

•

our ability to separate our product candidates, which are based on adult stem cells, from the ethical and political controversies associated with stem cell product candidates derived from human embryonic or fetal tissue;

•

ethical concerns that may arise regarding our commercial use of donated stem cells or donated human tissue of any kind, including adult stem cells, adult bone marrow and other adult tissues, in the manufacture of our product candidates;

•

the frequency and severity of adverse events or other undesirable side effects involving our product candidates or the products or product candidates of others that are stem cell-based; and

•

the cost of our products, the reimbursement policies of government and third-party payors and our ability to obtain sufficient third-party coverage or reimbursement.

We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.

Our industry is subject to rapid and intense technological change. We face, and will continue to face, intense competition from pharmaceutical, biopharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies engaged in drug discovery activities or funding, both in the United States and abroad. Some of these competitors are pursuing the development of drugs and other therapies that target the same diseases and conditions that we are targeting with our product candidates.

There are no therapies currently approved by the FDA to improve cord blood transplants, although other therapies are being developed to treat the underlying diseases that are treated with cord blood transplants. These competing therapies could be a competitive threat to our cord blood transplantation product candidates to the extent that alternative therapies diminish the need for cord blood transplants to treat these diseases. For example, some inherited metabolic diseases, including Hurler syndrome, are currently treated with approved and marketed enzyme replacement therapies. Additionally, a few inherited metabolic diseases can be treated with a transplant of primary cell lines that manufacture the deficient enzyme.

For our cardiovascular product candidates, we generally target patients without other revascularization options. Therefore, we do not believe that we will compete directly with pharmaceutical therapies being developed to treat less severe stages of our target indications. However, to the extent that therapies are developed that reverse the progression of the ischemic damage or improve blood flow, it could have the effect of reducing demand for our ALD-301 and ALD-201 product candidates. In addition, because our cardiovascular product candidates require the removal of bone marrow from the patient, potential competing cardiovascular products that do not require this invasive procedure may have a competitive advantage against our cardiovascular products. New pharmaceutical agents or devices that improve the repair of cardiac injury after a heart attack, with the result that fewer patients develop ischemic heart failure, would also represent a competitive threat for ALD-201. Furthermore, cell-based therapies, such as skeletal myoblasts and bone marrow-derived stem cell therapies, are being pursued by companies such as Aastrom Biosciences, Inc., Pluristem Therapeutics, Inc. and Bioheart, Inc. Some other companies, such as Harvest Technologies, Inc., Cytori Therapeutics, Inc. and Baxter International, Inc., are developing devices to facilitate the production of therapeutic cell populations by clinicians for the treatment of our target indications.

We may also face competition in the future from other companies that are researching and developing stem cell therapies. We are aware of many companies working in this area. Many of the companies competing against us have financial and other resources substantially greater than we do. In addition, many of our competitors have significantly greater experience in testing pharmaceutical and other therapeutic products, obtaining FDA and other regulatory approvals of products, and marketing and selling those products. If we obtain necessary regulatory approval and commence significant commercial sales of our products, we will also be competing with respect to manufacturing efficiency and marketing capabilities, areas in which we have limited or no

commercial-scale experience. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated by our competitors. Competition may increase further as a result of advances made in the commercial applicability of our technologies and greater availability of capital for investment in these fields.

As a result, our competitors may:

•

develop products that are safer or more effective than ours;

•

obtain FDA and other regulatory approvals or reach the market with their products more rapidly than we can, reducing the potential sales of our product candidates;

•

develop new or improved technologies and scientific advances;

•

obtain patent protection that could impact our ability to market our product candidates;

•

devote greater resources to market or sell their products;

•

initiate or withstand substantial price competition more successfully than we can;

•

recruit skilled scientific workers from the limited pool of available talent; and

•

take advantage of acquisition or other opportunities more readily than we can.

The successful commercialization of our product candidates will depend on obtaining reimbursement from third-party payors.

If we successfully develop and obtain the necessary regulatory approvals, we intend to sell our products initially in the United States. In the United States, the market for any pharmaceutical or biologic product is affected by the availability of reimbursement from third-party payors, such as government health administration authorities, private health insurers, health maintenance organizations and pharmacy benefit management companies. We anticipate that our products, if approved, will be expensive. If we cannot demonstrate a favorable cost-benefit relationship, we may have difficulty obtaining adequate reimbursement for our products from these payors. Third-party payors may also deny coverage or offer inadequate levels of reimbursement for any of our potential products if they determine that the product is experimental, unnecessary or inappropriate.

Should we seek to expand our commercialization internationally, we would be subject to the regulations of the European Union and other countries, where the pricing of prescription pharmaceutical products and services and the level of government reimbursement may be subject to governmental control. In these countries, pricing negotiations with governmental authorities can take six to 12 months or longer after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct one or more clinical trials that compares the cost effectiveness of our product candidates or products to other available therapies. Conducting one or more of these clinical trials would be expensive and result in delays in commercialization of our products.

Managing and reducing healthcare costs has become a major priority of federal and state governments in the United States. As a result of healthcare reform efforts, we might become subject to future regulations or other cost-control initiatives that materially restrict the price we can receive for our products. Third-party payors may also limit access and reimbursement for newly approved healthcare products generally or limit the indications for which they will reimburse patients who use any products that we may develop. Cost control initiatives could decrease the price for products that we may develop, which would result in lower product revenues to us.

We have only limited experience manufacturing our product candidates. We may not be able to manufacture our product candidates in compliance with evolving regulatory standards or in quantities sufficient for commercial sale.

Components of therapeutic products approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with current good manufacturing practices, or cGMP, as required by the FDA.

Manufacturers of cell-based product candidates such as ours also must comply with the FDA’s current good tissue practices, or cGTP. Manufacture of live cellular-based products is complex and subjects us to significant regulatory burdens that may change over time. We may encounter difficulties in the production of our product candidates due to our limited manufacturing capabilities. We have only limited manufacturing experience with our product candidates, and we currently do not have sufficient manufacturing capacity to support commercialization of any of our cardiovascular product candidates. These difficulties could reduce sales of our products, if they are approved for marketing, increase our costs or cause production delays, any of which could damage our reputation and hurt our profitability.

If we successfully obtain marketing approval for ALD-301 and ALD-201, which potentially have large addressable patient populations, we may not be able to efficiently produce sufficient quantities of these products to meet potential commercial demand. We expect that we would need to significantly expand our manufacturing capabilities to meet potential demand for these products. Such expansion would require additional regulatory approvals. We may also encounter difficulties in the commercial-scale manufacture of all of our product candidates.

We are currently developing new processes and are in discussions with other companies to develop new instruments to improve our manufacturing efficiency. Improving the speed and efficiency of our manufacturing process and the cell sorters and other instruments we use is a key element of our business plan. However, we cannot assure you that we will be able to develop process enhancements on a timely basis, on commercially reasonable terms, or at all. If we fail to develop these improvements, we could face significantly higher capital expenditures than we anticipate, increased facility and personnel costs and other increased operating expenses. We may need to demonstrate that our product candidates manufactured using any new processes or instruments are comparable to our product candidates used in clinical trials. Depending on the type and degree of differences, we may be required to conduct additional studies or clinical trials to demonstrate comparability.

In addition, some changes in our manufacturing processes or procedures, including a change in the location where a product candidate is manufactured, generally require prior FDA or foreign regulatory authority review and approval for determining our compliance with cGMP and cGTP. We may need to conduct additional preclinical studies and clinical trials to support approval of any such changes. Furthermore, this review process could be costly and time-consuming and could delay or prevent the commercialization of our product candidates.

If our sole clinical manufacturing facility is damaged or destroyed, our business and prospects would be negatively affected.

We have a manufacturing facility located at our corporate headquarters in Durham, North Carolina at which we produce product candidates for our clinical trials and we intend to produce ALD-101 if it is approved for marketing. If this facility or the equipment in it is significantly damaged or destroyed, we may not be able to quickly or inexpensively replace our manufacturing capacity or replace it at all. In the event of a temporary or protracted loss of this facility or equipment, we might not be able to transfer manufacturing to a third party. Even if we could transfer manufacturing to a third party, the shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with the necessary regulatory requirements and we would need FDA approval before selling any products manufactured at that facility. Such an event could delay our clinical trials or, if our product candidates are approved by the FDA, reduce our product sales.

Currently, we maintain insurance coverage totaling $3.8 million against damage to our property and equipment and approximately an additional $700,000 to cover business interruption and research and development restoration expenses. If we have underestimated our insurance needs with respect to an interruption in our clinical manufacturing of our product candidates, we may not be able to cover our losses.

We may use third-party collaborators to help us develop or commercialize our product candidates, and our ability to commercialize such candidates may be impaired or delayed if collaborations are unsuccessful.

We may in the future selectively pursue strategic collaborations for the development and commercialization of our cardiovascular product candidates and for the international development and commercialization of all of

our product candidates. For example, we anticipate that we will need to enter into a collaboration agreement with a third party to conduct and fund our planned larger, later-stage clinical trials of ALD-201. In addition, we may not be able to commercialize ALD-201 successfully without entering into an arrangement with a third party to provide an approved method of administration. ALD-201 is currently administered by injection directly into the appropriate areas of a patient’s heart muscle using a specialized catheter, but neither this method of administration nor the catheter has been approved or cleared by the FDA or any other regulatory authority. There can be no assurance that we will be able to identify suitable collaborators or negotiate collaboration agreements on terms that are acceptable to us or at all. In any future third-party collaboration, we would be dependent upon the success of the collaborators in performing their responsibilities and their continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. We cannot control the amount and timing of our collaborators’ resources that will be devoted to performing their responsibilities under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development and commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. Disputes with our collaborators could also result in product development delays, decreased revenues and litigation expenses.

If we market any approved products through a direct sales force, we would need to either hire a sales force with expertise in biologic products or contract with a third party to provide a sales force to meet our needs.

We do not currently have a sales or marketing organization, and we have no experience in the sale, marketing or distribution of biologic products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties. Our corporate strategy for our cord blood transplantation products includes a plan to develop an internal sales organization to promote these products, if approved.

We may be unable to establish marketing, sales and distribution capabilities necessary to commercialize and gain market acceptance for any of our product candidates and to be competitive. In addition, co-promotion or other marketing arrangements with third parties to commercialize product candidates could significantly limit the revenues we derive from these product candidates, and these third parties may fail to commercialize our product candidates successfully.

Ethical and other concerns surrounding the use of stem cell-based therapy or donated human tissue may negatively affect public perception of us or our product candidates, thereby reducing potential demand for our products.

The commercial success of our product candidates, which are based on adult stem cells, will depend in part on general public acceptance of the use of stem cell-based therapy and donated human tissue for the prevention or treatment of human diseases. The use of embryonic stem cells and fetal tissue for research and stem cell therapy has been the subject of substantial national and international debate regarding related ethical, legal and social issues. In the United States, for example, federal government funding of embryonic stem cell research has been limited to specifically identified cell lines and is not otherwise available. We do not use embryonic stem cells or fetal tissue in any of our product candidates, but the public may not be able to, or may fail to, differentiate our use of adult stem cells from the use by others of embryonic stem cells or fetal tissue. This could result in a negative perception of our company or our product candidates.

We derive ALD-101, ALD-151 and ALD-601 from cord blood units that we receive from public cord blood banks. These banks obtain the cord blood units from volunteer donors. Cord blood donors do not receive payment or other benefit from use of their cells. Some people have raised ethical concerns about the use of donated human tissue in a commercial setting, which could also negatively affect the perception of our product candidates and inhibit their commercialization in a successful manner.

ALD-101, ALD-151 and ALD-601 are derived from human cord blood sources and therefore have the potential for disease transmission.

Our use of donated human cord blood creates the potential for transmission of a number of communicable infectious diseases, including HIV, viral hepatitis, syphilis or Creutzfeldt-Jakob disease, which is the human form of mad cow disease, as well as other viruses and fungal or bacterial pathogens. We are required to comply with federal and state regulations intended to prevent the transmission of communicable disease, and public cord blood banks that supply our source material for ALD-101, ALD-151 and ALD-601 are required to comply with such regulations in connection with their collection, storage and supply to us. Despite taking what we believe are appropriate precautionary measures:

•

we or our suppliers may fail to comply with such regulations;

•

even with compliance, our product candidates might nevertheless be associated by the public with transmission of disease;

•

infectious agents that are currently undetectable, or that may cause diseases that are presently unknown, could also be found in human cord blood; and

•

a patient that contracts an infectious disease might assert that the use of our product resulted in disease transmission, even if the patient became infected through another source.

Any actual or alleged transmission of communicable disease could result in patient claims, litigation, distraction of management’s attention and potentially increased expenses. Further, any failure in screening, whether by us or other manufacturers of similar products, could adversely affect our reputation, the support we receive from the medical community and the overall demand for our products, if approved for marketing. As a result, such actions or claims, whether or not directed at us, could harm our reputation with our customers and our ability to market our products, if approved.

The use of our product candidates in human subjects may expose us to product liability claims, and we may not be able to obtain adequate insurance for these claims.

We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. None of our product candidates has been widely used over an extended period of time, and therefore our safety data are limited. We derive the raw materials for manufacturing of our product candidates from human cell sources, and therefore the manufacturing process and handling requirements are extensive, which increases the risk of quality failures and subsequent product liability claims.

We currently have product liability insurance with an aggregate limit of $3.0 million for our product candidates that are in clinical testing. We will need to increase our insurance coverage when we begin commercializing our product candidates, if ever. We may not be able to obtain or maintain product liability insurance on acceptable terms with adequate coverage or at all. If we are unable to obtain and maintain adequate insurance, or if claims against us substantially exceed our coverage, then our financial position could be significantly impaired.

Whether or not we are ultimately successful in any product liability litigation, such litigation could consume substantial amounts of our financial and managerial resources and could result in:

•

decreased demand for any products or product candidates we may develop;

•

significant awards against us;

•

substantial litigation costs;

•

injury to our reputation; and

•

withdrawal of clinical trial participants.

Risks Related to Our Intellectual Property

If our patent position does not adequately protect our product candidates or any future products, others could compete against us more directly.

Our success depends, in large part, on our ability to obtain and maintain intellectual property protection for our product candidates. The patent position of biotechnology companies is generally highly uncertain, involves complex legal and factual questions and has been the subject of much litigation.

The claims of the issued U.S. patents that are licensed to us, and the claims of any patents which may issue in the future and be owned by or licensed to us, may not confer on us significant commercial protection against competing products. Third parties may challenge, narrow, invalidate or circumvent any patents we own or license currently or in the future. Also, our pending patent applications may not issue, and we may not receive any additional patents. Our patents might not contain claims that are sufficiently broad to prevent others from utilizing our technologies. Consequently, our competitors may independently develop competing products that do not infringe our patents or other intellectual property. For instance, the two issued U.S. patents relating to our product candidates are limited to a particular chemistry in the manufacturing process. To the extent a competitor can develop similar products using a different chemistry, these patents will not prevent others from directly competing with us. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantages of the patent. For instance, one of our patents relating to our technology will expire in 2019. To the extent our product candidates based on that technology are not commercialized significantly ahead of this date, or to the extent we have no other patent protection on such product candidates, those product candidates would not be protected by patents beyond 2019. The background technologies used in the development of our product candidates are known in the scientific community, and it is possible to duplicate the methods we use to create our product candidates.

Similar considerations apply in any other country where we are prosecuting patents, have been issued patents, or have licensed patents or patent applications relating to our technology. The laws of foreign countries may not protect our intellectual property rights to the same extent as do laws of the United States.

If we are unable to protect the confidentiality of our proprietary information and know-how, our competitive position would be impaired.

A significant amount of our technology, especially regarding manufacturing processes, is unpatented and is maintained by us as trade secrets. In an effort to protect these trade secrets, we require our employees, consultants, collaborators and advisors to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements, however, may not provide us with adequate protection against improper use or disclosure of confidential information, and these agreements may be breached. Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. A breach of confidentiality could affect our competitive position. In addition, in some situations, these agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, collaborators or advisors have previous employment or consulting relationships. Also, others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets.

If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.

We currently license several patents and patent applications covering our ALDH^br technology from Duke and Johns Hopkins University, or JHU. Our existing licenses provide us rights to third party intellectual property that is necessary for our business, and we may seek to license additional intellectual property from third parties in the future if we believe it to be necessary or beneficial to our business.

Our existing licenses impose, and we expect that future licenses would impose, numerous obligations on us. For example, under each of our license agreements with Duke and JHU, we are required to pay minimum annual royalty amounts. In the case of the agreement with Duke, this minimum annual royalty amount is $5,000, subject to increase to $25,000 upon the achievement of specified milestones. In the case of the agreement with JHU, this minimum annual royalty amount is $10,000, and we are also obligated to pay additional amounts to JHU upon the achievement of specified development milestones. Under each agreement, we are also required to reimburse patent costs incurred by the licensor, and we may be obligated to pay additional running royalties, at specified rates, based on net sales of our product candidates that incorporate the licensed technology. We are also obligated under these agreements to pay a percentage of any future sublicensing revenues that we may receive. Future license agreements may also include payment obligations such as milestone payments or minimum expenditures for research and development. In addition to our payment obligations under our current licenses, we are required to comply with reporting, insurance and indemnification requirements under the agreements. We expect that any future licenses would contain similar requirements.

If we fail to comply with these obligations or otherwise breach a license agreement, the licensor may have the right to terminate the license in whole, terminate the exclusive nature of the license or bring a claim against us for damages. Any such termination or claim could prevent or impede our ability to market any product that is covered by the licensed patents. Even if we contest any such termination or claim and are ultimately successful, our financial results and stock price could suffer. In addition, upon any termination of a license agreement, we may be required to grant to the licensor a license to any related intellectual property that we developed.

If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed.

Our research, development and commercialization activities, including any product candidates resulting from these activities, may infringe or be claimed to infringe patents owned by third parties and to which we do not hold licenses or other rights. There may be applications that have been filed but not published that, when issued, could be asserted against us. These third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit.

For example, we are aware of patents owned by third parties that are directed toward sorting stem cells with different cell surface markers and the use thereof. Our preliminary research suggests that our product candidates, upon commercialization, would not infringe a valid claim of these patents. However, our review of these patents is still at an early stage, and our views are subject to change.

As a result of patent infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also affect our potential collaborators to the extent we have any collaborations then in place, which would also affect the success of the collaboration and therefore us.

There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference proceedings declared by the U. S. Patent and Trademark Office and opposition proceedings in the European Patent Office, regarding intellectual property rights with respect to our product candidates and technology. The cost to us of any patent

litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

We may become involved in lawsuits to protect or enforce our patents or the patents of our potential collaborators or licensors, which could be expensive and time consuming.

Competitors may infringe our patents or the patents of our potential collaborators or licensors. As a result, we may be required to file infringement claims to counter infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. We are aware of several companies that are employing stem cell sorting technology in their research and product development efforts. If these companies commercialize these products, there is no assurance that we would have a basis for initiating patent infringement proceedings or that if initiated we would prevail in such proceedings.

Interference proceedings brought by the U.S. Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications or those of our potential collaborators or licensors. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction to our management. We may not be able, alone or with our potential collaborators and licensors, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.

Risks Related to Regulatory Approval and Other Government Regulations

If we are not able to obtain the necessary regulatory approvals for any of our product candidates, we may not generate sufficient revenues to continue our business operations.

Our product candidates, and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in states and in other countries. Our failure to obtain regulatory approval for a product candidate will prevent us from commercializing the product candidate. We have not received regulatory approval to market any of our product candidates in any jurisdiction. Securing FDA approval typically requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each therapeutic indication to establish the product candidate’s safety and efficacy. Securing FDA approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA. Our future products may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or may prevent or limit commercial use.

We began enrolling patients in a pivotal Phase 3 clinical trial of ALD-101 in March 2008, and we plan to begin enrolling patients in a pivotal Phase 3 clinical trial of ALD-301 in 2010. We must complete clinical trials

to the FDA’s satisfaction before we can receive its approval to market either of these product candidates. These pivotal Phase 3 clinical trials alone may not be sufficient for approval of a BLA. Collection of data needed for submission of an acceptable BLA may take several years and will require the expenditure of substantial resources. The FDA could require more extensive clinical trials of ALD-101 or ALD-301, potentially including trials with greater numbers of sites and patients or trials using a different control group, as a condition to approval, or could impose other costly conditions prior to approval. For example, the FDA has issued a concurrence letter with respect to our SPA for the design of a pivotal Phase 3 clinical trial of ALD-301 to evaluate its efficacy in treating critical limb ischemia. This means that the FDA has determined that the design and planned analyses of the trial sufficiently address the trial’s objectives and that the trial is adequately designed to provide the necessary data that, depending on the outcome, could support a BLA submission. However, in issuing its concurrence letter, the FDA noted that the ultimate approvability of ALD-301 will depend on the quality and the results of adequate and well-controlled clinical studies. An SPA is not a guarantee of approval even if the protocol meets its endpoints, and the concurrence is not binding on the FDA, which can override the SPA if it considers it necessary to protect the public health. If we intend to seek approval of ALD-301 based on our planned single pivotal Phase 3 clinical trial, the data will need to be robust, consistent across study sites and consistent with outcomes provided from earlier studies. If our clinical trials fail to demonstrate to the FDA that ALD-101 or ALD-301 is safe and effective, in accordance with the FDA’s standards, the FDA will not grant regulatory approval.

The process of obtaining FDA and other regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved and challenges by competitors. Moreover, because all of our product candidates are based on our ALDH^br stem cell technology, any adverse events in our clinical trials of one of our product candidates could negatively affect the clinical trials and approval process for our other candidates. Changes in regulatory approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application or may make it easier for our competitors to gain regulatory approval to enter the marketplace. The FDA has substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying agency interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.

Any of the following factors, among others, may cause regulatory approval for our product candidates to be delayed, limited or denied:

•

our product candidates require significant clinical testing to demonstrate safety and effectiveness before applications for marketing approval can be filed with the FDA;

•

data obtained from preclinical and nonclinical animal testing and clinical trials can be interpreted in different ways, and the FDA may not agree with our interpretations or may require us to conduct additional testing;

•

it may take many years to complete the testing of our product candidates, and failure can occur at any stage of the process;

•

the FDA may not grant licensure for the use of cord blood in our target indications;

•

negative or inconclusive results or the occurrence of serious or unexpected adverse events during a clinical trial could cause us to delay or terminate development efforts for a product candidate; and

•

commercialization may be delayed if the FDA requires us to expand the size and scope of the clinical trials.

Any difficulties that we encounter in obtaining regulatory approval could have a substantial adverse impact on our ability to generate product sales and cause our stock price to decline significantly.

We will not be able to conduct our planned pivotal Phase 3 clinical trial of ALD-301 unless the FDA removes the partial clinical hold on our IND.

The FDA has issued a concurrence letter with respect to our SPA for the design of a pivotal Phase 3 clinical trial of ALD-301 to evaluate its efficacy in treating critical limb ischemia. However, the FDA has placed a partial clinical hold on the IND for ALD-301 relating to three chemistry, manufacturing and controls, or CMC, issues. These issues relate to lot release specifications, the stability of the product candidate during transport, and comparability of debulking procedures. A partial clinical hold stops the trial from proceeding until the issues are resolved. We are currently working with the FDA to resolve these issues. If we are unable to resolve the FDA’s concerns, we will not be cleared to conduct our planned pivotal Phase 3 clinical trial of ALD-301 for critical limb ischemia or pursuing other development efforts for ALD-301. A significant delay in securing release of the partial clinical hold on the IND would potentially delay the trial, resulting in additional costs and delays in trial enrollment and completion.

If we or our investigators are not able to conduct the clinical trials of our product candidates in accordance with regulations and accepted standards, and on schedule, regulatory approval by the FDA and other regulatory authorities may be delayed or denied.

To obtain marketing approvals for our products in the United States, we must, among other requirements, complete adequate and well-controlled clinical trials sufficient to demonstrate to the FDA that the product candidate is safe and effective, for each indication for which we seek approval. Several factors could prevent completion or cause significant delay of these trials, including an inability to enroll the required number of patients or failure to demonstrate adequately that our product candidates are safe and effective for use in humans. Negative or inconclusive results from, or serious adverse events during, a clinical trial could cause the clinical trial to be repeated or a development program to be terminated, even if other studies or trials relating to the program are successful. A serious adverse event is an event that results in significant medical consequences, such as hospitalization, disability or death, and must be reported to the FDA. We cannot predict whether safety concerns regarding our product candidates will or will not develop. The FDA can place a clinical trial on hold if, among other reasons, it finds that patients enrolled in the trial are or would be exposed to an unreasonable and significant risk of illness or injury. If safety concerns develop, we may, or the FDA or an institutional review board may require us to, stop our trials before completion.

The completion of our clinical trials may be delayed or terminated for many reasons, including if:

•

the FDA or other regulatory authority does not grant permission to proceed and places the trial on clinical hold;

•

subjects do not enroll in our clinical trials at the rate we expect;

•

subjects experience an unacceptable rate or severity of adverse side effects;

•

third-party clinical investigators do not perform our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices required by the FDA and other regulatory requirements, or other third parties do not perform data collection and analysis in a timely or accurate manner;

•

inspections of clinical trial sites by the FDA or by institutional review boards of research institutions participating in our clinical trials, reveal regulatory violations that require us to undertake corrective action, suspend or terminate one or more sites, or prohibit us from using some or all of the data in support of our marketing applications; or

•

the FDA or one or more institutional review boards suspends or terminates the trial at an investigational site, precludes enrollment of additional subjects or withdraws its approval of the trial.

Our development costs will increase if we have material delays in our clinical trials, or if we are required to modify, suspend, terminate or repeat a clinical trial. If we are unable to conduct our clinical trials properly and on schedule, marketing approval may be delayed or denied by FDA.

Any product for which we obtain marketing approval will be subject to extensive ongoing regulatory requirements, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.

Any product for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and comparable regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration requirements, cGMP and cGTP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, requirements relating to product labeling, advertising and promotion, and recordkeeping. Even if regulatory approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to other conditions of approval. For example, we will not be permitted to advertise or promote ALD-101 based on claims that a reduction in engraftment times could lead to reductions in post-transplant complications, length of hospital stays or reductions in costs associated with hospital stays. In addition, approval may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Discovery after approval of previously unknown problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:

•

restrictions on such products’ manufacturing processes;

•

restrictions on the marketing of a product;

•

restrictions on product distribution;

•

requirements to conduct post-marketing clinical trials;

•

warning letters;

•

withdrawal of the products from the market;

•

refusal to approve pending applications or supplements to approved applications that we submit;

•

recall of products;

•

fines, restitution or disgorgement of profits or revenue;

•

suspension or withdrawal of regulatory approvals;

•

refusal to permit the import or export of our products;

•

product seizure;

•

injunctions; or

•

imposition of civil or criminal penalties.

Failure to obtain regulatory approval in international jurisdictions would prevent us from marketing products abroad.

We may in the future seek to market some of our product candidates outside the United States. In order to market our product candidates in the European Union and many other jurisdictions, we must submit clinical data concerning our product candidates and obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval from foreign regulators may be longer than the time required to obtain FDA approval. The regulatory approval process outside the United States may include all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product candidate be approved for reimbursement before it can be approved for sale in that country. In some cases this may include approval of the price we intend to charge for our product, if approved. We may not

obtain approvals from regulatory authorities outside the United States on a timely basis, or at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA, but a failure or delay in obtaining regulatory approval in one country may negatively affect the regulatory process in other countries. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize any products in any market and therefore may not be able to generate sufficient revenues to support our business.

Our business involves the use of hazardous materials that could expose us to environmental and other liability.

Our manufacturing facility located at our corporate headquarters in Durham, North Carolina is subject to various local, state and federal laws and regulations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including chemicals, micro-organisms and various radioactive compounds used in connection with our research and development activities. In the United States, these laws include the Occupational Safety and Health Act, the Toxic Test Substances Control Act and the Resource Conservation and Recovery Act. We cannot assure you that accidental contamination or injury to our employees and third parties from hazardous materials will not occur. We do not have insurance to cover claims arising from our use and disposal of these hazardous substances other than limited clean-up expense coverage for environmental contamination due to an otherwise insured peril, such as fire.

Risks Related to this Offering

An active trading market for our common stock may not develop.

Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock has been determined through negotiations with the underwriters and may bear no relationship to the price at which the common stock will trade upon completion of this offering. Although we have applied to have our common stock listed on The NASDAQ Global Market, an active trading market for our shares may never develop or be sustained following this offering. If an active market for our common stock does not develop, it may be difficult to sell shares you purchase in this offering without depressing the market price for the shares or to sell your shares at all.

The trading price of the shares of our common stock is likely to be volatile, and purchasers of our common stock could incur substantial losses.

Our stock price is likely to be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the initial public offering price. The market price for our common stock may be influenced by many factors, including:

•

results of clinical trials of our product candidates or those of our competitors;

•

regulatory or legal developments in the United States and foreign countries;

•

variations in our financial results or those of companies that are perceived to be similar to us;

•

changes in the structure of healthcare payment systems;

•

announcements by us of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

•

market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts’ reports or recommendations;

•

sales of substantial amounts of our stock by existing stockholders;

•

sales of our stock by insiders and large stockholders;

•

general economic, industry and market conditions;

•

additions or departures of key personnel;

•

intellectual property, product liability or other litigation against us;

•

expiration or termination of our potential relationships with collaborators; and

•

the other factors described in this “Risk Factors” section.

In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management’s attention and resources.

If you purchase shares of our common stock in this offering, you will suffer immediate dilution of your investment.

We expect the initial public offering price of our common stock to be substantially higher than the net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our pro forma net tangible book value per share after this offering. Based on an assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of $ per share, representing the difference between our pro forma as adjusted net tangible book value per share after giving effect to this offering and the assumed initial public offering price. In addition, purchasers of common stock in this offering will have contributed approximately % of the aggregate price paid by all purchasers of our common stock but will own only approximately % of our common stock outstanding after this offering.

In addition, as of September 30, 2009, we had outstanding stock options to purchase an aggregate of 6,655,463 shares of common stock at a weighted-average exercise price of $0.32 per share and outstanding warrants to purchase an aggregate of 1,809,791 shares of our common stock, assuming the conversion of preferred stock issuable upon the exercise of the warrants, at a weighted average exercise price of $0.77 per share. To the extent these outstanding options and warrants are exercised, there will be further dilution to investors in this offering.

A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.

Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market following this offering, the market price of our common stock could decline significantly. Upon completion of this offering, we will have outstanding shares of common stock, assuming no exercise of outstanding options or warrants, other than warrants that expire upon the closing of this offering. Of these shares, the shares sold in this offering and additional shares will be freely tradable, additional shares of common stock will be eligible for sale in the public market beginning 90 days after the date of this prospectus, subject to volume, manner of sale and other limitations of Rule 144 and Rule 701, and additional shares of common stock will be available for sale in the public market beginning 180 days after the date of this prospectus following the expiration of lock-up agreements between our stockholders and the underwriters. The representatives of the underwriters may release these stockholders from their 180-day lock-up

agreements with the underwriters at any time and without notice, which would allow for earlier sales of shares in the public market. In addition, after this offering, holders of an aggregate of shares of our common stock will have rights, subject to some exceptions, limitations, and conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also intend to register the shares of common stock that we may issue in the future under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to the 180-day lock-up agreements with our underwriters.

Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result.

There are provisions in our certificate of incorporation and bylaws, as they will be in effect following this offering, that may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by you and other stockholders. For example, our board of directors will have the authority to issue up to shares of preferred stock. The board of directors can fix the price, rights, preferences, privileges, and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.

Our charter documents will also contain other provisions that could have an anti-takeover effect, including:

•

only one of our three classes of directors will be elected each year;

•

stockholders will not be entitled to remove directors other than by a 66²/3% vote and only for cause;

•

stockholders will not be permitted to take actions by written consent;

•

stockholders cannot call a special meeting of stockholders; and

•

stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder meetings.

In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which regulates corporate acquisitions. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock. These provisions may also prevent changes in our management.

Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.

Upon completion of this offering, our executive officers, directors and current beneficial owners of 5% or more of our common stock and their affiliates will, in aggregate, beneficially own approximately % of our outstanding common stock, after giving effect to the conversion of all outstanding shares of our convertible preferred stock into shares of our common stock and the automatic conversion of the October convertible bridge notes and the exercise of the related warrants, but assuming no exercise of the underwriters’ over-allotment option. These persons, acting together, will be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transactions. The interests of this group of stockholders may not coincide with our interests or the interests of other stockholders.

We have broad discretion in the use of proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree and in ways that may not yield a return.

We will have broad discretion over the use of proceeds from this offering. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment in us. Our failure to apply the net proceeds of this offering effectively could have a material adverse effect on our business, financial condition and results of operations.

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains.

We have not declared or paid cash dividends on our capital stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

As a public company, we will be subject to the requirements of Section 404 of the Sarbanes-Oxley Act. If we are unable to comply with Section 404 in a timely manner, it may affect the reliability of our internal control over financial reporting.

Assessing our staffing and training procedures to improve our internal control over financial reporting is an ongoing process. We are not currently required to comply with Section 404 of the Sarbanes-Oxley Act of 2002, and are therefore not required to make an assessment of the effectiveness of our internal control over financial reporting. Further, our independent registered public accounting firm has not been engaged to express, nor have they expressed, an opinion on the effectiveness of our internal control over financial reporting. However, in connection with our financial statement audits for the years ended December 31, 2005 and 2006, our independent registered public accounting firm informed us that they had identified material weaknesses in our internal controls as defined by the American Institute of Certified Public Accountants. A material weakness is a reportable condition in which our internal controls do not reduce to a low level the risk that misstatements caused by error or fraud in amounts that are material to our audited financial statements may occur and not be detected within a timely period by employees in the normal course of performing their assigned functions.

The material weakness reported by our independent registered public accounting firm relates to our controls for those prior periods over our financial statement close process, the lack of financial accounting and reporting expertise, a lack of sufficient levels of review and approval of the results of the closing procedures, and a lack of a formal process to assess the accounting implications of complex transactions.

During 2007 and 2008, we took remedial measures to improve the effectiveness of our internal controls. Specifically, we improved controls by:

•

strengthening our internal staffing and technical expertise in financial accounting and Securities and Exchange Commission, or SEC, reporting;

•

implementing executive-level review of financial statements and complex transactions;

•

enhancing and segregating duties within our accounting and finance department; and

•

upgrading our accounting software systems.

We plan to continue to assess our internal controls and procedures and intend to take further action as necessary or appropriate to address any other matters we identify. For the year ending December 31, , pursuant to Section 404 of the Sarbanes-Oxley Act, management will be required to deliver a report that assesses the effectiveness of our internal control over financial reporting. Under current SEC rules, our independent registered public accounting firm will also be required to deliver an attestation report on the operating effectiveness of our internal control over financial reporting beginning with the year ending December 31, .

We have been and will continue to be involved in a substantial effort to implement appropriate processes, document the system of internal control over key processes, assess their design, remediate any deficiencies identified and test their operation. However, the existence of a material weakness is an indication that there is a more than remote likelihood that a material misstatement of our financial statements will not be prevented or detected in a future period, and the process of designing and implementing effective internal controls and procedures is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate to satisfy our reporting obligations as a public company. We cannot be certain at this time that we will be able to successfully complete the procedures, certification and attestation requirements of Section 404 or that we or our independent registered public accounting firm will not identify additional material weaknesses in our internal control over financial reporting. If we fail to comply with the requirements of Section 404 or if we or our independent registered public accounting firm identify and report a material weakness, it may affect the reliability of our internal control over financial reporting, which could adversely affect our stock price.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the sections entitled “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business,” but are also contained elsewhere in this prospectus. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about:

•

the outcome, timing or success of preclinical studies and clinical trials;

•

the expected timing of clinical trial enrollments or results;

•

the possible clinical activities of our ALDH^br stem cell populations and their potential applicability in a variety of therapeutic areas;

•

our ability to obtain and maintain regulatory approval for our product candidates from the FDA or foreign regulatory authorities;

•

future demand for our product candidates and our ability to sustain such demand;

•

the size and growth of the potential markets for our product candidates;

•

the existing capacity of our manufacturing facility to produce our product candidates for our clinical trials;

•

plans for enhancements to our manufacturing capabilities;

•

our ability to sell our cord blood transplantation products, if approved for marketing, using a small internal sales force;

•

our plans to seek collaborative relationships and the success of those relationships;

•

the success of competing therapies that are or become available;

•

our anticipated cash needs and our estimates regarding our use of proceeds, future revenues, capital requirements and needs for additional financing;

•

our expectation that our research and development expense levels will remain high as we continue clinical trials and develop our product candidates;

•

our compliance with federal, state and foreign regulatory requirements, and regulatory developments that impact those requirements;

•

our estimates and assumptions with respect to disease incidence;

•

our intellectual property and our strategies regarding filing additional patent applications to attempt to strengthen our intellectual property rights;

•

our expected stock-based compensation expense in future periods;

•

our ability to retain key management, scientific, sales and marketing personnel;

•

our ability to implement financial controls and procedures on a timely basis; and

•

anticipated trends and challenges in our business and the markets in which we operate.

You should refer to the “Risk Factors” section of this prospectus for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

USE OF PROCEEDS

We estimate that the net proceeds from our issuance and sale of shares of our common stock in this offering will be approximately $ million, or approximately $ million if the underwriters exercise their over-allotment option in full, based upon an assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase or decrease in the assumed initial public offering price of $ per share would increase or decrease the net proceeds to us from this offering by approximately $ million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same.

We currently expect to use the net proceeds from this offering as follows:

•

approximately $ million to initiate and fund completion of a planned pivotal Phase 3 clinical trial for ALD-301;

•

approximately $ million to fund our development and commercialization activities for ALD-101, including:

•

completion of the ongoing pivotal Phase 3 clinical trial of ALD-101 and pursuing FDA marketing approval for the product candidate if that trial is successful; and

•

costs in connection with the establishment of a small internal sales force and related marketing functions, such as pursuing third-party payor reimbursement; and

•

the balance for other general corporate purposes and working capital.

In addition, we may use a portion of the net proceeds from this offering to acquire, invest in or in-license complementary products, technologies or businesses, but we currently have no agreements or commitments with respect to any potential acquisition, investment or in-license. We may allocate funds from other sources to fund some or all of these activities.

The expected use of net proceeds from this offering represents our intentions based upon our present plans and business conditions. We estimate that the net proceeds currently allocated to our clinical trials for ALD-301 and ALD-101 will be sufficient to complete these pivotal clinical trials. As described elsewhere in this prospectus, however, completion of these pivotal clinical trials may be delayed for a number of reasons, or the FDA might require us to conduct additional trials, in which case the net proceeds of this offering may not be sufficient to fully fund clinical development of these product candidates. To fulfill our plan of initiating larger, later-stage clinical trials of ALD-201, we anticipate that we will need to enter into a collaboration arrangement with a third party to conduct and fund those trials before we could pursue marketing approval for that product candidate. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the proceeds of this offering or the amounts that we will actually spend on the uses set forth above. The amount and timing of actual expenditures may vary significantly depending upon a number of factors, such as the progress of our development efforts, regulatory requirements, commercialization efforts in the event that we obtain regulatory approval, the amount of cash we generate from strategic collaborations that we may enter into, and the amount of cash used by operations. Accordingly, we will have significant flexibility in applying the net proceeds of this offering.

Pending their use, we intend to invest the net proceeds of this offering in a variety of capital-preservation investments, including short- and intermediate-term, interest-bearing, investment-grade securities.

DIVIDEND POLICY

We have never declared or paid any dividends on our common stock or any other securities. We anticipate that we will retain all of our future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the foreseeable future.

CAPITALIZATION

The following table sets forth our cash and cash equivalents and our capitalization as of September 30, 2009:

•

on an actual basis;

•

on a pro forma basis to give effect to:

•

our issuance of the October convertible bridge notes and our receipt of $7.3 million in net proceeds from that issuance;

•

the issuance of 26,285 shares of our Series B convertible preferred stock prior to the closing of this offering upon the exercise for cash of warrants that would otherwise expire upon the closing of this offering and our receipt of an aggregate of $26,285 in proceeds from these exercises;

•

the reclassification of the preferred stock warrant liability to additional paid-in capital upon conversion of the warrants to purchase convertible preferred stock into warrants to purchase common stock; and

•


	As of September 30, 2009
	Actual			Pro forma	Pro forma as adjusted
	(in thousands)
Cash and cash equivalents	$	8,786		$	$

Preferred stock warrant liability	$	1,614		$	$
Capital lease obligations, including current portion		40
Notes payable, including current portion		2,693
Series A and Series B redeemable convertible preferred stock, $0.001 par value, 14,963,785 shares authorized, 14,515,000 shares issued and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted		11,196
Series C and Series C-1 redeemable convertible preferred stock, $0.001 par value, 43,744,660 shares authorized, 42,379,634 shares issued and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted		42,002
Stockholders’ (deficit) equity:
Common stock, $0.001 par value, 80,000,000 shares authorized; 3,619,747 shares issued and outstanding, actual; shares issued and outstanding, pro forma; shares issued and outstanding, pro forma as adjusted		4
Additional paid-in capital		—
Deficit accumulated during the development stage		(48,050	)

Total stockholders’ (deficit) equity		(48,046	)

Total capitalization	$	9,499		$	$

The pro forma as adjusted information set forth above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, would increase or decrease pro forma as adjusted cash and cash equivalents, additional paid-in capital, total stockholders’ equity and total capitalization by approximately $ assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. Each $1.00 increase in the assumed initial public offering price of $ per share would decrease the aggregate number of shares issued upon the conversion of the October convertible bridge notes and upon net exercise of the related warrants by shares, and each $1.00 decrease in the assumed initial public offering price per share would increase the aggregate number of shares by the same amount. Every additional month after , 2009 that lapses before the closing of this offering would increase the aggregate number of shares issued upon the conversion of the October convertible bridge notes and upon net exercise of the related warrants by shares.

The number of shares of common stock outstanding in the table above does not include:

•

1,809,791 shares of our common stock issuable upon the exercise of outstanding warrants as of September 30, 2009, at a weighted-average exercise price of $0.77 per share; and

•

shares of our common stock to be reserved for future issuance under our equity incentive plans.

DILUTION

If you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. Net tangible book value per share is determined by dividing our total tangible assets less total liabilities and convertible preferred stock by the number of outstanding shares of our common stock.

As of September 30, 2009, we had a deficit in net tangible book value of $(48.0) million, or approximately $(13.27) per share of common stock. On a pro forma basis, after giving effect to the issuance of the October convertible bridge notes in October 2009 and our receipt of the net proceeds from that issuance, the issuance of shares of our Series B convertible preferred stock prior to the closing of this offering upon the exercise of warrants that would otherwise expire upon the closing of this offering and our receipt of the proceeds from these exercises, the conversion of the outstanding shares of our convertible preferred stock, including the Series B convertible preferred stock we expect to issue upon the exercise of warrants prior to the closing of this offering, into shares of our common stock, the conversion of outstanding principal and accrued interest on the October convertible bridge notes and the issuance of an aggregate of shares of our common stock upon such conversion and upon the net exercise of warrants we issued in connection with the October convertible bridge notes, assuming the initial public offering price in this offering is $ per share, the midpoint of the range set forth on the cover page of this prospectus, and assuming that this offering is closed on , 2009, and the reclassification of the preferred stock warrant liability to equity immediately prior to the closing of this offering, our net tangible book value would have been approximately $ million, or approximately $ per share of common stock.

Investors participating in this offering will incur immediate and substantial dilution. After giving effect to the issuance and sale of shares of our common stock in this offering at an assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of September 30, 2009 would have been approximately $ million, or approximately $ per share of common stock. This represents an immediate increase in the pro forma net tangible book value of $ per share to existing stockholders, and an immediate dilution in the pro forma net tangible book value of $ per share to investors purchasing shares of our common stock in this offering. The following table illustrates this per share dilution:


Assumed initial public offering price per share				$
Actual deficit in net tangible book value per share as of September 30, 2009	$	(13.27	)
Increase in net tangible book value per share attributable to issuance of October convertible bridge notes, issuance of convertible preferred stock, conversion of preferred stock, issuance of shares of common stock upon conversion of October convertible bridge notes and net exercise of related warrants, and reclassification of preferred stock warrant liability

Pro forma net tangible book value per share before this offering
Increase in pro forma net tangible book value per share attributable to new investors participating in this offering

Pro forma as adjusted net tangible book value per share after this offering

Dilution per share to investors participating in this offering				$

The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $ per share would increase or decrease our pro forma as

adjusted net tangible book value by approximately $ million, or approximately $ per share, and the dilution per share to investors participating in this offering by approximately $ per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same.

If the underwriters exercise their option in full to purchase additional shares of common stock in this offering, the pro forma as adjusted net tangible book value per share after the offering would be $ per share, the increase in the pro forma net tangible book value per share to existing stockholders would be $ per share and the dilution to new investors purchasing common stock in this offering would be $ per share.

The following table sets forth as of September 30, 2009, on the pro forma basis described above, the differences between the number of shares of common stock purchased from us, the total consideration paid and the weighted average price per share paid by existing stockholders and by investors purchasing shares of our common stock in this offering at an assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page on this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us:


	Shares purchased			Total consideration			Weighted average price per share
	Number	Percent		Amount	Percent		Weighted average price per share
Existing stockholders			%	$		%	$
New investors

Total		100	%	$	100	%

If the underwriters exercise their option to purchase additional shares in full, the common stock held by existing stockholders will be reduced to % of the total number of shares of common stock outstanding after this offering, and the number of shares of common stock held by investors participating in this offering will be increased to shares, or % of the total number of shares of common stock outstanding after this offering.

Each $1.00 increase or decrease in the assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, would increase or decrease the total consideration paid by new investors by $ million, and increase or decrease the percent of total consideration paid by new investors by percentage points, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same.

The table above excludes:

•

1,809,791 shares of our common stock issuable upon the exercise of outstanding warrants as of September 30, 2009, at a weighted-average exercise price of $0.77 per share; and

•

shares of our common stock to be reserved for future issuance under our equity incentive plans.

The shares of our common stock reserved for future issuance under our equity benefit plans will be subject to automatic annual increases in accordance with the terms of the plans. To the extent that options or warrants are exercised, new options are issued under our equity benefit plans, or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

SELECTED FINANCIAL DATA

You should read the following selected financial data together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and accompanying notes included later in this prospectus. The selected financial data in this section is not intended to replace our financial statements and the accompanying notes.

We have derived the selected statement of operations data for the years ended December 31, 2006, 2007 and 2008 and the selected balance sheet data as of December 31, 2007 and 2008 from our audited financial statements that are included in this prospectus. We have derived the selected balance sheet data as of December 31, 2004, 2005 and 2006 and the selected statement of operations data for the years ended December 31, 2004 and 2005 from our audited financial statements that are not included in this prospectus. We have derived the selected statement of operations data for the nine months ended September 30, 2009 and 2008 and for the period from March 3, 2000 (inception) through September 30, 2009 and the selected balance sheet data as of September 30, 2009 from our unaudited financial statements that are included in this prospectus.

Note 3 to our financial statements explains the method we used to compute basic and diluted net (loss) income per share allocable to common stockholders and pro forma basic and diluted net loss per share.

Our historical results are not necessarily indicative of the results to be expected in any future period and our results for any interim period are not necessarily indicative of the results that may be expected for a full fiscal year.


	Year Ended December 31,															Nine Months Ended September 30,						Period from March 3, 2000 (inception) through September 30, 2009
	2004			2005			2006			2007			2008			2008			2009
	(In thousands, except share and per share data)
Statement of Operations Data:
Revenues	$	28		$	59		$	105		$	211		$	179		$	166		$	337		$	1,144
Operating expenses:
Cost of product sales		9			18			46			75			76			62			130			387
Research and development		3,020			2,846			3,239			4,842			6,142			4,510			4,254			31,955
Selling, general and administrative		1,587			1,120			1,058			1,761			4,052			3,665			1,831			14,055

Total operating expenses		4,616			3,984			4,343			6,678			10,270			8,237			6,215			46,397

Loss from operations		(4,588	)		(3,925	)		(4,238	)		(6,467	)		(10,091	)		(8,071	)		(5,878	)		(45,253	)
Interest (expense) income, net		(67	)		(1,744	)		(1,630	)		(87	)		1			13			(110	)		(3,916	)
Other income (expense), net		—			5			92			(147	)		(98	)		(38	)		(724	)		(868	)

Loss before income tax benefit and cumulative effect of change in accounting principle		(4,655	)		(5,664	)		(5,776	)		(6,701	)		(10,188	)		(8,096	)		(6,712	)		(50,037	)
Income tax benefit		—			—			—			—			8			—			—			8

Loss before cumulative effect of change in accounting principle		(4,655	)		(5,664	)		(5,776	)		(6,701	)		(10,180	)		(8,096	)		(6,712	)		(50,029	)
Cumulative effect of change in accounting principle		—			(1,470	)		—			—			—			—			—			(1,470	)

Net loss		(4,655	)		(7,134	)		(5,776	)		(6,701	)		(10,180	)		(8,096	)		(6,712	)		(51,499	)
Accretion of redeemable convertible preferred stock		(1,120	)		(1,214	)		(1,223	)		(2,120	)		(3,588	)		(2,579	)		(2,994	)		(13,964	)
Gain on exchange of redeemable convertible preferred stock		—			—			14,518			—			—			—			—			14,518
Beneficial conversion feature		—			—			—			—			—			—			—			(128	)

Net income (loss) attributable to common stockholders		(5,775	)		(8,348	)		7,519			(8,821	)		(13,768	)		(10,675	)		(9,706	)	$	(51,073	)

Income allocable to preferred stockholders		—			—			(5,621	)		—			—			—			—

Net income (loss) allocable to common stockholders	$	(5,775	)	$	(8,348	)	$	1,898		$	(8,821	)	$	(13,768	)	$	(10,675	)	$	(9,706	)

Basic net income (loss) per share allocable to common stockholders	$	(3.02	)	$	(2.72	)	$	0.56		$	(2.53	)	$	(3.80	)	$	(2.95	)	$	(2.68	)

Diluted net income (loss) per share allocable to common stockholders	$	(3.02	)	$	(2.72	)	$	0.32		$	(2.53	)	$	(3.80	)	$	(2.95	)	$	(2.68	)

Shares used to compute basic net income (loss) per share allocable to common stockholders		1,911,000			3,065,795			3,411,000			3,487,396			3,619,747			3,619,747			3,619,747

Shares used to compute diluted net income (loss) per share allocable to common stockholders		1,911,000			3,065,795			5,918,171			3,487,396			3,619,747			3,619,747			3,619,747

Pro forma net loss per share—basic and diluted													$	(0.22	)				$	(0.15	)

Pro forma weighted-average shares outstanding—basic and diluted														62,877,255						62,877,255



	As of December 31,															As of September 30, 2009
	2004			2005			2006			2007			2008			As of September 30, 2009
	(In thousands)
Balance Sheet Data:
Cash and cash equivalents	$	975		$	916		$	6,751		$	7,513		$	16,056		$	8,786
Working capital		452			(2,542	)		5,808			6,282			12,158			5,264
Total assets		2,406			1,992			7,620			8,710			17,662			10,517
Preferred stock warrant liability		—			4,030			625			773			870			1,614
Notes payable, including current portion		570			3,343			3,078			3,240			3,175			2,693
Total liabilities		1,021			7,695			4,754			5,506			6,005			5,366
Redeemable convertible preferred stock		18,696			18,240			19,270			28,293			50,204			53,198
Deficit accumulated during the development stage		(17,314	)		(24,448	)		(16,407	)		(25,093	)		(38,550	)		(48,050	)
Total stockholders’ deficit		(17,312	)		(23,944	)		(16,404	)		(25,089	)		(38,546	)		(48,046	)

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of our operations together with our financial statements and the related notes to those statements included later in this prospectus. In addition to historical financial information, this discussion contains forward-looking statements reflecting our current plans, estimates, beliefs and expectations that involve risks and uncertainties. As a result of many important factors, particularly those set forth under “Special Note Regarding Forward-Looking Statements” and “Risk Factors,” our actual results and the timing of events may differ materially from those anticipated in these forward-looking statements.

Overview

We are a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. Our product candidates consist of specific populations of adult stem cells that we isolate using our proprietary technology. Our most advanced product candidates are ALD-101, ALD-301 and ALD-201. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving engraftment following umbilical cord blood transplants used to treat inherited metabolic diseases in pediatric patients. In addition, based on the results of our Phase 1/2 clinical trial of ALD-301, we intend to commence a pivotal Phase 3 clinical trial of ALD-301 in 2010 to evaluate its efficacy in treating critical limb ischemia. We have received an SPA concurrence letter from the FDA for the design of this trial. We have also completed a Phase 1 clinical trial of ALD-201 for the treatment of ischemic heart failure. We are also developing additional product candidates for the improvement of engraftment following cord blood transplants used to treat leukemias, for the treatment of inherited metabolic diseases and for the post-acute treatment of ischemic stroke.

We are a development stage company and have incurred significant losses since our inception. As of September 30, 2009, we had a deficit accumulated since inception of $48.0 million. We incurred a net loss of $6.7 million for the nine months ended September 30, 2009 and $10.2 million for the year ended December 31, 2008. We expect our losses to continue over the next several years as we continue clinical trials of our product candidates prior to receiving any potential regulatory approval to market these products. In addition, even if one or more of our product candidates are approved for marketing, we will incur significant expenses for regulatory approval and the initiation of commercialization activities.

Financial Operations Overview

Revenues

All of our revenues are currently derived from the sales of two research and diagnostic products, ALDEFLUOR and ALDECOUNT. ALDEFLUOR is a reagent system for use in research activities to identify and isolate stem cells and progenitor cells based on ALDH activity. We have sold ALDEFLUOR to researchers since 2003. ALDECOUNT is a diagnostic product for identification and counting of ALDH^br cells in vitro using flow cytometry. We have sold ALDECOUNT to clinical and research laboratories since 2004. We currently sell both ALDEFLUOR and ALDECOUNT through a third-party distributor.

From our inception through September 30, 2009, we have generated cumulative aggregate product revenues of approximately $1.0 million attributable to the sale of ALDEFLUOR and, to a lesser extent, ALDECOUNT. Because these product revenues have been insufficient to fund our operations, we have financed our operations primarily through a combination of privately placed convertible preferred stock sales, convertible promissory notes, bank financing, capital lease agreements for the purchase of equipment and, during 2002 and 2003, approximately $109,000 in non-recurring research and development grants from governmental authorities. Until we receive regulatory approval to market our product candidates, if ever, we expect that our only source of product revenue will be from sales of ALDEFLUOR and ALDECOUNT. We anticipate that revenues from these products will continue to be minimal.

Cost of Product Sales

Our cost of product sales relates to direct costs of raw materials in producing ALDEFLUOR and ALDECOUNT by a third party. Historically, these costs have averaged between 35% and 45% of our product sales revenues.

Research and Development Expenses

Our research and development expenses primarily consist of personnel-related costs, including employee salaries and benefits, non-cash stock-based compensation expense for stock option grants, patent expenses and facility, operational support and insurance costs allocated to the research and development function. Research and development expenses also include the costs of manufacturing our product candidates for clinical trials and the costs of supplies required in the clinical trial process. In addition, research and development expenses include costs paid to third parties to conduct our clinical trials. Costs for clinical trials are generally attributable to contracted services, such as services by clinical research organizations and clinical investigators, and costs associated with enrolling patients in clinical trials. We expense research and development costs as they are incurred.

Conducting a significant amount of research and development is a central part of our business model. From our inception through September 30, 2009, we have incurred $32.0 million in research and development expenses, and we plan to continue to make significant investments in research and development in order to realize the potential of our product candidates. The following table summarizes our research and development expense for the periods indicated:


	Year Ended December 31,						Nine Months Ended September 30, 2009		Period from March 3, 2000 (inception) through September 30, 2009
	2006		2007		2008		Nine Months Ended September 30, 2009
	(in thousands)
Direct research and development expense by program:
ALD-101	$	272	$	246	$	385	$	290	$	1,377
ALD-301		159		690		895		150		1,894
ALD-201		521		1,351		1,177		167		3,466
ALD-151		—		—		178		167		345

Total direct research and development program expense		952		2,287		2,635		774		7,082
Indirect research and development expense		2,287		2,555		3,507		3,480		24,873

Total research and development expense	$	3,239	$	4,842	$	6,142	$	4,254	$	31,955

There have been no significant research and development expenses for ALD-601 or ALD-401 to date.

We do not allocate salaries, employee benefits, or other indirect costs related to our research and development function to specific product candidates and have included those expenses in “Indirect research and development expense” in the table above.

We expect our research and development expenses to increase as we advance into later-stage development of our product candidates. We expect to fund our research and development expenses from our current cash and cash equivalents, a portion of the net proceeds from this offering, interest income on these balances and, potentially, additional financing transactions.

We expect to receive final efficacy results from our pivotal Phase 3 clinical trial of ALD-101 in pediatric patients undergoing cord blood transplants for the treatment of inherited metabolic diseases in the second quarter

of 2011. If this trial yields positive results and the FDA separately approves the use of cord blood for the treatment of inherited metabolic diseases, we intend to submit a BLA to the FDA for this product candidate. We may also initiate clinical trials to evaluate the potential efficacy of ALD-101 in pediatric patients undergoing cord blood transplants for the treatment of leukemias and other genetic disorders.

We have also completed a Phase 1/2 clinical trial of ALD-301 and we intend to commence a pivotal Phase 3 clinical trial of ALD-301 to treat critical limb ischemia in 2010. Investigators have completed a Phase 1 clinical trial of ALD-201. Based on the results of this trial, we plan to seek a third-party collaborator to help us conduct and fund larger, later-stage clinical trials. We also plan to conduct or support early-stage clinical trials for ALD-601 to treat inherited metabolic diseases through in utero stem cell transplantation and ALD-401 for post-acute treatment of ischemic stroke.

We also plan to conduct preclinical studies and clinical trials for new product candidates targeting additional therapeutic indications.

At this time, we cannot reasonably estimate or know the nature, specific timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of our product candidates, or the period, if any, in which material net cash inflows may commence from our product candidates. This is due to the numerous risks and uncertainties associated with developing our product candidates, including the currently limited clinical data concerning their benefits, the uncertain cost and outcome of ongoing and planned clinical trials, the possibility that regulators may require us to conduct clinical or non-clinical testing in addition to trials that we have planned, the rapid and significant technological changes, frequent new product and service introductions and enhancements, evolving industry standards in the life sciences industry and our future need for additional capital.

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

Selling, General and Administrative Expenses

Our selling, general and administrative expenses consist primarily of salaries and benefits, non-cash stock-based compensation expense for stock option grants and professional fees related to our administrative, finance, human resources, legal and information technology activities. In addition, selling, general and administrative expenses include an allocation of infrastructure expenses, including the cost of rent and utilities. Over the next several years, we anticipate that our selling, general and administrative expenses will continue to increase. We expect the increase to be attributable to accelerated selling and marketing activities, if we receive required regulatory approvals for any of our product candidates. In addition, we will need to add additional personnel in all of the key functional areas that support the growth of our general operations, including accounting and finance, legal and human resources as a result of becoming a public company. If we obtain approval to market ALD-101, we intend to commercialize ALD-101 with a small, specialized internal sales force. The development and expansion of this sales force would result in an increase in selling expenses.

Interest Income

Interest income consists of interest earned on our cash and cash equivalents. We expect our interest income to increase following this offering as we invest the net proceeds from the offering pending their use in our operations.

Interest Expense

Interest expense to date has consisted primarily of interest expense on capital leases and loan balances and the amortization of debt discounts and debt issuance costs. Our debt discounts represent the initial value of warrants issued in connection with promissory notes, and any related beneficial conversion features associated with the debt. We currently have a term loan from a bank with an outstanding principal balance of $2.6 million as of September 30, 2009. This loan carries an annual interest rate equal to the bank’s prime rate plus 2.5%. We also currently pay interest on an equipment loan with a principal balance of approximately $122,000 as of September 30, 2009. This loan bears interest at a fixed rate of 10.61% per annum.

In October 2009, we issued $7.3 million in aggregate principal amount of the October convertible bridge notes. These notes bear interest at 8% per annum. The outstanding principal and interest on the notes will be automatically converted into shares of our common stock upon completion of this offering.

Critical Accounting Policies and Significant Judgments and Estimates

We have prepared our financial statements in accordance with U.S. generally accepted accounting principles. Our preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the financial statements, as well as revenues and expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in note 2 to our financial statements included later in this prospectus, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.

Expenses Accrued Under Contractual Arrangements with Third Parties

A substantial portion of our ongoing research and development activities are performed under contractual arrangements we enter into with external service providers, including contract research organizations and clinical investigators. We accrue for costs incurred under these arrangements based on our estimates of service performed and costs incurred as of a particular balance sheet date. We base our estimates of expenses incurred on facts and circumstances known to us. The factors we consider include the level of services performed, patient enrollment in clinical trials, administrative costs incurred, and other indicators of services completed. The majority of our service providers invoice us in arrears, and to the extent that amounts invoiced differ from our estimates of expenses incurred, we accrue for additional costs. Furthermore, based on amounts invoiced to us by our service providers, we may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as services are rendered. We make these estimates as of each balance sheet date in our financial statements.

Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting expenses that are too high or too low in any particular period. Any such difference may result in adjustments in future periods.

Stock-Based Compensation

Effective January 1, 2006, we adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 718, legacy Statement of Financial Accounting Standards, or SFAS, No. 123R, Share-Based Payment, or SFAS No. 123R, as interpreted by Staff Accounting Bulletin No. 107,

Share-Based Payment, or SAB 107. SFAS No. 123R is a revision of SFAS No. 123, Accounting for Stock Based Compensation, and supersedes Accounting Principles Board No. 25, Accounting for Stock Issued to Employees, or APB 25. ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Pro forma disclosure is no longer an alternative.

Prior to January 1, 2006, we accounted for employee stock-based compensation in accordance with the provisions of APB 25 and complied with the disclosure provisions of SFAS No. 123, and related SFAS No. 148, Accounting for Stock-Based Compensation—Transition and Disclosure. Under APB 25, we measured compensation cost for stock options granted to employees and non-employee directors as the excess, if any, on the date of the grant, of the fair value of the stock over the exercise price an employee or non-employee director must pay to acquire the stock. Prior to 2006, the exercise price for all options we granted was equal to the fair value of the stock on the date of grant, as determined by our board of directors. As a result, there was no compensation expense recorded for stock options granted to employees and non-employee directors in 2005. Our board of directors, which included members who were experienced in valuing the securities of early-stage companies, considered both objective and subjective factors in determining the estimated fair value of our common stock on each option grant date.

Effective January 1, 2006, with the adoption of ASC 718, we elected to use the Black-Scholes option pricing model to determine the fair value of options granted. In accordance with ASC 718, we recognize the compensation expense of share-based awards on a straight-line basis over the vesting period of the award. Vesting is generally based upon continued service to our company. We adopted the provisions of ASC 718 using the prospective transition method. Under this method, the provisions of ASC 718 apply to all awards granted or modified after January 1, 2006. We continue to account for awards outstanding at January 1, 2006 using the accounting principles originally applied to the award.

The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of our stock and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. We do not have a history of market prices of our common stock. In connection with retrospective valuations of our common stock we performed in 2006 and 2007, we determined the volatility of comparable publicly traded companies, and in accordance with SAB 107 we used these historical volatilities. We estimate the expected life of awards to employees based on the “SEC Shortcut Approach,” as defined in SAB 107, which is the midpoint between the vesting date and the end of the contractual term. For non-employees, we use the contractual term of the award. We use a risk-free interest rate based on interest rates for U.S. Treasury notes with lives approximating the expected life of the stock options. We use a dividend yield of zero based on our history and expectation of paying no dividends. We estimate forfeitures based on the discrete groupings of employees, management and non-employee directors and the historical rate of forfeitures for those groups. We estimate forfeiture rates at the time of grant and revise these rates, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense recognized during the year ended December 31, 2006 and thereafter is based on awards that we ultimately expect to vest. If there are any modifications or cancellations of the underlying unvested securities, we may be required to accelerate, increase or cancel any remaining unrecognized stock-based compensation expense.

After our adoption of ASC 718 in 2006, our board of directors continued to set exercise prices for stock options based on its estimate of the fair market value of our common stock. Our board of directors considered a number of factors in determining the fair market value of our common stock, including the sales price of our Series C convertible preferred stock, which we had sold to outside investors at $0.7278 per share in December 2006 and September 2007 in arm’s-length transactions, and the rights, preferences and privileges of our Series A, Series B and Series C convertible preferred stock. Our board of directors, with the assistance of management, initially determined that the fair market value of our common stock continued to be $0.20 per share for all of 2006 and 2007.

In connection with the preparation of our financial statements for the year ended December 31, 2007, however, our board of directors directed management to retrospectively assess our enterprise value and the fair value of our common stock and preferred stock at December 31, 2006 and December 31, 2007. Management completed this assessment in February 2008 and then performed an internal reassessment of the fair value of our common stock for stock option grants between January 1, 2007 and December 31, 2007.

In connection with our Series C-1 convertible preferred stock financing round, which closed on April 15, 2008, we performed a contemporaneous valuation of the fair value of our common stock as of that date. This contemporaneous valuation used the same methodology as had been used for the retrospective valuations as of December 31, 2006 and 2007. As of September 15, 2009, we performed an additional contemporaneous valuation of our common stock that is described below.

December 31, 2006 and 2007 and April 15, 2008 Valuations

In conducting both our retrospective and our contemporaneous valuations during 2006, 2007 and 2008, our valuation methodology used the probability-weighted expected return, or PWER, method to allocate our estimated enterprise value between our common stock and our preferred stock. This method is generally considered appropriate to use when there are several distinct liquidity scenarios to be considered. Under the PWER method, we analyzed the future values of our company using several likely liquidity scenarios, which included a strategic sale or merger, an initial public offering, or IPO, and a dissolution of our company in which the holders of our preferred stock receive all of the proceeds and our common stock has no value, as well as a dissolution or other liquidity scenario in which all of the existing equity of our company has no value or is significantly diluted. We determined the value of each of our common stock and our preferred stock for each scenario at the time of each future liquidity event and discounted back to the present using a risk-adjusted discount rate. We then weighted the present values under each scenario based upon the probability of each occurring in order to determine an indication of value.

After calculating the estimated values of our common stock and preferred stock in each liquidity scenario, we then tested our expected pre-money enterprise values for our IPO and acquisition scenarios using the guideline public company, or GPC, method within the market approach. We believe this two-step approach is consistent with the guidance set forth by the American Institute of Certified Public Accountants in the AICPA Technical Practice Aid, “Valuation of Privately-Held-Company Equity Securities Issued as Compensation,” which we refer to as the AICPA Practice Aid.

As described in the AICPA Practice Aid, the market approach is one of three generally accepted valuation approaches. The market approach, and more specifically the GPC method within that approach, considers market transactions in businesses to develop measures that can be used in the valuation of the subject business. We believe that this method is useful if adequate information is available. Guideline public companies are publicly traded companies that provide a reasonable basis for comparison to the characteristics of the company being valued. Once these guideline companies have been identified, the GPC method then consists of developing ratios of value, or market multiples, based on the traded market value of each selected public company, as well as operating performance and financial condition indicators such as revenues, earnings and cash flow.

Valuation models require the input of highly subjective assumptions, and the valuation model we used is not the only valuation model available. Therefore, we cannot assure you of the accuracy of any particular valuation of our stock. Because our common stock has characteristics significantly different from that of publicly traded common stock and because changes in the subjective input assumptions can materially affect the fair value estimate, the models we used do not, in management’s opinion, necessarily provide a reliable, single measure of the fair value of our common stock, and we will not use them to value our common stock once this offering is complete. Accordingly, you are cautioned not to place undue reliance on the valuation methodology described below as an indicator of future stock prices.

Liquidity Scenarios

For the retrospective valuations as of December 31, 2006 and 2007 and the contemporaneous valuation as of April 15, 2008, we considered a number of different liquidity scenarios, including an IPO of our common stock and an acquisition of our company. In some of these scenarios, the proceeds of the liquidation event were sufficient to provide a return to the holders of common stock. We also considered other scenarios involving an acquisition of our company in which the proceeds of the transaction were sufficient to fully or partially satisfy the liquidation preferences of our Series A, Series B, Series C and Series C-1 convertible preferred stock, but in which no proceeds would remain to be distributed to the holders of our common stock. We considered a final scenario in which we would be liquidated at a value that is insufficient to pay the liquidation preferences of any of the preferred stock.

IPO and acquisition scenarios in which holders of common stock will realize a return. For all of the valuations, we assigned probabilities to successful IPO scenarios in 2008 or 2009 and to acquisition scenarios during 2008 or 2009 that would result in a return to the holders of our common stock. We considered that our success in completing either an IPO or acquisition that resulted in a return to the holders of our common stock would be dependent upon our realization of clinical milestones, together with our execution of our business plan and a receptive marketplace. Our probability weightings assigned to IPO scenarios and acquisition scenarios for our April 2008 contemporaneous valuation were higher than those used in the prior retrospective valuations because we had held an organizational meeting in March 2008 with our investment banks in anticipation of initiating an initial public offering, which was subsequently abandoned, in 2008.

For each of the valuations, our assumptions as to our company’s enterprise value in the acquisition scenarios were the same as in the IPO scenarios but, consistent with the PWER method, in the acquisition scenarios we took into account the liquidation preferences that would be payable to the shares of our convertible preferred stock before any distribution of proceeds to holders of our common stock. We also considered that the holders of the convertible preferred stock would have the right to participate, after payment of the convertible preferred stock liquidation preference, in receiving their pro rata share of remaining proceeds payable to the common stock, up to a maximum amount per share of convertible preferred stock set forth in our certificate of incorporation. As a result, the values per share of our common stock in the acquisition scenarios were less than the corresponding values per share of common stock in the IPO scenarios.

GPC analysis. For each of our valuations, we first analyzed the pre-money valuations of life science companies that had completed an IPO in 2006, 2007 and 2008, as applicable. We noted that the assumed values for our company we used in our IPO scenarios fell within the observed range of IPO values for the identified companies. Next, we analyzed a subset of these companies for their IPO pre-money valuations relative to their fully diluted post-money valuations at the time of their last round of private financing prior to their IPO. As part of this analysis, we concluded that the implied step-up in value for our IPO scenarios and acquisition scenarios was within the observed range of step-up multiples for the identified companies and that the number of days between our expected last round of financing and our IPO scenarios was also within the same range as was observed for the identified companies. Finally, we selected a subset of the public companies we considered to be most similar to our company. These companies were Aastrom Biosciences, Inc., Cytori Therapeutics, Inc., Geron Corporation, Osiris Therapeutics, Inc. and Stemcells, Inc. In the case of the December 31, 2006 retrospective valuation, the guideline companies also included ViaCell, Inc. ViaCell was acquired in 2007 and, accordingly, was not included in the guideline public company analyses as of December 31, 2007 and April 15, 2008. We determined that each of these public companies was comparable to our company at the respective valuation dates because they are small capitalization companies focused on the development of therapeutic products derived from stem cells or other stem cell-related products that are generally either in a pre-commercial stage or in the early stages of commercialization. As of each valuation date, we evaluated the market value of these stem cell companies’ equity, excluding cash, and noted that these values were consistent with the enterprise values that we assumed as part of our IPO scenarios and acquisition scenarios under the PWER method.

Liquidity scenarios in which holders of common stock will not realize any return. In addition to assigning probability weightings to successful IPO and acquisition scenarios in which holders of both our common stock and preferred stock would receive a return, for each of our retrospective and contemporaneous valuations, we also assigned probabilities to acquisition scenarios in which the proceeds of the transaction would be sufficient to pay all or a portion of our preferred stock liquidation preferences, but no proceeds would be available to holders of our common stock. We also assigned a probability to an additional scenario in which we would be dissolved for no value and no proceeds would be available for any stockholder. In this scenario, we assumed that our common stock had a value of zero, since no proceeds would be available for distribution to the holders of common stock. Our probability weightings assigned to these scenarios for our April 2008 contemporaneous valuation were lower than those used in the prior retrospective valuations because, by that time, we had determined that an IPO or acquisition at a higher valuation was more likely.

Discount Rate

Once we had allocated the per share values to our common stock and to each series of our convertible preferred stock at each of the future dates in our various scenarios, we calculated the present values of each per share amount to the valuation date, using a discount rate of 30% for our convertible preferred stock and 35% to 40% for our common stock. We believe that these discount rates are consistent with the required rates of return described in the AICPA Practice Aid for companies in a similar stage of development to us. Under the criteria set forth in the AICPA Practice Aid, we determined that our company was no longer in the start-up stage but had generally not progressed beyond the first or early stage of development. For the April 2008 contemporaneous valuation, the discount rate we used to determine the value of the common stock was lower than in the prior retrospective valuations because we believed that our stage of development had progressed during 2008 under the framework described in the AICPA Practice Aid. For example, we made additional progress in our product development during 2008, including the receipt of interim data from our Phase 1/2 clinical trial of ALD-301 in February 2008. We also commenced efforts to conduct an IPO and hired a new chief financial officer with public-company experience in March 2008. In April 2008, we closed our $18.3 million Series C-1 convertible preferred stock transaction.

September 15, 2009 Valuation

In conducting our contemporaneous valuation as of September 15, 2009, we used the PWER method to allocate our estimated enterprise value between our common stock and our preferred stock. Under the PWER method, we analyzed the future values of our company using several likely liquidity scenarios, which included a strategic sale or merger at various future dates and enterprise valuations, as well as an IPO at various future dates. We determined the value of each of our common stock and our preferred stock for each scenario at the time of each future liquidity event and discounted back to the present using a risk-adjusted discount rate. We then weighted the present values under each scenario based upon the probability of each scenario occurring in order to determine an indication of value.

Liquidity Scenarios

For the contemporaneous valuation as of September 15, 2009, we considered a number of different liquidity scenarios, including an IPO of our common stock and an acquisition of our company. In all of these scenarios, the proceeds of the liquidation event were sufficient to provide a return to the holders of common stock.

We assigned probabilities to successful IPO scenarios at various dates in 2010 and to acquisition scenarios between 2010 and 2012. We considered that our success in completing either an IPO or acquisition would be

dependent upon our realization of clinical milestones, together with our execution of our business plan and a receptive marketplace. Our probability weightings assigned to IPO scenarios and acquisition scenarios for our September 2009 contemporaneous valuation were higher than those used in the prior valuations because of the clinical progress that we made subsequent to the last valuation.

For each of the IPO scenarios, our assumption as to our company’s enterprise value were the same, although we assumed different IPO completion dates. For each of the acquisition scenarios, we assumed different enterprise valuations and different dates and, consistent with the PWER method, in the acquisition scenarios we took into account the liquidation preferences that would be payable to the shares of our convertible preferred stock before any distribution of proceeds to holders of our common stock. We also considered that the holders of the convertible preferred stock would have the right to participate, after payment of the convertible preferred stock liquidation preference, in receiving their pro rata share of remaining proceeds payable to the common stock, up to a maximum amount per share of convertible preferred stock set forth in our certificate of incorporation.

GPC analysis. As with our prior valuations, we first analyzed the pre-money valuations of life science companies that had completed an IPO in 2006, 2007 and 2008. We noted that the assumed value for our company we used in our IPO scenarios fell within the observed range of IPO values for the identified companies. Next, we analyzed a subset of these companies for their IPO pre-money valuations relative to their fully diluted post- money valuations at the time of their last round of private financing prior to their IPO. As part of this analysis, we concluded that the implied step-up in value for our IPO scenarios was within the observed range of step-up multiples for the identified companies and that the number of days between our expected last round of financing and our IPO scenarios was also within the same range as was observed for the identified companies. Finally, we selected a subset of the public companies we considered to be most similar to our company. The companies were Aastrom Biosciences, Inc., Cytori Therapeutics, Inc., Geron Corporation, Osiris Therapeutics, Inc. and Stemcells, Inc. We determined that each of these entities was comparable to our company at the respective valuation dates because they are small capitalization companies focused on the development of therapeutic products derived from stem cells or other stem cell-related products that are generally either in a pre-commercial stage or in the early stages of commercialization. We evaluated the market value of these stem cell companies’ equity, excluding cash, and noted that these values were consistent with the enterprise value that we assumed as part of our IPO scenarios and acquisition scenarios under the PWER method.

To analyze our valuations for each of our acquisition scenarios, we utilized the guideline transaction method. In this analysis, we reviewed acquisitions of 48 companies in the biotechnology industry occurring after December 31, 2004 with enterprise valuations between $50 million and $500 million and compared the multiples from these transactions to the implied multiples for the acquisition scenarios. We noted that the implied multiples for the acquisition scenarios were consistent with those multiples observed in the guideline transactions, although for the near term acquisition scenarios the multiples were not considered relevant due to our current low revenue levels.

Discount Rate

Fair Value Estimates

After taking into account all of the assumptions and estimates described in our application of the PWER method and the GPC method within the market approach, we determined the fair value of our common stock to

be approximately $0.24 per share as of December 31, 2006, approximately $0.40 per share as of December 31, 2007, approximately $0.63 per share as of April 15, 2008 and approximately $0.96 per share as of September 15, 2009. During 2006, we granted options to purchase an aggregate of approximately 950,000 shares of our common stock, all with an exercise price of $0.20 per share. These options had a weighted-average Black-Scholes value of $0.14 per share at issuance, which we are recognizing as expense ratably over the respective vesting periods of the options.

Our internal reassessment of the fair value of our common stock for options granted between the December 31, 2006 and December 31, 2007 valuation dates was based upon the timing of achievement of clinical and regulatory milestones and the closing of an additional round of equity financing in September 2007. Based on this internal reassessment, we believed that the fair market value of our common stock did not change during the first half of 2007 from the $0.24 per share calculated as of December 31, 2006, because there were no material developments in our business during this time. We granted options to purchase an aggregate of approximately 1.9 million shares of our common stock during this period. Using the estimated fair value of our common stock of $0.24 per share and an exercise price of $0.20 per share, the weighted-average fair value, determined using the Black-Scholes formula, of options granted during the first quarter of 2007 was $0.17 per share at issuance and during the second quarter of 2007 was approximately $0.16 per share at issuance, which we are recognizing as expense ratably over the respective vesting periods of the options.

During the third quarter of 2007, we established a manufacturing facility at our corporate headquarters that we believe operates in compliance with the FDA’s cGMP and cGTP regulations to manufacture our product candidates, which has enhanced our manufacturing capabilities. In addition, in July 2007, we added three new sites for our clinical trial of ALD-301 for the treatment of critical limb ischemia. On September 15, 2007, we completed a second closing of our Series C convertible preferred stock financing in which we raised an additional $7.0 million. As a result of these developments, we determined that the fair market value of our common stock had increased from $0.24 per share to $0.35 per share as of September 15, 2007.

In the fourth quarter of 2007, we submitted an IND to the FDA for a pivotal Phase 3 clinical trial of ALD-101 for pediatric inherited metabolic diseases. During this period, our sponsored investigator also received clearance from the FDA to proceed with a Phase 1 clinical trial of ALD-151. We believe that these additional developments in the fourth quarter of 2007 justified the further increase in the fair market value of our common stock from $0.35 per share to approximately $0.40 per share as of December 31, 2007, as determined by the retrospective valuation. We granted options to purchase 342,500 shares of our common stock during the fourth quarter at an exercise price of $0.40 per share. The Black-Scholes fair value of these options was between $0.18 per share and $0.26 per share at issuance, which we are recognizing as expense ratably over the respective vesting periods of the options.

Using the retrospective valuation of our common stock of $0.40 per share as of December 31, 2007, we granted options to purchase an aggregate of approximately 1.2 million shares in January 2008 with an exercise price equal to the estimated fair value of the common stock of $0.40 per share. In February 2008, we granted an additional option to purchase 60,000 shares of common stock at an exercise price of $0.40 per share. There were no other options granted during the quarter ended March 31, 2008. The options granted during the quarter ended March 31, 2008 had a weighted-average Black-Scholes fair value of $0.25 per share, which we are recognizing as expense ratably over the vesting periods of the respective options. On April 10, 2008, we granted an option to purchase 17,505 shares of common stock at an exercise price of $0.40 per share, which had a Black-Scholes fair value of $0.23 per share, which we are recognizing as expense ratably over the vesting period of the option.

Between December 31, 2007 and April 15, 2008, we closed a Series C-1 convertible preferred stock financing in which we raised $18.3 million, which we believe justified the further increase in the fair market value of our common stock from $0.40 per share to $0.63 per share as of April 15, 2008, as determined by our contemporaneous valuation as of that date. Using the contemporaneous valuation of our common stock of $0.63 per share as of April 15, 2008, we granted options to purchase an aggregate of approximately 1.0 million shares

of our common stock between April 15, 2008 and September 15, 2008 with an exercise price equal to the estimated fair value of $0.63 per share and a Black-Scholes fair value of $0.37 per share to $0.40 per share, which we are recognizing as expense ratably over the respective vesting periods of the options. In October 2008 we formally withdrew our proposed IPO. Between October 2008 and September 15, 2009, we granted options to purchase an aggregate of 20,000 shares of our common stock with an exercise price of $0.63 per share, which had a Black-Scholes fair value of $0.35 per share to $0.45 per share, which we are recognizing as expense ratably over the respective vesting periods of the options.

In the first half of 2008, we began enrolling patients in our pivotal Phase 3 clinical trial of ALD-101 and, in October 2008, we received orphan drug designation from the FDA for ALD-101 for improving engraftment times in patients with inherited metabolic diseases undergoing cord blood transplants. In August 2009, we received an SPA concurrence letter from the FDA for the design of a pivotal Phase 3 clinical trial of ALD-301 to evaluate its efficacy in treating critical limb ischemia. Also in 2009, we completed a new manufacturing facility capable of meeting our Phase 3 clinical trial needs and early commercial production of ALD-101, preclinical work was completed on ALD-401 and an IND was cleared for a Phase 1 clinical trial for ALD-601. We believe these developments justified the further increase in the fair market value of our common stock from $0.63 per share to $0.96 per share as of September 15, 2009, as determined by our contemporaneous valuation as of that date. We have not granted any options subsequent to September 15, 2009.

Based on an assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, the intrinsic value of stock options outstanding at September 30, 2009 would have been $ million, of which $ million and $ million related to stock options that were vested and unvested, respectively, at that date.

Results of Operations for the Nine Months Ended September 30, 2009 and 2008

Revenues

Revenues for the nine months ended September 30, 2009 were $337,000, increasing from $166,000 for the same period in 2008. The 103% increase in revenue was primarily due to an increase in ALDEFLUOR product sales as a result of increased use of the product in cellular research activities.

Cost of Product Sales

Cost of product sales for the nine months ended September 30, 2009 was $130,000, or 38% of revenues, increasing from $62,000, or 37% of revenues, for the same period in 2008. The 1% increase in cost of product sales as a percentage of revenues was primarily due to an increase in manufacturing costs for our ALDEFLUOR and ALDECOUNT products, including increases in the cost of raw materials, for the nine months ended September 30, 2009 as compared to the same period in 2008.

Research and Development Expenses

Research and development expenses for the nine months ended September 30, 2009 were $4.3 million, decreasing from $4.5 million for the same period in 2008. The 6% decrease was primarily due to a $1.1 million decrease in direct development expenses for our clinical trial activities related to ALD-301 and ALD-201, offset in part by a $900,000 increase in personnel-related expenses and costs associated with the 2009 expansion of our manufacturing facility used to support our clinical trial activities, including costs for additional rent and laboratory supplies.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the nine months ended September 30, 2009 were $1.8 million, decreasing from $3.7 million for the same period in 2008. The 51% decrease was primarily due to a $1.9 million charge for expenses incurred in 2008 in connection with our abandoned IPO, including legal, consulting

and accounting expenses incurred in connection with the preparation and filing with the SEC of the registration statement related to the proposed offering. We initially capitalized these costs as a deferred charge and then we expensed them upon the withdrawal of the registration statement in September 2008.

Interest Income or Expense, net

Interest expense, net, for the nine months ended September 30, 2009 was $110,000, compared to interest income, net, of $14,000 for the same period in 2008. The change was primarily due to a decrease in interest income as a result of a decrease in our average cash balance during the nine months ended September 30, 2009, as compared to the same period in 2008, and a 1% increase in the interest rate on our term loan effective beginning in April 2009.

Other Income (Expense), net

Beginning in 2005, we have accounted for our outstanding warrants to purchase convertible preferred stock at the end of each reporting period by recording changes in fair value during the period as a component of other income or expense. For the nine-month periods ended September 30, 2009 and 2008, we recorded $712,000 and $38,000, respectively, as other expense to reflect the increase in fair value of all preferred stock warrants. The increase was primarily due to an increase in the fair value of our preferred stock during the nine months ended September 30, 2009 as compared to the same period in 2008. Upon the completion of this offering, these preferred stock warrants will convert to warrants to purchase common stock, as a result of which the preferred stock warrant liability will be reclassified to stockholders’ (deficit) equity and there will be no further adjustments to the fair value of these warrants and, accordingly, no further effect on our statement of operations.

Results of Operations for the Years Ended December 31, 2008, 2007 and 2006

Revenues

Total revenues for the years ended December 31, 2008, 2007 and 2006 were $179,000, $211,000 and $105,000, respectively. The fluctuation in revenues was primarily due to changes in demand for our ALDEFLUOR product.

Cost of Product Sales

Cost of product sales was $75,000, or 42% of revenues, for the year ended December 31, 2008, $75,000, or 36% of revenues, for the year ended December 31, 2007, and $46,000, or 44% of revenues, for the year ended December 31, 2006. The fluctuation in the cost of product sales as a percentage of revenues was primarily due to fluctuations in the cost of outsourced manufacturing expenses associated with the assembly of ALDEFLUOR.

Research and Development Expenses

Research and development expenses for the year ended December 31, 2008 were $6.1 million, increasing from $4.8 million for the year ended December 31, 2007 and $3.2 million for the year ended December 31, 2006. The $1.3 million increase for 2008, as compared to 2007, was primarily due to a $348,000 increase in direct development costs, including the initiation of the Phase 3 clinical trial of ALD-101 and our Phase 1 clinical trial of ALD-151, a $528,000 increase in personnel-related costs and a $424,000 increase in manufacturing costs, including the cost of laboratory supplies used in clinical trial activities.

The $1.6 million increase for 2007, as compared to 2006, was primarily due to a $531,000 increase in direct development expenses for clinical trial activities related to ALD-301, a $830,000 increase in direct development expenses for clinical trial activities related to ALD-201 and a $239,000 increase in other costs, including personnel-related costs. The increase in clinical trial expenses for ALD-301 was the result of the expansion of our Phase 1/2 clinical trial activities, including site initiation and enrollment, while the increase in clinical trial expenses for ALD-201 was a result of an increase in patient enrollment during 2007 as compared to 2006.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the year ended December 31, 2008 were $4.1 million, increasing from $1.8 million for the year ended December 31, 2007 and $1.1 million for the year ended December 31, 2006. The increase for 2008, as compared to 2007, was primarily due to the $1.9 million charge for expenses incurred in 2008 in connection with our abandoned initial public offering and a $512,000 increase in personnel-related expenses. The increase for 2007, as compared to 2006, was primarily due to a $293,000 increase in personnel-related expenses, a $218,000 increase in consulting, accounting and legal fees and a $189,000 increase in other expenses associated with our corporate infrastructure.

Interest Income or Expense, net

Interest income, net, for the year ended December 31, 2008 was $1,000, compared to interest expense, net, of $87,000 for the year ended December 31, 2007 and interest expense, net, of $1.6 million for the year ended December 31, 2006. The change for 2008, as compared to 2007, was primarily due to an increase in interest income as a result of an increase in our average cash balance available for investing during the 2008, as compared to 2007. We incurred non-cash interest expense of $1.5 million during 2006. The non-cash interest expense was due primarily to the amortization of debt discounts associated with warrants we issued in connection with a term loan during 2006. These debt discounts were fully amortized as of December 2006.

Other Income (Expense), net

Other income and expense reflects the change in the fair value of outstanding warrants to purchase our convertible preferred stock at the end of each reporting period. For the year ended December 31, 2008, we recorded an expense of $98,000, reflecting the increase in fair value of all preferred stock warrants during 2008. For the year ended December 31, 2007, we recorded an expense of $147,000, reflecting the increase in fair value of all preferred stock warrants during 2007. For the year ended December 31, 2006, we recorded other income of $191,000, reflecting the decrease in fair value of all preferred stock warrants during 2006.

Also during 2006, we entered into a series of amendments to our $3.0 million commercial credit agreement. In accordance with ASC 470-50, legacy Emerging Issues Task Force, or EITF, 96-19, Debtors Accounting for a Modification or Exchange of Debt Instruments, two of these amendments resulted in exchanges of debt instruments with substantially different terms, resulting in a $99,000 loss on extinguishment of debt reflected in other income (expense), net for the year ended December 31, 2006.

Gain on Exchange of Redeemable Convertible Preferred Stock

In December 2006, we issued shares of our Series C convertible preferred stock. In connection with that transaction, there were substantive modifications to the rights, preferences and privileges of our existing Series A convertible preferred stock and Series B convertible preferred stock, which we refer to as the junior preferred stock. For example, we extended the redemption date of the junior preferred stock from January 2008 to December 2012, cancelled all accrued dividends on the junior preferred stock and eliminated the right to future dividends on the junior preferred stock. In accordance with ASC 260-10, legacy EITF D-42, The Effect on the Calculation of Earnings per Share for the Redemption or Induced Conversion of Preferred Stock, we accounted for this transaction as a redemption of the existing Series A convertible preferred stock and Series B convertible preferred stock and the issuance of new junior preferred stock. Upon the closing of that transaction, we recorded a gain of $14.5 million, which represented the excess of the carrying value of the securities and other financial instruments redeemed over the fair value of the new equity and financial instruments issued.

Liquidity and Capital Resources

Sources of Liquidity

Since our inception, we have financed our operations primarily through a combination of privately placed convertible preferred stock sales, convertible promissory notes and associated warrants to purchase shares of our

preferred and common stock, bank financing, capital lease agreements for the purchase of equipment and, during 2002 and 2003, research and development grants from governmental authorities. From our inception through September 30, 2009, we have raised approximately $51.5 million in cash proceeds, net of issuance costs, through the issuance of convertible preferred stock and the issuance of bridge loans that were subsequently converted into convertible preferred stock.

In March 2006, we raised $1.5 million for our working capital requirements from the issuance of a promissory note to a commercial bank, which was originally scheduled to mature in July 2006 or, if earlier, the date on which we received at least $5.0 million in additional equity financing. This loan was collateralized by all of our equipment. We have entered into a series of amendments with the commercial bank to, among other things, increase the amount borrowed to $3.0 million, extend the maturity date to September 2010, increase the interest rate to the lender’s prime rate plus 2.5%, and revise the collateral underlying the loan. The promissory note, as amended to date, is payable in 14 equal monthly installments that began in August 2009. As of September 30, 2009, the principal amount of $2.6 million was outstanding.

During 2007, we entered into a $260,000 loan and security agreement with a venture finance company for the purpose of financing the acquisition of equipment. This loan bears interest at 10.61% per year and is payable in monthly installments through March 2011. As of September 30, 2009, we owed approximately $122,000 on this loan.

In April 2008, we raised approximately $18.3 million through the issuance of Series C-1 convertible preferred stock to accredited investors, all of which were existing stockholders in our company. This issuance of Series C-1 convertible preferred stock was contemplated at the time of the second closing of our Series C convertible preferred stock financing in September 2007, upon the achievement of specified milestones. All of the terms of the Series C-1 convertible preferred stock, including its price, were determined at the time of the second closing of the Series C convertible preferred stock financing, except that the proceeds of the Series C-1 convertible preferred stock financing were initially contemplated to be $6.1 million. In conjunction with the closing of the Series C-1 convertible preferred stock issuance in April 2008, we amended our certificate of incorporation to increase the number of authorized shares of Series C-1 convertible preferred stock.

In October 2009, we raised approximately $7.3 million in net proceeds from the issuance of the October convertible bridge notes to accredited investors. The notes bear interest at 8% per annum. The October convertible bridge notes mature in full upon the next qualified equity financing, which includes this offering, but no later than October 22, 2010. The outstanding principal and interest on the October convertible bridge notes will be automatically converted into shares of our common stock upon completion of this offering.

Cash Flows

We had cash and cash equivalents of $8.8 million at September 30, 2009, $16.1 million at December 31, 2008 and $7.5 million at December 31, 2007. The change in our cash balance during the first nine months of 2009 was primarily the result of our net loss during the period. The change in our cash balance during 2008 was primarily the result of our net loss during the year, offset by the $18.3 million in net proceeds from our April 2008 issuance of Series C-1 convertible preferred stock. We have no agreements with investors, banks or other entities to provide new sources of funding.

Net cash used in operating activities was $6.3 million for the nine months ended September 30, 2009, $7.2 million for the nine months ended September 30, 2008, $9.0 million for the year ended December 31, 2008, $5.9 million for the year ended December 31, 2007 and $3.4 million for the year ended December 31, 2006. Net cash used during these periods primarily reflected our net losses and changes in working capital during those periods, offset in part by non-cash depreciation and amortization, non-cash stock-based compensation expense, changes in the fair value of our preferred stock warrant liabilities and, for the year ended December 31, 2006, non-cash interest expense associated with the amortization of debt discounts.

Our cash used in investing activities relates to our purchases and sales of property and equipment. During the nine months ended September 30, 2009 and the years ended December 31, 2008 and 2007, we purchased approximately $492,000, $734,000 and $502,000, respectively, in computer and laboratory equipment and leasehold improvements for the expansion of our manufacturing facility. We had nominal cash expenditures for investing activities during the nine months ended September 30, 2008 and the year ended December 31, 2006.

Net cash used in financing activities was $494,000 for the nine months ended September 30, 2009, and net cash provided by financing activities was $18.3 million for the nine months ended September 30, 2008. Net cash provided by financing activities was $18.2 million for the year ended December 31, 2008, $7.1 million for the year ended December 31, 2007 and $9.2 million for the year ended December 31, 2006.

Our cash flows from financing activities are primarily proceeds from the issuance of notes payable and shares of our convertible preferred stock. In December 2006, we issued shares of our Series C convertible preferred stock in an initial closing for net cash proceeds of $6.5 million, excluding conversion of bridge notes and accrued interest thereon. In September 2007, we completed a second closing of our Series C convertible preferred stock financing, in which we issued shares of Series C convertible preferred stock to some of our existing investors for net cash proceeds of $6.9 million. During 2006, we also entered into the $3.0 million term loan with a commercial bank. In April 2008, we issued shares of our Series C-1 convertible preferred stock for net cash proceeds of $18.3 million. During 2007, we also received $260,000 in cash proceeds from an equipment loan and approximately $42,000 in cash from the exercise of employee stock options. During 2006, 2007 and 2008, we repaid approximately $266,000, $118,000 and $81,000 of borrowings under notes payable and capital leases. During the nine months ended September 30, 2009, we repaid approximately $494,000 of borrowings under notes payable and capital leases.

Capital Resources and Expenditure Requirements

We expect to continue to incur substantial operating losses in the future and to make expenditures to expand our clinical trials and other research and development programs, which we expect to fund in part with a portion of the net proceeds of this offering. It may take several years, if ever, to achieve these goals. We expect that we will use a portion of the net proceeds from this offering and our existing cash and cash equivalents, including the net proceeds of the issuance of the October convertible bridge notes and related warrants, for working capital requirements and for general corporate purposes, including the increased costs associated with being a public company. We may also use a portion of the net proceeds of this offering to acquire or invest in complementary businesses, technologies, services or products, although we do not have any current plans to do so.

We currently believe that our cash and cash equivalents, together with the net proceeds from this offering and interest income on these balances, will be sufficient to meet our anticipated cash requirements for at least the next 24 months. However, our present and future funding requirements will depend on many factors, including:

•

the scope, progress and results of our research and preclinical development programs;

•

the costs of building, operating and enhancing our manufacturing facilities and capabilities to support our clinical activities, and, if our product candidates are approved, our commercialization activities;

•

the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and liabilities;

•

revenues received from sales of our product candidates, if approved by the FDA;

•

the costs of additional general and administrative personnel, including accounting and finance, legal and human resources employees, as a result of becoming a public company; and

•

the costs of developing our anticipated internal sales, marketing and distribution capabilities.

Until we obtain regulatory approval to market our product candidates, if ever, and can generate a sufficient amount of product revenues to finance our cash requirements, which we may never do, we may seek to finance future cash needs through public or private equity offerings, debt financings, borrowings or strategic collaborations. We cannot assure you that additional capital will be available when needed on acceptable terms, or at all. The issuance of equity securities may result in dilution to stockholders. If we raise additional funds through the issuance of debt securities, these securities would have rights, preferences and privileges senior to those of our common stock and the terms of the debt securities could impose significant restrictions on our operations. If we raise additional funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our technologies or products, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we may have to scale back our operations or limit our research and development activities, which would have a material adverse impact on our business prospects and results of operations.

Future Contractual Obligations

The following table reflects a summary of our estimates of future contractual obligations as of December 31, 2008. The information in the table reflects future unconditional payments and is based on the terms of the relevant agreements, appropriate classification of items under generally accepted accounting principles currently in effect and certain assumptions, such as the interest rate on our variable debt that was in effect as of December 31, 2008. Future events could cause actual payments to differ from these amounts. In April 2009, we entered into an amendment to our loan agreement with a commercial bank, which increased the interest rate by 1% to prime plus 2.5%, extended the maturity date to September 2010 and delayed our obligations to begin repayment until August 2009. The table below does not give effect to repayments of borrowings under notes payable and capital leases in the aggregate amount of $494,000 during the nine months ended September 30, 2009. The table below also does not give effect to the issuance of the October convertible bridge notes in the aggregate principal amount of $7.3 million in October 2009. The October convertible bridge notes mature on October 22, 2010 unless earlier converted in accordance with their terms.


	Payments Due By Period
	Total		2009		2010-2011		2012-2013		After 2013
	(in thousands)
Principal and interest under promissory notes	$	3,199	$	2,206	$	993	$	—	$	—
Capital lease obligations, including interest, for equipment		58		20		36		2		—
Operating lease obligations relating to corporate headquarters and manufacturing facility		730		161		384		185		—

Total	$	3,987	$	2,387	$	1,413	$	187	$	—

Quantitative and Qualitative Disclosures about Market Risk

Our exposure to market risk is confined to our cash and cash equivalents, all of which have maturities of less than one year. The goals of our investment policy are liquidity and capital preservation. Our cash and cash equivalents as of September 30, 2009 consisted primarily of money market funds. Due to the short duration of our cash equivalents and the high quality of the underlying securities, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash or cash equivalents. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our cash equivalents.

At September 30, 2009, we had $2.6 million outstanding under a term loan with a variable interest rate that adjusts periodically based on the prime rate. If the interest rate on this loan had been one percentage point higher during all of 2008, our interest expense with respect to this loan for the year ended December 31, 2008 would have increased by $30,000. Our equipment loans have fixed interest payments. Therefore, we are not subject to market risk with respect to these loans.

We have no operations outside the United States, and all of our operating expenses and capital expenditures are denominated in U.S. dollars. As a result, we are not subject to market risk with respect to currency exchange rate fluctuations.

We have not entered into, and do not expect to enter into, hedging or derivative instrument arrangements.

Off-Balance Sheet Arrangements

Since inception, except for standard operating leases, we have not engaged in any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K, such as the use of unconsolidated subsidiaries, structured finance, special purpose entities or variable interest entities.

Other Recent Accounting Pronouncements

In April 2009, the FASB issued ASC 825-10, legacy FASB Staff Position, or FSP, FAS 107-1 and APB No. 28-1, Interim Disclosures About Fair Value of Financial Instruments, which expands the fair value disclosures required for financial instruments to interim reporting periods for publicly traded companies, including disclosure of the significant assumptions used to estimate the fair value of financial instruments. We adopted ASC 825-10 effective June 15, 2009. The adoption of ASC 825-10 did not impact our financial position or results of operations.

In May 2009, the FASB issued ASC 855-10, legacy SFAS No. 165, Subsequent Events, which provides authoritative accounting literature for a topic that was previously addressed only in the auditing literature. Three modifications to the subsequent events guidance in ASC 855-10 are (1) to name the two types of subsequent events either as recognized subsequent events or non-recognized subsequent events, (2) to modify the definition of subsequent events to refer to events or transactions that occur after the balance sheet date, but before the financial statements are issued and (3) to require entities to disclose the date through which they have evaluated subsequent events and the basis for that date. We adopted ASC 855-10 effective June 15, 2009. The adoption of ASC 855-10 did not impact our financial position or results of operations.

In June 2009, the FASB issued ASC 105, Generally Accepted Accounting Principles, which established the FASB Accounting Standards Codification as the sole source of authoritative generally accepted accounting principles. Pursuant to the provisions of ASC 105, we have updated references to GAAP in our financial statements issued for the period ended September 30, 2009. The adoption of ASC 105 did not impact our financial position or results of operations.

BUSINESS

Overview

Our most advanced product candidates are:

•

ALD-101 to improve engraftment following cord blood transplants used to treat pediatric inherited metabolic diseases. ALD-101 is the population of ALDH^brstem cells we produce from a portion of a cord blood unit using our proprietary technology. ALD-101 is infused into a patient shortly after the transplant of the remaining portion of the cord blood unit. In a Phase 1 clinical trial, we observed a statistically significant reduction in the time to platelet and neutrophil engraftment in patients receiving ALD-101 following their cord blood transplant, as compared to similar patients who had received a cord blood transplant without ALD-101 in an earlier independent clinical trial. We believe that reduction in engraftment time could reduce risks associated with cord blood transplants and decrease the length and cost of the related hospital stay. In March 2008, we began a pivotal Phase 3 clinical trial of ALD-101 to further evaluate its ability to accelerate engraftment following cord blood transplants in pediatric patients with inherited metabolic diseases. We expect to complete enrollment of this trial in the first quarter of 2011 and to receive the efficacy results of the trial in the second quarter of 2011. In October 2008, we received orphan drug designation from the FDA for ALD-101 for improving engraftment times in patients with inherited metabolic diseases undergoing cord blood transplants.

•

ALD-301 to treat critical limb ischemia. ALD-301 is the population of ALDH^br stem cells we produce using our proprietary technology to sort a specified quantity of bone marrow collected from the patient receiving the therapy. ALD-301 is injected into the patient’s leg muscle. In 2008, we completed a 21-patient Phase 1/2 clinical trial of ALD-301 to assess its safety and potential efficacy as a treatment for advanced critical limb ischemia in patients with no revascularization treatment options. The product candidate was well-tolerated, and we believe that the trial data provided initial evidence of improved blood flow and improved clinical status within the ALD-301 treatment group. For example, at 24 weeks following the injection, ten of the 11 patients in the ALD-301 treatment group were alive and

had not required amputation of their affected limbs. Typically, up to 35% of critical limb ischemia patients with no options for restoring blood supply to the affected limb require an amputation within six months. In August 2009, we received an SPA concurrence letter from the FDA for the design of a pivotal Phase 3 clinical trial of ALD-301 for the treatment of critical limb ischemia. We plan to commence enrollment of the pivotal trial in 2010.

•

ALD-201 to treat ischemic heart failure. ALD-201 is the population of ALDH^br stem cells we produce using our proprietary technology to sort a specified quantity of bone marrow collected from the patient receiving the therapy. ALD-201 is injected directly into the patient’s heart muscle. This procedure is currently performed using a specialized catheter. Investigators have completed a 20-patient Phase 1 clinical trial of ALD-201 to assess its safety and potential efficacy as a treatment for ischemic heart failure in patients with no further options for restoring blood supply to the heart. The product candidate was well-tolerated, and we believe that the trial data provided initial evidence of improved blood flow and improved clinical status within the ALD-201 treatment group.

We manufacture all of our product candidates at a facility located at our corporate headquarters in Durham, North Carolina. We believe that this facility is in substantial compliance with the current good manufacturing practices, or cGMP, and current good tissue practices, or cGTP, standards required by the FDA. We believe that our current facility has the capacity to manufacture the quantities of our product candidates necessary for Phase 3 clinical trials of ALD-101, ALD-301 and ALD-201, as well as initial commercial quantities of ALD-101 if it is approved for marketing. In addition, we believe that we can scale our current manufacturing process to support future clinical development programs and potential commercialization efforts.

Our technology and the stem cell populations it produces, which form the basis for our current product candidates, are protected by an intellectual property portfolio consisting of four issued U.S. patents and four U.S. patent applications, as well as a number of issued foreign patents and pending foreign patent applications. Our issued patents and pending patent applications cover the method we use to manufacture ALDH^br cell populations, the chemistry used in this manufacturing process, kits that embody this chemistry, the composition of ALDH^br cell populations and the therapeutic use of these cell populations. We believe that the patents and patent applications that cover our current product candidates and our technology will generally be applicable to other target indications that we may seek to pursue in the future.

Our Business Strategy

•

Continue clinical development of our most advanced product candidates. We are currently enrolling patients in a pivotal Phase 3 clinical trial of ALD-101, for which we expect to receive final efficacy results in the second quarter of 2011. We have also completed a Phase 1/2 clinical trial of ALD-301, and we intend to commence enrollment of a pivotal Phase 3 clinical trial of ALD-301 to treat critical limb ischemia in 2010. Investigators have completed a Phase 1 clinical trial of ALD-201. Based on the results of this trial, we plan to seek a third-party collaborator to help us conduct and fund larger, later-stage clinical trials of ALD-201.

•

Commercialize our cord blood transplant product candidates with an internal sales force. Children receiving cord blood transplants for the treatment of inherited metabolic diseases are treated at a

relatively small number of treatment centers in the United States. Our pivotal Phase 3 clinical trial of ALD-101 is currently being conducted at three of these treatment centers, and we are recruiting additional centers for the trial. We estimate that the investigators in our ALD-101 clinical trial treat the majority of the pediatric patients in the United States receiving cord blood transplants for inherited metabolic diseases. Because of the relatively small number of treatment centers and investigators involved in cord blood transplants for pediatric inherited metabolic diseases, we believe that we can effectively market ALD-101 using a small, focused and specialized internal sales force. In addition, we expect that we will be able to use the experience of an internal sales force gained in promoting ALD-101 to market other cord blood transplant products, such as ALD-151 or ALD-601, if they are approved for marketing by the FDA.

•

Selectively pursue strategic collaborations. We intend to explore collaboration arrangements with leading pharmaceutical or biotechnology companies for the commercialization of ALD-301 and ALD-201, which we are developing for target indications with large addressable patient populations that we believe are better served by large sales and marketing organizations. Furthermore, if we choose to pursue approval of any of our product candidates by foreign regulatory authorities, we would evaluate the potential for collaborations with third parties to assist in the development and commercialization of these product candidates in international markets.

•

Expand and enhance our manufacturing capabilities. We currently manufacture all of our product candidates for use in our clinical trials and research and development efforts at our facility located at our corporate headquarters in Durham, North Carolina. We believe that our current facility has the capacity to manufacture the quantities of our product candidates necessary for Phase 3 clinical trials of ALD-101, ALD-301 and ALD-201, as well as initial commercial quantities of ALD-101 if it is approved for marketing. In addition, we believe that we can scale our manufacturing processes to support future clinical development programs and potential commercialization of our product candidates. If any of our product candidates are approved for marketing by the FDA, we intend to manufacture these products ourselves. We are currently developing new processes and are in discussions with other companies to develop new instruments to improve our manufacturing efficiency. If we receive marketing approval for any of our product candidates, we also intend to evaluate the need for strategically located regional facilities where we could produce our cell populations in close proximity to key treatment centers or major airports.

•

Develop new product candidates to target additional indications based on our technology. We intend to continue investing in our product pipeline by pursuing additional therapeutic indications for which we believe that adult stem cell populations isolated using our proprietary technology may provide potential benefit to patients. For example, we are currently developing ALD-151 in a Phase 1 clinical trial and supporting the development of ALD-601 in a Phase 1 clinical trial. ALD-401 is in preclinical development.

Scientific Background of Stem Cells

The human body contains many types of cells, each with individual characteristics and specific functions. Cells with a defined or specialized function are called differentiated cells. Examples of differentiated cells include blood cells, nerve cells and skin cells. Stem cells are rare, undifferentiated cells within the human body that have the potential to replace and renew differentiated cells. Stem cells can also produce additional stem cells. In some cases, stem cells generate an intermediate cell type before they achieve their fully differentiated state. The intermediate cells, called progenitor cells, are partially differentiated cells that then divide and become fully differentiated cells. While stem cells may have the capability to differentiate into multiple cell types, progenitor cells are limited to differentiating along a particular cellular development pathway.

Human adult stem cells can be derived from a variety of sources, including bone marrow, blood from an umbilical cord removed after childbirth and blood circulating throughout the body, which is known as peripheral blood. Bone marrow can be obtained from a patient or from a suitable, appropriately matched donor. Blood from

umbilical cords, referred to as cord blood, is stored frozen in cord blood banks throughout the world and made available for therapeutic use. Currently, there are over 200,000 cord blood units available from public cord blood banks. Stem cells can also be derived from the tissue of human embryos, but we do not use embryonic stem cells in our product candidates. Our product candidates are derived from bone marrow and cord blood units.

There are many types of adult stem cells and progenitor cells found in the human body, including:

•

Hematopoietic stem cells. Hematopoietic stem cells generate all of the blood and immune system cells in the body, including red blood cells, platelets and neutrophils.

•

Mesenchymal stem cells. Mesenchymal stem cells differentiate into many cell types, including bone, cartilage, fat, muscle, tendon and other connective tissues.

•

Neural stem cells. Neural stem cells are capable of differentiating into neurons and cells that support nerve tissue.

•

Endothelial progenitor cells. Endothelial progenitor cells differentiate into the cells that line the blood vessels.

Many researchers believe that stem cells hold significant promise in the treatment of a wide variety of diseases. Researchers have reported progress in the development of new therapies utilizing stem cells for the treatment of cancer as well as neurological, immunological, genetic, cardiac, pancreatic, liver and degenerative diseases. In seeking to apply stem cell therapies to these diseases, researchers have explored both autologous and allogeneic stem cell therapies. Autologous therapies use stem cells derived from the patient receiving the therapy, while allogeneic therapies use stem cells derived from a separate donor.

Stem cells represent a very small fraction, typically less than 1%, of the cells in a cord blood or bone marrow source. As a result, we believe that the proper selection of the stem cells that are expected to have the greatest therapeutic effect, and the isolation of those cells from the other cells in the cord blood or bone marrow source, is critical to the successful development of any regenerative therapy based on stem cells.

Our ALDH^brTechnology

Our proprietary technology represents a novel approach to isolating adult stem cells for therapy. We identify, select and isolate adult stem cells that express high levels of the enzyme ALDH. We believe that the use of ALDH expression as a marker for stem cells has a strong biological rationale. ALDH plays an important role in controlling the developmental state of stem and progenitor cells. It converts Vitamin A into retinoic acids, which are molecules that regulate genes and influence the differentiation of blood, neural, endothelial and other types of stem and progenitor cells. To identify ALDH^br cells, we use a proprietary chemical compound that accumulates in cells with high ALDH levels and causes these cells to emit a green florescence that can be detected by a cell sorting device.

We believe that the ALDH^br stem cell populations produced using our technology have several potential advantages, including:

•

Broad potential applicability. In preclinical studies, ALDH^br cell populations produced using our technology exhibited a variety of activities that suggest these cells could be active in promoting the regeneration of multiple types of cells and tissues. Accordingly, we believe that ALDH^br cell populations may have a variety of therapeutic uses.

•

Heterogeneous mix of stem cells and progenitor cells. We believe that ALDH^br cell populations contain a diverse, or heterogeneous, mix of stem cells and progenitor cells, potentially including hematopoietic, mesenchymal and neural stem cells and endothelial progenitor cells. Other companies are pursuing stem cell therapeutic approaches to tissue repair that consist of homogeneous cell populations containing only one of these types of cells. Because of the diversity of the stem cell types included in

our ALDH^brcell populations, we believe that our cell populations may promote repair in a variety of ways. Based on preclinical research, we believe that ALDH^br cell populations promote the formation of new tissue either because progenitor cells present in ALDH^br cell populations themselves differentiate into new tissue, or because ALDH^br cells induce the generation of new tissue from existing tissue or from other progenitor cells within the patient.

•

Well-characterized stem cell populations. Our technology produces stem cell populations that are well characterized, meaning that each population produced has a high level of purity and a consistent set of physical and chemical characteristics. We believe that our ability to produce well-characterized cell populations based on ALDH activity enhances our ability to meet regulatory requirements related to the safety and efficacy of therapeutic cell products.

•

Rapid manufacturing process. Our technology currently allows for the sorting of the ALDH^br cell populations and their administration to the patient typically in less than 36 hours. We are developing process enhancements that we believe may decrease turnaround time. Additionally, the ALDH^br cell populations produced using our technology do not require any expansion in the size of the cell population or other manipulation before infusion. Other methodologies may require cell culturing, for example, which can take several days or weeks.

Our Product Development Pipeline

The following table summarizes our product candidates and their stages of clinical development. We hold the worldwide commercialization rights for each of these product candidates.


Product Candidate	Target Indications	Status of Development	Upcoming Milestones
ALD-101	Improvement of engraftment following cord blood transplants used to treat pediatric inherited metabolic diseases	Pivotal Phase 3 underway	Enrollment expected to be completed in first quarter of 2011; results expected in second quarter of 2011

ALD-301	Treatment of critical limb ischemia	Completed Phase 1/2, received SPA concurrence letter for design of pivotal Phase 3 trial	Expect to initiate Phase 3 trial in 2010

ALD-201	Treatment of ischemic heart failure	Completed Phase 1	Complete design of later-stage clinical trial program; seek collaboration to conduct and fund clinical trials

ALD-151	Improvement of engraftment following cord blood transplants used to treat leukemia in pediatric patients	Phase 1 underway	Results expected in 2010

ALD-601	Treatment of inherited metabolic diseases through in utero stem cell transplantation	Phase 1 IND cleared	Commence enrollment for Phase 1 trial

ALD-401	Post-acute treatment of ischemic stroke	Preclinical	IND submission in 2010

ALD-101 – Our Most Advanced Cord Blood Transplant Product Candidate

Background of Cord Blood Transplantation

According to the National Marrow Donor Program, an estimated 45,000 to 50,000 transplants using hematopoietic stem cells derived from bone marrow, peripheral blood or cord blood are performed annually worldwide to treat patients with life-threatening cancers as well as some inherited diseases that are not cancers. The group of diseases treatable with hematopoietic stem cell transplants include inherited metabolic diseases, such as Krabbe disease, metachromatic leukodystrophy, Hurler syndrome and adrenoleukodystrophy. These diseases are progressive, degenerative and often fatal. In many cases, the only treatment available to patients with these diseases is a hematopoietic stem cell transplant. The results of these transplants improve when children are treated early. In some cases, doctors attempt to perform transplants in children with inherited metabolic diseases within the first six months of life.

Children and adults with leukemia, a group of cancers of the blood or bone marrow characterized by abnormal proliferation of malignant blood cells that invade and disrupt the functioning of tissues, may also be candidates for hematopoietic stem cell transplants in order to restore their ability to produce new blood cells following chemotherapy. For leukemia patients with no other treatment alternatives, high doses of chemotherapy or radiation are administered to kill their cancerous cells, but this regimen also has the effect of destroying the patient’s ability to produce new blood cells. Other disorders of blood cell formation that may be treated with hematopoietic stem cell transplants include lymphomas, multiple myeloma and other plasma cell disorders, severe aplastic anemia and other marrow failure states, inherited immune system diseases, sickle cell disease and other malignancies.

Although comparable outcomes have been achieved with transplants of hematopoietic stem cells derived from bone marrow, cord blood and peripheral blood, the selection of the source of stem cells to be used in a transplant is based on several patient-specific factors. For cases in which a patient needs a transplant from another individual, also known as an allogeneic transplant, physicians usually search for a bone marrow donor or cord blood unit that closely or identically matches the patient’s human leukocyte antigen, or HLA, type. HLA markers are features of cell surfaces used by the body’s immune system to recognize which cells belong in the body and which do not. Because HLA tissue types are inherited, a patient’s best chance of finding a matched source is from a close relative. The National Marrow Donor Program estimates, however, that 70% of patients do not have a suitable bone marrow donor in their family. Finding, obtaining and qualifying an unrelated bone marrow donor for transplant can take months, often resulting in unacceptable progression of the underlying disease.

When a related, type-matched bone marrow donor cannot be located quickly or at all, the physician may recommend a cord blood transplant. In a cord blood transplant, umbilical cord blood of a known HLA type is obtained from a donor bank to be infused into the patient. The use of cord blood transplants has increased for both children and adults, but they are more frequently used in the treatment of children, such as in the case of pediatric inherited metabolic diseases and pediatric leukemias. Because the number of hematopoietic stem cells that can form blood cells in the transplant recipient is proportional to his or her weight, smaller patients need fewer hematopoietic stem cells than larger patients.

In October 2009, the FDA issued final guidance to cord blood banks outlining the BLA requirements for cord blood transplants intended to treat, among other conditions, Hurler syndrome, Krabbe disease and adrenoleukodystrophy, three of the inherited metabolic diseases that are included in our pivotal Phase 3 clinical trial of ALD-101. To our knowledge, no cord blood banks have filed a BLA under the FDA guidance, although we expect that banks will soon begin to seek such licenses.

We believe that umbilical cord blood has a number of advantages as a source of hematopoietic stem cells for transplant, compared to other potential allogeneic transplant sources such as bone marrow. In particular, a well-developed and reliable international infrastructure allows doctors to search for and obtain high-quality, type-

matched cord blood from public cord blood banks in a matter of days. Currently, there are over 200,000 publicly banked, frozen cord blood units worldwide that have been collected from healthy donors, screened for genetic diseases, tested for infectious diseases and typed by a variety of blood-matching characteristics. Compared to transplants of bone marrow from unrelated donors, cord blood transplants generally result in fewer instances of severe graft-versus-host disease, or GvHD, a condition in which a donor’s immune cells attack the patient’s body after the transplant. This lower risk of GvHD permits the matching of donor cord blood to the patient’s blood characteristics to be less exact than in the case of a bone marrow transplant, which simplifies donor selection. As a result of the availability of high-quality, type-matched cord blood from public cord blood banks and the reduced risk of severe GvHD, umbilical cord blood transplants are more common than bone marrow transplants for patients who do not have related donors.

Cord blood transplants also carry several risks. Prior to the transplant, the patient undergoes a treatment regimen involving chemotherapy that destroys the patient’s bone marrow cells. As a result, the patient has fewer platelets, which are cell fragments that circulate in the blood and promote blood clotting, and neutrophils, which are white blood cells that protect against infections. Following the cord blood transplant, new platelets and neutrophils are produced over time from the stem cells contained in the donated cord blood. During this process, known as engraftment, the donated hematopoietic stem cells establish themselves in the patient, begin to divide and then to differentiate to form new blood cells, including platelets and neutrophils. Engraftment time is generally measured as the period of time required to re-establish specified levels of platelets or neutrophils circulating in the patient’s bloodstream. Neutrophil engraftment typically takes several weeks, and platelet engraftment can take several months. The time to engraftment and the restoration of acceptable levels of platelets and neutrophils is generally longer in the case of cord blood transplants than for a matched bone marrow transplant. Following the transplant, while platelet and neutrophil levels are depressed, there is significant risk of life-threatening infections, bleeding and transfusion-related reactions. During this engraftment period, patients are typically isolated in special hospital sterile rooms and may require repeated platelet transfusions. We believe that a reduction in engraftment times could reduce these risks associated with conventional cord blood transplants and decrease the length and cost of the related hospital stay and the cost of post-hospitalization treatment for these patients.

Trinity Partners, a consulting firm specializing in the pharmaceutical and biotechnology industries, estimates that over 1,600 cord blood transplants will be performed in 2009 in the United States and Europe and that the total will grow to over 2,600 cord blood transplants in 2012. Trinity Partners estimates that about half of these cord blood transplants are administered to pediatric patients to treat inherited metabolic diseases and pediatric leukemias. Data from the National Marrow Donor Program cited by Trinity Partners indicate that the proportion of hematopoietic stem cell transplants utilizing cord blood, as opposed to bone marrow or peripheral blood, is growing.

Preclinical Research — Rationale for the Use of ALDH^br Cell Populations in Cord Blood Transplants

We and researchers at other institutions, including Duke, Washington University in St. Louis and the Terry Fox Laboratory, have conducted preclinical research indicating that ALDH^br cell populations exhibit hematopoietic, or blood production, activity. In these studies, when researchers used our technology to sort human cord blood, they produced isolated ALDH^brcell populations that included:

•

a high concentration of the multilineage hematopoietic stem cells, which are very early-stage stem cells that are capable of differentiating into any type of blood cell, contained in the original cord blood;

•

virtually all of the human stem cells contained in the original cord blood unit that durably engrafted in mice with compromised immune systems, meaning that those stem cells were able to continue to generate blood cells and regenerate themselves beyond eight weeks; and

•

virtually all of the early-stage platelet progenitor cells contained in the original cord blood.

In a preclinical study on which we collaborated with researchers at Duke, we studied data from prior cord blood transplants and were able to retrospectively predict whether the dose of ALDH^br cells delivered in a particular cord blood unit would result in neutrophil engraftment. In this study, researchers analyzed a small sample of the specific cord blood units that had been transplanted in previous procedures. In each case, these samples had been set aside and saved in a frozen state for future research. The researchers determined the number of ALDH ^br cells present in each of the preserved samples and compared that data with the ultimate outcome of the corresponding transplant. In this study, whether engraftment occurred was correlated with the number of ALDH^br cells in the originally transplanted cord blood. We believe that this study suggests that the dose of ALDH^br cells in a cord blood unit may be a determinant of whether that unit ultimately results in platelet and neutrophil engraftment.

We also believe that isolating the ALDH^br cells from the cord blood has clinical benefits. Although an unsorted cord blood unit would be expected, on average, to include a similar number of ALDH^br cells to that of a sorted ALDH^br cell population, sorting removes other cell types that might impair the ability of the ALDH^br cells to engraft. Because ALDH^br cells make up only a very small portion of the total cells in a cord blood unit, and sorting removes the other cells, the sorted cell population will have a much higher percentage of ALDH^br cells than an unsorted cell population.

We performed a preclinical study in collaboration with investigators at Duke to evaluate neutrophil and platelet engraftment of sorted ALDH^br cell populations in mice, as compared to unsorted cord blood containing the same number of ALDH^br cells. In this study, four weeks after the cells were administered to mice whose immune functions had been compromised, more human cells were recovered from the bone marrow of the mice receiving the sorted ALDH^br cell populations than those receiving the unsorted cord blood. The sorted ALDH^br cell populations yielded over 10 times more human neutrophils and other cells that are clinically important than did the unsorted cord blood. The presence of human platelets reached levels of detectability in the mice that received the sorted ALDH^br cell populations but was undetectable in the mice that received the unsorted cord blood. We believe that this research suggests that there may be other factors in unsorted cord blood that impede the ability of ALDH^br cells to engraft and develop into blood cells and that sorting can remove these other factors.

In this study, we also administered unsorted cord blood to a group of the immune-compromised mice and then, four hours later, administered a sorted ALDH^br cell population to the same animals. This procedure models the way that ALD-101 is administered in our clinical trials to supplement transplantation with unsorted cord blood. Four weeks later, the mice had developed human neutrophils, other cells that are clinically important and detectable levels of human platelets in the blood in numbers similar to the mice that had received only the sorted ALDH^br cell population. This suggests that factors in unsorted cord blood that may impede the ability of ALDH^br cells to engraft and develop into blood cells are no longer active when ALDH^br cells are administered four hours after unsorted cord blood.

Based on this preclinical research, we believe that ALDH^brstem cell populations may encourage stable, accelerated and long-term engraftment following a cord blood transplant. We also believe that administering sorted ALDH^br cells following a conventional cord blood transplant may promote improved engraftment when compared to administering unsorted conventional cord blood units.

We commenced our clinical trials of ALD-101 to evaluate this potential.

ALD-101

ALD-101 is the population of sorted ALDH^brstem cells we produce from a portion of a cord blood unit using our proprietary technology. We are developing ALD-101 to improve engraftment following cord blood transplants used to treat pediatric inherited metabolic diseases. In October 2008, we received orphan drug designation from the FDA for ALD-101 for this indication.

The production of ALD-101 begins when a physician orders a cord blood unit from a cord blood donor bank. Banked cord blood units are customarily frozen and packaged in a dual compartment bag, with 80% of the blood unit in one compartment and 20% in the other. The original banked cord blood unit is delivered frozen to the hospital where the transplant will occur. The hospital removes and delivers the 20% portion of the unit to us at our manufacturing facility and retains the 80% portion to be transplanted into the patient. We process the portion of the cord blood unit we receive to isolate and capture the ALDH^br cells. Typically within 24 hours of our receipt of the 20% portion of the cord blood unit, we ship the resulting ALD-101 to the hospital. ALD-101 is then infused into the patient approximately four hours after the transplantation of the 80% portion of the cord blood unit.

Market Opportunity for ALD-101

In a study that we commissioned, Trinity Partners estimates that there are over 12,000 patients in the United States and Europe living with the inherited metabolic diseases included in our pivotal Phase 3 clinical trial of ALD- 101. The inclusion criteria for the pivotal Phase 3 clinical trial include patients with Krabbe disease, metachromatic leukodystrophy, Hurler syndrome, adrenoleukodystrophy and 13 other inherited metabolic diseases. Trinity Partners also estimates that approximately 700 children in the United States and Europe are born with these diseases each year. Not every patient diagnosed with one of these inherited metabolic diseases will undergo a hematopoietic stem cell transplant, and some of those who are diagnosed with these diseases will undergo a bone marrow transplant, rather than a cord blood transplant, if a type-matched bone marrow donor can be located. We believe, however, that the implementation of newborn screening for inherited metabolic diseases, such as a pilot program initiated in the State of New York in 2006 to screen for Krabbe disease, could lead to earlier and wider identification of pediatric patients that can be effectively treated with cord blood transplants.

According to the Healthcare Cost and Utilization Project, a family of databases sponsored by the Agency for Healthcare Research and Quality of the U.S. Department of Health and Human Services, the median cost of the initial hospital stay associated with a cord blood transplant in the United States is approximately $360,000, including costs associated with post-transplant complications during hospitalization, such as infections and GvHD. In an analysis prepared for us in connection with potential product pricing, Trinity Partners assumes that non-hospitalization costs associated with a cord blood transplant average approximately $197,000. We believe that ALD-101, if proven to be effective in accelerating engraftment times in patients following a cord blood transplant, could result in a reduction in post-transplant complications and a corresponding decrease in the length of the average hospital stay and the related costs of care.

Clinical Development of ALD-101

Phase 1 Clinical Trial

In the second half of 2008, investigators completed a 24-patient Phase 1 clinical trial of ALD-101, which we refer to as the UCBT-001 trial. This trial was conducted at Duke.

Trial Design. The UCBT-001 trial was a single-arm study, meaning that all subjects received ALD-101. In this trial, investigators infused ALD-101 into patients approximately four hours after the transplant of the 80% portion of the cord blood unit. Investigators monitored patients over a one-year period following the transplant to observe safety of the infusion, the rate of platelet and neutrophil engraftment and clinical outcomes.

Endpoints. The primary objective of the UCBT-001 trial was to evaluate the safety of ALD-101. Endpoints of the trial included the time to neutrophil and platelet engraftment, overall survival at day 180, median time to reconstitution of the immune system and the incidence and severity of GvHD. For purposes of this trial, platelet engraftment was defined as the restoration of platelet levels to at least 50,000 per microliter of blood for three consecutive days without a platelet transfusion during the preceding seven days. Neutrophil engraftment was defined as the restoration of circulating absolute neutrophil count to at least 500 per microliter of blood for three consecutive measurements over three or more days prior to day 42. Investigators also monitored patients for any adverse events associated with the administration of ALD-101.

We compared the patient outcomes in the UCBT-001 trial to patient outcomes observed in a subset of subjects in the Cord Blood Transplantation, or COBLT, trial sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health. The COBLT trial was a Phase 2 clinical trial that commenced in 1999 and was completed in 2007. The study included 364 cord blood transplant patients at 26 participating institutions, including 69 patients with inherited metabolic diseases. The goal of the COBLT trial was to determine if banked cord blood from unrelated donors could serve as an adequate hematopoietic stem cell source for adults and children with malignancies, immune deficiencies, inherited bone marrow failure, or inherited metabolic diseases. The largest group of patients in the COBLT trial were pediatric patients with various leukemias.

The primary endpoint of the COBLT trial was 180-day survival after the cord blood transplant. Secondary endpoints of the COBLT trial included disease-free survival and platelet and neutrophil engraftment, using the same standard measures of platelet and neutrophil levels used in the UCBT-001 trial, the frequency and severity of acute and chronic GvHD, overall patient survival and immune system reconstitution.

Inclusion and Exclusion Criteria. The primary inclusion criterion for the UCBT-001 trial participants was a diagnosis of a hematological malignancy, such as leukemia, an inherited metabolic disease or one of a variety of other conditions. Of the patients enrolled in the trial, 11 had been diagnosed with leukemia and other non-metabolic diseases and 13 had been diagnosed with an inherited metabolic disease. Key exclusion criteria for the trial participants were active central nervous system disease in patients with malignancies, uncontrolled infection, life expectancy of less than three months, and other specified conditions that would render the patient at too high of a risk for treatment. These patient inclusion and exclusion criteria were largely the same as those used in the COBLT trial.

Results. The adverse event profile of patients in the UCBT-001 trial was similar to that reported in the COBLT trial, and we did not observe any toxicity associated with the ALD-101 infusion. The results of the UCBT-001 trial did not indicate any increase in the rate of failure of the recipients to accept the transplanted cells when compared with the COBLT trial or any delay in platelet or neutrophil engraftment when compared to the COBLT trial. The overall survival rates at 180 days in the UCBT-001 trial were higher than the comparable rates observed in the COBLT trial.

In the UCBT-001 trial, observed engraftment results included:

•

statistically significant reduction in the median time to platelet engraftment, compared to the COBLT trial;

•

statistically significant improvement in the cumulative incidence of platelet engraftment, which means the percentage of patients who achieved platelet engraftment, at 180 days following the cord blood transplant, compared to the COBLT trial;

•

statistically significant reduction in the median time to neutrophil engraftment, compared to the COBLT trial; and

•

statistically significant improvement in the cumulative incidence of neutrophil engraftment at 42 days following the cord blood transplant, compared to the COBLT trial.

The following table compares the engraftment results of the 12 patients in the UCBT-001 trial who suffered from inherited metabolic diseases and commenced the trial with a Lansky performance score of 80% or higher with the results of the 57 patients in the COBLT trial who fit the same description. The Lansky performance score is a standard scale used by clinicians to assess a patient’s physical and mental developmental status. Researchers have observed that patients with inherited metabolic diseases and Lansky performance scores of less than 80% tend to do poorly following a cord blood transplant. Consequently, researchers now consider such patients to be poor transplant candidates. The original protocol for the UCBT-001 trial did not specify that we analyze the specific endpoints and subgroups in the table below and it did not contemplate that we would exclude

the patients with Lansky performance scores below 80%. We believe, however, that excluding the patients with Lansky performance scores below 80% is appropriate in this analysis because it more closely tracks current treatment conventions. We are also excluding these patients from participating in our ongoing pivotal Phase 3 clinical trial of ALD-101.

For the purposes of the following table, we determined statistical significance based on a widely used, conventional statistical method that establishes a measure known as the p-value of clinical results. Under this method, a p-value of 0.05 or less represents statistical significance, meaning that there is a less than one-in-twenty likelihood that the observed results occurred by chance.


Endpoint	UCBT-001 (n=12)		COBLT (n=57)		p-value
Median time to platelet engraftment	53 days		97 days		0.04
Cumulative incidence of platelet engraftment at day 180	83.3	%	64.9	%	0.04
Median time to neutrophil engraftment	19 days		24 days		0.03
Cumulative incidence of neutrophil engraftment at day 42	91.7	%	78.9	%	0.03

Pivotal Phase 3 Clinical Trial

In the first half of 2008, we began a pivotal Phase 3 clinical trial, which we refer to as the UCBT-002 trial. The purpose of the UCBT-002 trial is to further evaluate the efficacy of ALD-101 in accelerating the engraftment of platelets and neutrophils in pediatric patients undergoing cord blood transplants for the treatment of inherited metabolic diseases. We anticipate that we will complete enrollment of the patients in the first quarter of 2011 and that the efficacy results of this trial will be available in the second quarter of 2011.

Trial Design. The design of the UCBT-002 trial is similar to that of the UCBT-001 trial, with the exception that the UCBT-002 trial will be conducted at multiple sites, the number of patients to be enrolled will be increased to 40 patients, all of whom will be children with inherited metabolic diseases and Lansky scores of at least 80%, and the primary endpoint will be time to platelet engraftment. The UCBT-002 trial is a single-arm trial. As with the UCBT-001 trial, we will compare results for patients treated with ALD-101 in the UCBT-002 trial to results for patients who received cord blood transplants for inherited metabolic diseases and had Lansky scores of at least 80% in the COBLT trial. Lansky scores were not part of the inclusion or exclusion criteria for enrollment in the COBLT trial.

The UCBT-002 trial will be monitored by an independent data safety and endpoint committee. This committee of experts in the field of cord blood transplantation will be responsible for comparing the safety of the patients enrolled in our trial against the known adverse events observed in the historical cord blood transplantation literature as well as in the COBLT trial and in the UCBT-001 trial. The charter of the committee requires review of safety and efficacy endpoints after the 180-day follow-up evaluations of the first 20 patients. After that review, the committee will make recommendations to us relating to continuation of the trial based on predetermined parameters.

Although the FDA prefers the use of randomized, controlled trials, in which enrolled patients are randomly assigned to one of two treatment groups, and has raised specific concerns about the use of a single-arm study with a historical control for the UCBT-002 trial, the FDA has acknowledged the unique issues associated with our targeted patient population for ALD-101. However, the FDA may require that we complete a randomized, controlled trial of ALD-101 with appropriately sized treatment and concurrent control groups before it would agree to review a biologics license application, or BLA, for marketing approval. We believe that enrolling such a trial would take approximately five to seven years due to the limited number of pediatric patients with inherited metabolic diseases. In such a lengthy trial, investigators might also seek to change treatment regimens, which could cause additional enrollment delays.

The FDA also has raised concerns regarding the acceptability of the COBLT trial as the specific historical comparator for the UCBT-002 trial. We believe, however, that the COBLT trial is the best historical control

comparator for the UCBT-002 trial because the COBLT trial was a relatively large trial conducted by an independent party that included patients from the same patient population that we are using in the UCBT-002 trial. There is substantial similarity in treatment regimens, endpoint measurements, patient inclusion and exclusion criteria and patient population between the COBLT trial and the UCBT-002 trial.

The FDA has stated that time to engraftment in the COBLT trial was longer than in other published studies, raising the possibility that a comparison of our results to the COBLT trial will be seen by the FDA as overstating the potential efficacy of ALD-101. The FDA asked us to comment on this discrepancy. In our response to the FDA, we reviewed the published studies they cited and concluded that, in each case, either the study was not comparable to the COBLT trial or there were unrelated reasons for the shorter engraftment times. However, the FDA may ultimately disagree with our view.

The FDA has suggested that, as an alternative to the COBLT trial, we consider using a case-match historical control trial, which would involve seeking specific cases in historical databases that match a variety of clinical characteristics similar to those of each patient being studied in the UCBT-002 trial. These cases would then serve as the control group for comparative purposes. We are currently evaluating several historical databases, including the COBLT trial results, to determine the likelihood that they include suitable historic cases for use in a case-match historical control. If the FDA does not ultimately agree with our use of the COBLT trial as a historical control, we believe that we could implement a case-match historical control procedure, which we would then apply after the actual results from the patients in the UCBT-002 trial are revealed to us by our investigators.

Endpoints. The primary endpoint of the UCBT-002 trial is the time to platelet engraftment. Secondary endpoints of this trial include the time to neutrophil engraftment and the incidence of platelet and neutrophil engraftment. We are also evaluating the safety profile of ALD-101 as well as overall patient survival rates. For purposes of the UCBT-002 trial, platelet and neutrophil engraftment will be measured in the same manner as in the UCBT-001 trial.

Inclusion and Exclusion Criteria. The patient inclusion and exclusion criteria to be used in the UCBT-002 trial are largely the same as those used for patients with inherited metabolic diseases in the COBLT trial. The primary inclusion criterion for the UCBT-002 trial is a diagnosis of one of several inherited metabolic diseases, including Krabbe disease, metachromatic leukodystrophy, Hurler syndrome and adrenoleukodystrophy. Key exclusion criteria include uncontrolled infections, uncontrolled seizures, apnea, evidence of aspiration pneumonia, prior allogeneic stem cell transplant within 12 months of enrollment, availability of related donors that are type-matched, and evidence of brain stem involvement on MRI scans. In the UCBT-002 trial, but not in the COBLT trial, subjects must also have a Lansky performance score of at least 80%.

Plans for Future Development. If the UCBT-002 trial yields positive results, we intend to submit a BLA to the FDA seeking marketing approval for ALD-101. We may also initiate clinical trials to evaluate the efficacy of ALD-101 in accelerating the engraftment time of platelets and neutrophils in pediatric patients undergoing cord blood transplants for the treatment of leukemias.

ALD-301 and ALD-201—Our Most Advanced Cardiovascular Product Candidates

Preclinical Research—Rationale for the Use of ALDH^br Cell Populations in Cardiovascular Ischemic Repair

Preclinical research suggests that ALDH^br cells derived from bone marrow may promote the repair of ischemic tissue damage, which is tissue damage caused by inadequate blood flow resulting from the obstruction of blood vessels supplying blood to the tissue. Decreased blood flow causes a shortage of oxygen in the tissue, or ischemia, because oxygen is carried to tissue by red blood cells. One way in which ALDH^br cells may contribute to tissue repair is by promoting the creation of new blood vessels in the damaged tissue, which could result in an influx of cells and other molecules that are necessary for tissue repair.

To test the hypothesis that ALDH^br cells promote the formation of new blood vessels, which could in turn promote the repair of ischemic tissue damage, we commissioned a preclinical animal study at the Washington University School of Medicine. This study used a mouse model of hind limb ischemic damage. In this study, researchers induced ischemic damage in one leg of each mouse. Researchers then injected the mice with one of the following:

•

a vehicle control, which contained the solution in which the other cell populations described below were suspended, but no cells;

•

a cell population consisting of unsorted human bone marrow cells;

•

a cell population consisting of all the non-ALDH^br cells sorted from human bone marrow, which we refer to as ALDH^low cells; or

•

a cell population consisting of all the ALDH^br cells sorted from human bone marrow.

The researchers then observed the mice at four days, seven days, 10 days, 14 days and 21 days after the injection and measured the amount of blood flow, or perfusion, using laser Doppler imaging. Results were expressed as the ratio of perfusion in the ischemic limb after the injection as compared to perfusion in a non-ischemic limb of the mouse. Key findings of this study included:

•

mice receiving ALDH^br cells experienced more improvement in blood flow to the injured tissue within one week of injection than did mice in the vehicle control group, and the improvement in blood flow compared to the vehicle control group increased progressively over the first three weeks of the experiment, and doubled the extent of improvement over the vehicle control group at day 21;

•

mice receiving ALDH^low cells did not experience any more improvement in blood flow to the injured tissue than did the vehicle control group as measured at the first four measurement dates, with only minor improvement at the 21-day measurement; and

•

mice receiving ALDH^br cells experienced more blood flow improvement than did those receiving unsorted human bone marrow cells, which we believe suggests that other cells or proteins in bone marrow may inhibit tissue repair activity and that sorting and isolating ALDH^br cells may increase their effectiveness in repairing ischemic damage.

The following chart illustrates these results.

LOGO

The researchers in this study also examined mice from each group following the end of the study to determine the density of capillaries, which are small blood vessels, at the site of the tissue damage. Capillary density was measured by counting the number of capillaries in a given volume of tissue and was expressed as a percentage of the capillary density of the vehicle control group. The following chart indicates the changes in capillary density. Only the mice that received injections of ALDH^br cells exhibited a statistically significant increase in capillary density when compared to the vehicle control group. The p-value for this increase was less than 0.05.

LOGO

The researchers also injected into the mice ALDH^br or ALDH^low cells that had been labeled with material allowing them to be detected by magnetic imaging. This allowed the investigators to determine the final location of the injected cells in the mice. The investigators observed that ALDH^br cells were highly concentrated at the site of the ischemic damage and that these ALDH^br cells could be detected at the damage site for up to two weeks after injection. ALDH^low cells, on the other hand, could not be detected at the damage site. This research suggests that ALDH^br cells may specifically migrate to sites of ischemic damage and induce the formation of new blood vessels, a process known as angiogenesis, at those sites.

We have performed further preclinical research into the potential mechanisms by which ALDH^br cell populations might promote angiogenesis. While progenitor cells present in ALDH^br cell populations might themselves differentiate into blood vessels, we believe that ALDH^br cells might also induce the generation of new blood vessels from existing vessels or from other progenitor cells within the patient by secreting angiogenic proteins and providing chemical signals that promote angiogenesis. In our preclinical research, we have observed a number of growth-enhancing and protective characteristics of ALDH^br cells, including:

•

ALDH^br cells produce factors that protect endothelial cells, which are the cells that line the blood vessels, from damage under conditions of inadequate oxygen and nutritional stress;

•

ALDH^br cells highly express many angiogenic growth factors, proteins and cellular matrix remodeling molecules;

•

The expression of 35 different angiogenic factors is increased, or upregulated, in ALDH^br cells exposed to endothelial cells under conditions of inadequate oxygen;

•

ALDH^br cells protect serum-starved endothelial cells from cell death; and

•

ALDH^br cells rapidly migrate to and are retained at the sites of ischemic endothelial cells.

Based on this preclinical research, we believe that ALDH^br cells are useful in the treatment of ischemic diseases because they may induce angiogenesis at sites of ischemic damage and promote perfusion. We initiated a Phase 1/2 clinical trial of ALD-301 and sponsored a Phase 1 clinical trial of ALD-201 to evaluate their safety and potential efficacy in treating critical limb ischemia and ischemic heart failure, respectively.

ALD-301

To produce ALD-301, we receive 150 milliliters of bone marrow extracted from the patient. At our manufacturing facility, we process the bone marrow to isolate and capture the ALDH^br cells. Typically within 36 hours of our receipt of the bone marrow, we deliver the resulting ALD-301 cells either to an interventional cardiologist or to a vascular surgeon, who then administers ALD-301 to the patient by intramuscular injection into the patient’s leg. A total of 10 milliliters of ALD-301 is administered in ten 1-milliliter injections.

Critical Limb Ischemia

Critical limb ischemia is a condition characterized by significant impairment of blood flow to the legs and feet caused by a blockage of the arteries. Patients with severe cases of critical limb ischemia may experience persistent pain in their lower extremities and may also suffer from severe tissue damage in the affected area. There are no drugs currently approved by the FDA for the treatment of this condition. The predominant treatment options for patients with critical limb ischemia are surgical procedures to restore blood flow, or revascularization, such as implanting a new blood vessel to bypass the blockage, or endovascular approaches, such as angioplasty, in which the vessel is unblocked from the inside using a balloon catheter or by installing a stent inside the vessel to maintain its opening.

The American College of Cardiology and the American Heart Association estimate that 50% of patients with a diagnosis of critical limb ischemia will either die or require amputation of the affected limb within one year of diagnosis. In a study published in the journal Cardiovascular and Hematological Disorders, researchers estimated that approximately 10% to 40% of critical limb ischemia patients are not considered candidates for surgical revascularization or endovascular procedures. For these patients, amputation is often the only available clinical option. The Sage Group, an independent research and consulting firm specializing in vascular diseases in the lower limbs, estimates that within six months of diagnosis up to 35% of critical limb ischemia patients will require limb amputation and approximately 20% will die.

Market Opportunity for ALD-301

The Sage Group estimates that approximately 2.0 million people in the United States have been diagnosed with critical limb ischemia and projects that this patient population will grow to nearly 2.8 million by 2020. The Sage Group also estimates that there are approximately 160,000 leg amputations performed on critical limb ischemia patients annually in the United States. According to the Healthcare Cost and Utilization Project, the median hospital cost associated with a leg amputation was approximately $38,000 in 2005.

Clinical Development of ALD-301

In the fourth quarter of 2008, we completed a 21-patient Phase 1/2 clinical trial of ALD-301. We conducted this trial at five sites in the United States to evaluate the safety and potential efficacy of ALD-301 as a treatment for patients with advanced critical limb ischemia.

Trial Design. This trial was a randomized, controlled trial with two treatment groups. A total of 21 patients were randomly selected to receive an injection of either ALD-301 or an unsorted quantity of their own bone marrow. We elected to use unsorted bone marrow as the control for this trial to facilitate recruitment of patients, because clinical studies using unsorted bone marrow cells have indicated that they may promote the restoration of limb function and the repair of tissue damage where there has been a loss of blood supply. Of the 21 patients in the trial, 11 were treated with ALD-301 and 10 were treated with unsorted bone marrow. The trial was double- blind, meaning that neither the clinician or the sponsor, on the one hand, nor the patient, on the other hand, knew the group to which the patient had been assigned. Thirteen of the patients were male and eight were female. The mean age of the patients was 72 years old. Ten of the patients had been diagnosed with diabetes.

Endpoints. The primary objective of this trial was to evaluate the safety of ALD-301. Patients were monitored for serious adverse events, including death, amputation, stroke, heart attack and hospitalization. Secondary endpoints of the trial included change in clinical status from baseline to 12 weeks, as measured by the Rutherford scale, a well- accepted clinical categorization for the extent of critical limb ischemia. The Rutherford scale places patients in one of the following seven categories based on their clinical status:

•

Category 0 patients are not symptomatic;

•

Category 1 patients experience mild claudication, or cramp-like pains after activities such as walking;

•

Category 2 patients experience moderate claudication;

•

Category 3 patients experience severe claudication;

•

Category 4 patients experience ischemic pain while at rest;

•

Category 5 patients have suffered minor tissue loss; and

•

Category 6 patients have suffered major tissue loss.

In addition, we measured change in clinical status by two other well-accepted clinical tools for assessing the extent of critical limb ischemia, the ankle-brachial index or ABI, and transcutaneous pressure of oxygen, or TcPO₂. ABI measures the ratio of blood pressure in the leg to blood pressure in the arm. When blood flow is increased in the leg, the blood pressure in the leg more closely approaches blood pressure in the arm providing for a higher ratio. TcPO₂ measures oxygen in the skin tissues of the leg. When blood flow is increased, TcPO₂, measured in millimeters of mercury, or mmHg, also increases because blood carries oxygen to the tissues. Other endpoints included change in ulceration and change in nerve conduction ability. We assessed patients in this clinical trial for endpoints for the first 12 weeks after injection and followed them for a total of 24 weeks after injection.

Inclusion and Exclusion Criteria. Only patients assessed within categories 4 or 5 on the Rutherford scale who had no revascularization treatment options and exhibited objective evidence of severe peripheral arterial disease, among other criteria, were eligible for participation in this clinical trial. Patients with poorly controlled diabetes, renal insufficiency, congestive heart failure, cognitive impairments or a past malignancy affecting the bone marrow were excluded from participation in the trial.

Safety Results. Both ALD-301 and the unsorted bone marrow cells were well-tolerated. None of the patients in either treatment group experienced a serious adverse event that was considered by the clinical investigators to be related to treatment. Over the course of the trial, one patient in the ALD-301 treatment group and one patient in the unsorted bone marrow treatment group required amputation of the treated leg. The data safety monitoring board for the trial determined that the safety results supported further study of ALD-301 in critical limb ischemia.

Efficacy Results. We observed the following regarding clinical status:

•

At 12 weeks following the injection, the mean Rutherford category of the patients in the ALD-301 treatment group improved from 4.1 at baseline to 3.5 at 12 weeks. Four of the 11 patients in the ALD-301 treatment group experienced an improvement in Rutherford category to the degree that they were no longer classified as having critical limb ischemia. None of the 11 patients in the ALD-301 treatment group experienced any worsening in Rutherford category.

•

At 24 weeks following the injection, ten of the 11 patients in the ALD-301 treatment group were alive and had not required amputation of their affected limbs. Typically, up to 35% of critical limb ischemia patients with no revascularization treatment options require an amputation within six months.

Additionally, measurements at 12 weeks following injection were consistent with our hypothesis that the angiogenic properties of the ALDH^br cell populations may help restore blood flow in areas of ischemia and bring about the clinical improvements we observed. Specifically, we observed the following changes in blood flow in the treated limb:

•

The mean ABI of the patients in the ALD-301 treatment group increased from 0.22 at baseline to 0.36 at 12 weeks. This ABI improvement of 0.14 was statistically significant, with a p-value of 0.03. None of the 11 patients in the ALD-301 treatment group experienced a decline in ABI. An improvement in ABI of 0.1 is viewed as clinically meaningful.

•

The mean TcPO₂ of the patients in the ALD-301 treatment group improved from 33.6 mmHg at baseline to 40.2 mmHg at 12 weeks. Two of the nine patients in the ALD-301 treatment group with an evaluable baseline and 12-week TcPO₂ measurement experienced a decline in TcPO₂. We view this improvement in mean TcPO₂ as clinically meaningful because patients with a TcPO₂ value of greater than 30.0 mmHg have the ability to heal their skin ulcers.

Although this study was not powered to detect a difference between the ALD-301 treatment group and the unsorted bone marrow treatment group, there were indications that the ALD-301 may have outperformed the unsorted bone marrow treatment group, including:

•

Two of the 10 patients in the unsorted bone marrow treatment group experienced a worsening in Rutherford category, while none of the 11 patients in the ALD-301 treatment group experienced a worsening.

•

There was a similar mean increase in ABI among the unsorted bone marrow treatment patients as a group to that in the ALD-301 treatment group. However, none of the 11 patients in the ALD-301 treatment experienced a decline in ABI, while one of the nine patients in the unsorted bone marrow treatment group with an evaluable baseline and 12-week ABI measurement experienced a decline.

•

The mean improvement from baseline in TcPO₂ for the unsorted bone marrow treatment group was 0.7 mmHg compared to a mean improvement of 6.6 mmHg in the ALD-301 treatment group.

Planned Pivotal Phase 3 Clinical Trial

In August 2009, based on the data from our Phase 1/2 trial, we received an SPA concurrence letter from the FDA for the design of a pivotal Phase 3 clinical trial of ALD-301 for the treatment of critical limb ischemia. An SPA is a written agreement between the trial’s sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of the Phase 3 trial to be used in support of a BLA. The SPA concurrence letter we received from the FDA states that the planned Phase 3 trial is adequately designed to provide necessary data that, depending on its outcome, could support a BLA submission. We intend to commence this pivotal trial in 2010. Before we commence this trial, however, we must resolve a partial clinical hold on the existing IND for ALD-301 relating to three CMC issues, which we are currently addressing.

Trial Design. The Phase 3 trial will be a double-blind, placebo-controlled trial designed to assess the ability of ALD-301 to improve clinical outcomes in patients with critical limb ischemia. The trial size will be approximately 750 patients, with equal numbers randomly receiving an injection of either ALD-301 or placebo in the affected limb. Up to four interim analyses are planned to allow an independent data monitoring committee to review the appropriateness of the sample size and whether the trial should be terminated early, either for positive or negative reasons. The first interim analysis is scheduled to occur after the first 75 patients have completed their six-month follow-up evaluations, which we anticipate will occur within 18 months after the trial is initiated.

Endpoints. The primary endpoint of the Phase 3 trial will be amputation-free survival over 24 weeks for critical limb ischemia patients receiving ALD-301 compared to those receiving the placebo. Amputation-free survival means the patient is still alive and has not undergone a major amputation of the affected limb. Secondary endpoints of this trial include reduction in ischemic rest pain, improvement in the incidence of complete ulcer healing, improvement in Rutherford category, increase in tissue oxygenation and change from baseline in ABI score.

Inclusion and Exclusion Criteria. Only patients assessed within categories 4 or 5 on the Rutherford scale who have no revascularization treatment options and have exhibited objective evidence of severe peripheral arterial disease, among other criteria, will be eligible for participation in this clinical trial. Patients with poorly controlled diabetes, renal insufficiency, congestive heart failure or a past malignancy or previous chemotherapy or radiation affecting their bone marrow will be excluded from participation in the trial. These patient inclusion and exclusion criteria are similar to those used in the Phase 1/2 trial of ALD-301.

Plans for Future Development. If the results of the pivotal Phase 3 clinical trial are positive, we intend to submit a BLA to the FDA seeking marketing approval for ALD-301.

ALD-201

To produce ALD-201, we receive 100 milliliters of bone marrow collected from the patient. At our manufacturing facility, we process the bone marrow to isolate and capture the ALDH^br cells. Typically within 36 hours of our receipt of the bone marrow, we deliver the resulting ALD-201 to an interventional cardiologist, who then administers ALD-201 to the patient by injection directly into the appropriate areas of the patient’s heart muscle using a specialized catheter.

Ischemic Heart Failure

Ischemic heart failure is caused by an obstruction of the arteries feeding blood to the heart tissue. The resulting damage to the heart muscle from insufficient oxygen and nutrients reduces the heart’s ability to pump blood efficiently to the rest of the body. Current treatment options for ischemic heart failure include surgical procedures, bi-ventricular pacers, drug therapies, implantable cardiac defibrillators, and ventricular assist devices. For some patients, these treatments are not effective or appropriate. Once ischemic heart failure patients have exhausted all potential revascularization options, their only other option is a heart transplant, if they are eligible for one.

Market Opportunity for ALD-201

According to the American Heart Association, 5.7 million patients in the United States suffer from heart failure, with an additional 670,000 new cases of heart failure diagnosed each year. In a study we commissioned, Trinity Partners estimates that approximately 70% of U.S. heart failure patients, or approximately 3.7 million patients, have ischemic heart failure. There is no definitive data on the number of ischemic heart failure patients who no longer have revascularization options and whose only treatment option is a heart transplant. However, Trinity Partners estimates that there are between 200,000 and 300,000 patients who fall into this category. According to the Healthcare Cost and Utilization Project, the median hospital cost associated with heart transplantation is approximately $307,000 per transplant.

Clinical Development of ALD-201

In August 2008, investigators at the Texas Heart Institute completed a 20-patient Phase 1 clinical trial of ALD-201. This trial was designed to evaluate the safety and potential efficacy of ALD-201 as a treatment for ischemic heart failure.

Trial Design. This clinical trial was conducted as a randomized, double-blind, placebo-controlled trial. Patients in the ALD-201 treatment group received an injection of ALD-201. Patients in the placebo control group received an injection of an equivalent volume of placebo using the same catheter delivery system. Investigators assessed patients for endpoints for the first six months after the injection and then followed them for an

additional six months. After the initial six-month assessment, patients in the control group were offered the opportunity to be treated with ALD-201 and then evaluated as though they had been initially placed in the ALD-201 treatment group.

The clinical investigators in this trial used the NOGA^® XP Cardiac Navigation System and the MyoStar catheter developed by Biosense Webster Inc. for the injection of ALD-201 and the placebo. The MyoStar catheter is a highly specialized, experimental catheter designed to inject agents into the heart. It has not been approved by the FDA for use with ALD-201 or any commercial use. The catheter is used together with the NOGA electromechanical mapping system, which creates a real-time, three-dimensional map of the patient’s heart. The location information displayed on the mapping system screen gives the location of the catheter tip, which allows for precise targeting of injections into the appropriate areas of the heart muscle. When used in connection with the injection of ALD-201, the NOGA mapping system helps identify ischemic but viable heart muscle.

Endpoints. The primary objective of this clinical trial was to evaluate the safety of ALD-201. Secondary endpoints included efficacy evaluations, including aerobic capacity and walking distance. Other endpoints included change in clinical status, blood flow measures, imaging tests, such as echocardiograms and single-photon-emission computed tomography, or SPECT, and subjective measures of quality of life.

To assess aerobic capacity, we used a customary measure known as maximum oxygen consumption during exercise, or MVO₂. MVO₂ is measured in terms of milliliters of oxygen used by the patient per kilogram of body mass per minute, or ml/kg/min. We believe that MVO₂ is important because impaired MVO₂ is predictive of mortality in patients with ischemic heart failure.

To evaluate echocardiography results, we used a measure of the adequacy of cardiac function known as left ventricular end-systolic volume, or LVESV. LVESV, measured in milliliters, or ml, is the volume of the heart’s left ventricle at the end of a contraction. A smaller volume reflects an improvement in cardiac function. A reduction in LVESV associated with medical interventions has also been shown to correlate with survival of patients with ischemic heart failure. The reported LVESV measurements were determined by the average of two readings performed by independent echocardiography specialists. The second reading was taken after the results of the initial reading were known and was not part of the initial trial design.

Inclusion and Exclusion Criteria. Only patients with no further revascularization options were eligible to participate in this trial. In addition, patients were required to have an observed ejection fraction no greater than 45%, meaning that their left ventricle pumps less than 45% of the total blood in the ventricle per heartbeat, and to be in specified classes under the Canadian Cardiovascular Society system for the measurement of angina or to have symptoms of heart failure. Patients were also required to have a reversible perfusion defect on SPECT. Key exclusion criteria included high-risk acute coronary syndrome, a recent heart attack or a left ventricular wall thickness of less than eight millimeters at the target injection site.

Safety Results. We have analyzed safety results for all patients in the trial through the initial six-month period following injection. ALD-201 was well-tolerated in the trial. Adverse events in general were distributed similarly between the ALD-201 treatment group and the placebo group. One patient in the ALD-201 treatment group experienced an acute myocardial infarction, or heart attack, which did not occur near the time of the injection and was considered by the investigator to be unrelated to treatment. There were no procedural complications that occurred during or shortly after the catheter injection procedure in the ALD-201 treatment group. In the placebo group one patient experienced a ventricular arrhythmia and another patient experienced a ventricular tachycardia. Both events occurred during the NOGA mapping procedure and were considered to be related to the procedure.

Efficacy Results. We observed the following efficacy results in patients at their initial six-month assessment:

•

The improvement in MVO₂ was greater in the ALD-201 treatment group than in the placebo group at the end of the six-month period. The mean MVO₂ in the ALD-201 treatment group improved by

14.2%, from 15.5 ml/kg/min at baseline to 17.7 ml/kg/min at the six-month evaluation. The mean MVO₂ in the placebo group improved by 3.5%, from 14.1 ml/kg/min at baseline to 14.6 ml/kg/min at the six-month evaluation. This difference was not statistically significant.

•

The improvement in LVESV was greater in the ALD-201 treatment group than in the placebo group at the end of the six-month period. The mean LVESV in the ALD-201 treatment group improved by 7.8%, from 93.2 ml at baseline to 85.9 ml at the six-month evaluation. The mean LVESV in the placebo group improved by 0.2%, from 94.9 ml at baseline to 94.7 ml at the six-month evaluation. This difference was also not statistically significant.

Additionally, the results were consistent with our hypothesis that the angiogenic properties of the ALDH^br cell populations may help restore blood flow in areas of ischemia. Specifically, we observed a statistically significant reduction of ischemia in the patients in the ALD-201 treatment group, as compared to the placebo group. There was a reduction in mean amounts of ischemia, as measured by SPECT, in the ALD-201 treatment group from 6.6% at baseline to 2.6% at the six-month evaluation. In comparison, the mean amount of ischemia in the placebo group increased from 4.3% at baseline to 8.0% at the six-month evaluation. These findings had a p-value of 0.045. In some patients in the ALD-201 treatment group, the areas of reduction in ischemia as shown by SPECT were also the areas of the heart into which ALD-201 had been injected, as identified by the NOGA mapping system.

Plans for Future Development. Based on the results of this Phase 1 clinical trial, we plan to seek a third-party collaborator to help us conduct and fund larger, later-stage clinical trials of ALD-201.

ALD-151, ALD-601 and ALD-401—Our Other Product Candidates

ALD-151

ALD-151 is the population of ALDH^brstem cells we produce from a full cord blood unit using our proprietary technology. We are currently developing ALD-151 to improve engraftment following cord blood transplants used to treat leukemias.

A single cord blood unit typically contains a sufficient number of hematopoietic stem cells to treat a patient weighing less than approximately 90 pounds. To provide larger patients with a higher stem cell dose than would be available in a single cord blood unit, some clinicians transplant two full cord blood units, each from a different donor. Early data, however, suggest that patients receiving two cord blood units have a higher risk of contracting GvHD.

ALD-151 presents another approach to increasing the dose of stem cells from a cord blood transplant for larger patients. To produce ALD-151 we receive one full unit of cord blood from a cord blood bank. An additional full cord blood unit is separately shipped to the hospital for the transplant. We process the full cord blood unit we receive to isolate and capture the ALDH^br cells. Typically within 24 hours of our receipt of the full cord blood unit, we ship the resulting ALD-151 to the hospital. ALD-151 is then infused into the patient approximately four hours after the transplant of the other cord blood unit. ALD-151, when administered in conjunction with a full-unit cord blood transplant, can provide a larger dose of hematopoietic stem cells than would be available in a transplant from a single cord blood unit, while reducing the number of cells that could lead to GvHD from the number that would be present following a transplant using two cord blood units.

In February 2008, investigators began enrolling patients in a Phase 1 clinical trial of ALD-151 that is being conducted at Duke. The purpose of this trial is to evaluate the safety and potential efficacy of ALD-151 in accelerating the engraftment time of platelets and neutrophils in patients undergoing cord blood transplants for the treatment of leukemia or inherited metabolic diseases. To date, investigators have treated six patients with ALD-151 in this trial, and we expect a total of up to 10 patients to be enrolled. We expect that the results of this clinical trial will be available in 2010.

If the results of this Phase 1 clinical trial are positive, we plan to conduct further clinical trials of ALD-151 in adult leukemia patients undergoing cord blood transplants. Additionally, investigators at the Terry Fox Laboratory have received funding from the Canadian Stem Cell Network to support a clinical trial in which ALD-151 will be used to treat adult cancer patients. We have agreed to manufacture ALD-151 for this Phase 1 trial. The investigators are currently proceeding with trial design and the regulatory process in Canada, and we anticipate that the trial will receive regulatory clearance in the first half of 2010.

ALD-601

We are currently developing ALD-601 to treat inherited metabolic disorders by delivering ALDH^br cells to a fetus while still in the womb, a procedure we refer to as in utero stem cell transplantation. The goal of in utero stem cell transplantation is to provide cells that can produce the missing enzyme that causes the metabolic disorder. ALD-601 consists of a relatively small number of ALDH^br stem cells that we produce by sorting a portion of a cord blood unit.

Because the results of hematopoietic stem cell transplants for inherited metabolic diseases improve when children are treated early, doctors often attempt to perform necessary transplants within the first six months of the patient’s life. Babies with some inherited metabolic disorders may, however, have damage that occurred in the womb and cannot be reversed when the transplant is performed after birth, even in the first few months. Researchers believe that, in general, the earlier the transplant occurs, the less damage is likely to occur in the baby’s tissues and the greater the chance the donor cells will reduce or prevent clinical problems. Accordingly, we believe that in utero stem cell transplantation may be beneficial.

After a physician diagnoses the presence of an inherited metabolic disorder, and the parents consent to treatment, ALD-601 would be injected directly into the abdomen of the fetus at 12 to 14 weeks of gestation. At birth, the baby would be tested to determine whether the donor cells are present and whether they are producing the missing enzyme necessary to address the disorder. If the donor cells are not present or are not making the enzyme, the baby would be eligible for a conventional hematopoietic stem cell transplant, using either cord blood or bone marrow.

In July 2009, investigators at Duke received clearance from the FDA to begin a Phase 1 clinical trial of ALD-601. The purpose of this trial is to evaluate the safety, feasibility and potential efficacy of using ALD-601 to treat specified inherited metabolic disorders. The disorders specified for the trial are Krabbe disease, metachromatic leukodystrophy, Pelizaeus-Maerzbacher disease, Tay-Sachs disease and Sandoff disease. To date, investigators have not treated any patients in the trial. Due to the rarity of the inherited metabolic disorders cleared for the trial, we are not certain when the first patient will be enrolled, how many patients may ultimately be enrolled or at what rate they will be enrolled. Depending on their efficacy in treating inherited metabolic disorders, we believe that in utero stem cell transplantation of ALDH^br stem cells may ultimately be used to treat more common disorders such as sickle cell anemia and thalassemia.

ALD-401

ALD-401 is the population of ALDH^br stem cells we produce from human bone marrow using our proprietary technology. We are currently developing ALD-401 for post-acute treatment of ischemic stroke.

Strokes are characterized by the rapidly developing loss of brain function due to a disturbance in the blood supply to the brain. Strokes are typically classified into two major categories, ischemic and hemorrhagic. Ischemic strokes result from an inadequate supply of blood and oxygen to the brain due to blockage of an artery, such as by a blood clot, while hemorrhagic strokes result from rupture of a blood vessel or an abnormal vascular structure. Ischemic strokes represent approximately 80% of all cases.

Patients suffering an ischemic stroke can receive a drug called tissue plasminogen activator, or tPA, which is currently the only FDA-approved acute treatment for ischemic stroke. tPA is administered intravenously to

break up clots and restore blood flow to the brain. However, it is only approved for use within three hours of the onset of symptoms, and many patients who have suffered an ischemic stroke are unable to reach a hospital for diagnosis and treatment within this period. The use of tPA can also lead to bleeding in the brain. There are no currently approved therapies for post-acute treatment of ischemic stroke.

We have completed an initial preclinical study in collaboration with academic researchers at Duke to study the use of ALDH^br cells in treating ischemic stroke up to two weeks following the stroke. In this study, the middle cerebral artery in mice was temporarily blocked in order to induce a stroke. One group of mice was treated 14 days later by injecting ALDH^br cells from human bone marrow into their carotid arteries, while a second group was untreated. In this study:

•

Imaging showed that the ALDH^br cells migrated to the area of the tissue damage in the brain resulting from the stroke.

•

At four weeks after the injection of ALDH^br cells, or six weeks after the stroke, researchers assessed the neuromuscular coordination and motor abilities of the mice by testing their ability to maintain their balance on a rotating rod. The recovery of motor function in the mice treated with ALDH^br cells improved by 41% within the four-week period, compared to an improvement of 11% in the untreated group. This finding was statistically significant, with a p-value of less than 0.05.

•

The researchers also measured brain volumes of the mice following the strokes and noted that the mice treated with ALDH^br cells experienced a statistically significant slowing of decreased brain volume following the stroke when compared to the untreated mice, with a p-value of less than 0.05.

•

The researchers used magnetic resonance spectroscopy of biomarkers to measure stroke-induced decrease in cell viability, noting that the mice receiving treatment with ALDH^br cells had a statistically significant reversal of stroke-induced decline in cell viability in the brain hemisphere opposite the stroke when compared to the untreated group, with a p-value of less than 0.05.

We believe that these results suggest that ALDH^br cell populations may have potential as a non-acute treatment for ischemic stroke. We intend to submit an IND to the FDA in 2010 to initiate a Phase 1 clinical trial of ALD-401 for this indication.

Potential Use of ALDH^br Cell Populations in Other Therapeutic Areas

In addition to the potential role of ALDH^br cells in accelerating engraftment following cord blood transplants, as well as in the treatment of ischemic damage, we believe that these cells may have broad applicability in a variety of other therapeutic areas. For example, in a preclinical study conducted by academic researchers at Washington University using a mouse model of multi-organ failure in human lysosomal storage disease, researchers injected human ALDH^br cells into the mice and then observed that the cells were present in the damaged tissue. Furthermore, these ALDH^br cells appeared to have differentiated into a variety of tissue types depending on the nature of the damaged tissue. We believe that these results suggest that ALDH^br cell populations could have the potential to help promote the repair of a variety of tissues in clinical indications such as in orthopedics, eye diseases, diabetes, kidney diseases and neurological disorders.

Our Research and Diagnostic Products

In addition to our therapeutic product candidates in clinical development, we have commercialized two research and diagnostic products based on our technology. We sell both of these products through a third-party distributor.

ALDEFLUOR

ALDEFLUOR is a reagent system for use only in research activities to identify and isolate stem cells and progenitor cells based on ALDH activity. ALDEFLUOR is optimized for identifying human hematopoietic cells,

but has also been adapted for use with other cell types. ALDEFLUOR is not capable of producing any of our therapeutic product candidates. We have sold ALDEFLUOR units to researchers since 2003 and have received cumulative revenues of approximately $1.0 million from our inception through September 30, 2009.

ALDECOUNT

ALDECOUNT is a diagnostic product for identification and counting of ALDH ^br cells in vitro using flow cytometry. The FDA has given pre-market clearance to ALDECOUNT for use with fresh or frozen human peripheral blood, umbilical cord blood and bone marrow and for use in leukapheresis, a process by which white blood cells are separated from a sample of blood. Researchers and diagnostic laboratories use ALDECOUNT for a variety of applications, including the assessment of cardiovascular health by counting circulating progenitor cells and the assessment of bone marrow transplant quality by counting hematopoietic stem cells. A multicenter clinical trial funded by the National Marrow Donor Program is underway to assess the use of ALDECOUNT as a standard assay for prospectively measuring cord blood unit potency during the process of selecting a unit for a patient. We also use ALDECOUNT internally in our clinical trials to assess the stem cell count in our product candidates. We have sold ALDECOUNT to clinical and research laboratories since 2004 and have received only nominal revenues to date from the sale of ALDECOUNT.

Manufacturing

Historically, we and several contractors manufactured our product candidates for preclinical studies and clinical trials. In 2007, we consolidated all of our manufacturing functions at our facility at our corporate headquarters in Durham, North Carolina. In March 2009, we completed construction of a new manufacturing facility at our corporate headquarters. The facility contains 3,500 square feet of clean room space for manufacturing activities and 1,500 square feet of support space, including a quality control laboratory for performing final product testing and release. The facility was designed and constructed to meet all FDA and European Union regulatory requirements for good manufacturing practices. This facility is registered with the FDA as a cell manufacturing establishment, and we believe that we are operating it in compliance with the cGMP and cGTP standards required by the FDA. We believe this facility has the capacity to manufacture the quantities of our product candidates necessary for Phase 3 trials of ALD-101, ALD-301 and ALD-201, as well as initial commercial quantities of ALD-101 if it is approved for marketing.

We currently use traditional cell sorting equipment to manufacture our product candidates. We believe that our current isolation methodologies are sufficient to produce a sufficient number and quality of ALDH^br cells to advance our product candidates through clinical trials and to commence commercialization if we receive marketing approval. However, we believe that there are a number of ways to enhance our processes that could reduce our manufacturing costs and allow us to efficiently scale our production capacity in the event that all of our product candidates receive marketing approval. As a result, we are currently developing new processes and are in discussions with other companies to develop new instruments to improve our manufacturing efficiency.

Sales and Marketing

We currently have limited sales and marketing capabilities and no distribution capabilities. If we receive regulatory approval for ALD-101, we plan to market ALD-101 using a small, focused and specialized internal sales force. We believe that such a sales force could address the relatively small number of treatment centers and investigators involved in cord blood transplants for inherited metabolic diseases in pediatric patients. We also believe that, by developing our own sales force, we can control marketing efforts more effectively and obtain better access to the physicians that we would target. In addition, we expect that we would be able to use the experience of an internal sales force gained in promoting ALD-101 to market our other cord blood transplant products, such as ALD-151 and ALD-601, if they are approved for marketing by the FDA.

We also plan to pursue strategic collaborations to support and facilitate the development and commercialization of some of our product candidates. In particular, we are exploring collaboration arrangements

with leading pharmaceutical or biotechnology companies for the commercialization of ALD-301 and ALD-201, which we are developing for target indications with large addressable patient populations that we believe are better served by large sales and marketing organizations. Furthermore, if we choose to pursue approval of any of our product candidates by foreign regulatory authorities, we would evaluate the potential for collaborations with third parties to assist in the development and commercialization of these product candidates in international markets.

When appropriate, we also plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we market through our own sales force and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to any approved products and establishing relationships with influential practitioners in relevant fields of medicine.

Intellectual Property

We currently have exclusive licenses to four issued U.S. patents, including two with claims directed to our product candidates. Foreign counterparts to these patents, including composition of matter claims, have been filed, and we own or hold licenses to three issued or allowed patents in Europe, Australia and Singapore. We also have four additional pending U.S. patent applications and 14 related pending patent applications on file in foreign countries. The issued patents and pending patent applications included in our portfolio are directed to the method used to manufacture cell populations that express high levels of ALDH, the chemistry used in this manufacturing process, kits that embody this chemistry, the composition of sorted cell populations that express high levels of ALDH, and the therapeutic use of these cell populations. We are committed to protecting our intellectual property position and to aggressively pursuing our patent portfolio.

For most of our product candidates, we rely on multiple patents in combination. The following provides a summary of our key U.S. patents and pending U.S. patent applications.


U.S. Patent	Subject Matter	Related Product Candidates	Expiration
US5,876,956	Methods for Identification or Purification of Cells Containing an Enzymatic Intracellular Marker	—	2016
US6,537,807	Hematopoietic Stem Cells	—	2018

US6,627,759	Method of Isolating Stem Cells	All	2019
US6,991,897	Method of Isolating Stem Cells	All	2020

Pending U.S. Applications
—	Method of Isolating Stem Cells	All	—
—	Stem Cell Populations and Methods of Use	ALD-201, 301, 401	—
—	Methods For Improved Engraftment Following Stem Cell Transplantation	ALD-101, 151	—
—	Methods For Using ALDH^br Cells to Supplement Stem Cell Transplantation	ALD-101, 151	—

Patent life determination depends on the date of filing of the application or the date of patent issuance and other factors as promulgated under patent law. The United States Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, permits a patent extension of up to five years as compensation for patent term lost during the FDA regulatory development and review process. The patent term restoration period is one-half of the time between the effective date of an investigational new drug, or IND, application and the submission date of a biologics license application, or BLA, plus the time between the submission date of a BLA and the approval of the product. Only one patent applicable to the earliest approved product containing a particular active ingredient is eligible for the extension. The U.S. Patent and Trademark

Office, in consultation with the FDA, reviews and approves applications for patent term extension. We expect to apply for patent term extensions for eligible patents and products to add patent life beyond the expiration date, depending on the expected length of clinical trials and other factors involved in the filing of a BLA.

Through our experience with product development with stem cells sorted by ALDH activity, we have developed expertise and know-how in this field. To protect this non-patentable know-how, our policies require confidentiality agreements with our employees, consultants, contractors, manufacturers, outside collaborators, sponsored researchers, and advisors. These agreements generally provide for protection of confidential information, restrictions on the use of materials and assignment of inventions conceived during the course of performance for us. These agreements might not effectively prevent disclosure of our confidential information.

License Agreements with Duke University and Johns Hopkins University

We were founded on the basis of technology obtained from Duke and JHU. In 2000, we entered into separate technology transfer and license agreements with Duke and JHU. Pursuant to these license agreements, we obtained exclusive worldwide licenses to specified patents owned by Duke and JHU, with the right to grant sublicenses. These licenses are subject to specified rights of the United States government, based on governmental agencies’ partial funding of the research underlying the licensed patents. The licenses are also subject to Duke’s and JHU’s retained rights under the granted patents for non-commercial research, testing and educational purposes. We are responsible for all patent prosecution costs under both license agreements and, along with Duke and JHU, we have the right to enforce the licensed patents.

Under our license agreement with Duke, we licensed, on an exclusive basis, several issued patents and patent applications that cover the methods used to isolate and manufacture our ALDH^br cell populations that are the basis for all of our product candidates. Our continuing material obligations under this agreement include:

•

the payment to Duke, through the termination or expiration of the agreement, of low single-digit running royalties, subject to specified limitations, based on net sales of products covered by, and revenue received from sublicenses of, the granted patents;

•

the payment of minimum annual royalties of $5,000, subject to increase to $25,000 upon the achievement of specified development and commercialization milestones;

•

the reimbursement of patent costs incurred by Duke; and

•

the satisfaction of specified commercialization requirements.

To date, we have paid Duke an aggregate total of approximately $85,000 in cash, which includes reimbursements for patent costs and minimum annual royalties, including royalty payments based on net sales of ALDEFLUOR and ALDECOUNT. In connection with entering into the license agreement in 2000, we also issued 300,000 shares of our common stock to Duke, which we valued at $30,000 at the time of issuance.

The patent license is terminable by Duke if there is an uncured material breach of the agreement by us, or for our fraud, willful misconduct or illegal conduct. Otherwise, the term of the exclusive license from Duke will extend until 2020, the expiration of the last underlying patent that is the subject of the license, at which point it will become non-exclusive.

Under our license agreement with JHU, we licensed one patent covering flow sorting of stem cell populations based on a fluorescent ALDH substrate, which is useful for ALDEFLUOR and ALDECOUNT as well as our therapeutic product candidates. In 2009, we entered into an amendment to our agreement with JHU to revise the development milestones with respect to our product candidates. Our continuing material obligations under the amended agreement include:

•

the payment to JHU, through the termination or expiration of the agreement, of mid-single-digit running royalties, based on net sales of ALDEFLUOR, ALDECOUNT or other products covered by the licensed technology;

•

the payment of minimum annual royalties and maintenance fees in the amount of $10,000, regardless of sales or other milestones, although the payment of any minimum annual royalty will be credited against the required payment of a running royalty in the corresponding year;

•

the reimbursement of patent costs incurred by JHU; and

•

the payment of additional amounts upon the satisfaction of specified development milestones.

To date, we have paid JHU an aggregate total of approximately $150,000 under this agreement, which includes upfront license fees, reimbursement of patent costs and minimum annual royalties, including royalty payments based on net sales of ALDECOUNT and ALDEFLUOR, and an amendment fee.

The patent license is terminable by JHU if we fail to meet specified development and commercialization milestones, if there is an uncured material breach of the agreement by us or if we become the subject of a bankruptcy proceeding. Unless earlier terminated, the term of the exclusive license from JHU will extend until 2016, the expiration of the patent that is the subject of the license.

Competition

Many of the companies competing against us have financial and other resources substantially greater than ours. In addition, many of our competitors have significantly greater experience in testing pharmaceutical and other therapeutic products, obtaining FDA and other regulatory approvals of products, and marketing and selling those products. Accordingly, our competitors may succeed more rapidly than us in obtaining FDA approval for products and achieving widespread market acceptance. If we obtain necessary regulatory approval and commence significant commercial sales of our products, we will also be competing with respect to manufacturing efficiency and marketing capabilities, areas in which we have limited or no commercial-scale experience.

The primary competitors and potential competitors for our most advanced product candidates include:

•

ALD-101. There are no therapies currently approved by the FDA, and we are not aware of any other therapy being pursued, for use following a cord blood transplant in an effort to accelerate engraftment in pediatric patients with inherited metabolic diseases. Cord blood transplants, if successful, can cure these diseases. Other therapies are being developed, however, to treat the underlying diseases, which could be a competitive threat to the extent that cord blood transplants become less necessary for our target indications.

Some inherited metabolic diseases, including Hurler syndrome, are currently treated with approved enzyme replacement therapies marketed by companies such as Genzyme and Biomarin. Other companies, such as Shire Pharmaceuticals and Protalix BioTherapeutics, market enzyme replacement therapies for other indications. Unlike a cord blood transplant, enzyme replacement therapies do not cure inherited metabolic diseases, and patients require ongoing infusions over the course of their lives. Enzyme replacement therapy is also very expensive and is not available for many inherited metabolic diseases. Alternatively, a few inherited metabolic diseases can be treated with a transplant of primary cell lines that manufacture the deficient enzyme. Such therapies, which are approved in Europe, are now being sold and developed by Shire Pharmaceuticals. As with enzyme replacement therapy, these cell-based therapies do not cure the underlying diseases.

•

ALD-301. We are developing ALD-301 for the treatment of critical limb ischemia patients with no further revascularization options and who face amputation of the affected limb. ALD-301 would compete with pharmaceutical therapies and cell-based therapies being developed to treat critical limb ischemia, although there are no FDA-approved therapies for the treatment of this condition. To the extent that therapies are developed that reverse the progression of the ischemic damage, it could have the effect of reducing demand for ALD-301. Potential pharmaceutical therapies being developed for critical limb ischemia include several strategies to use the tissue repair activities of cytokines, which are regulatory proteins released by the immune system, to increase blood flow to the damaged limb tissue. In some strategies, purified recombinant cytokines, such as hepatocyte growth factor, are being administered locally to the damaged limb. Gene constructs for cytokines are also being administered on the theory that cells taking up the gene will manufacture cytokines locally. Cell-based therapies, such as other bone marrow-derived stem cell therapies, are being pursued by companies such as Aastrom Biosciences and Pluristem Therapeutics. In addition, some companies, such as Harvest Technologies, are developing devices to facilitate the production of therapeutic cell populations by clinicians for the treatment of critical limb ischemia.

•

ALD-201. We are developing ALD-201 for the treatment of ischemic heart failure patients with no further revascularization options. Accordingly, we do not believe that ALD-201 would compete directly with other therapies that have been exhausted by the patient. However, to the extent that therapies are developed that reverse the progression of the ischemic damage or restore blood flow, it could have the effect of reducing demand for ALD-201. New pharmaceutical agents or devices that improve the repair of cardiac injury after a heart attack, with the result that fewer patients develop ischemic heart failure, would also represent a competitive threat. Cell-based therapies such as skeletal myoblasts and adipose-derived stem cells are being pursued for the treatment of ischemic heart failure by companies such as Bioheart. In addition, some companies, such as Cytori Therapeutics and Baxter International, are developing devices to facilitate the production of therapeutic cell populations by clinicians for the treatment of ischemic heart failure.

We may also face competition in the future from other companies that are researching and developing stem cell therapies. In addition to the companies mentioned above, we are aware of other companies working in this area, including Angioblast Systems, Inc. and Athersys, Inc. We expect to compete based upon, among other things, the efficacy of our product candidates and our intellectual property portfolio. Our ability to compete successfully will depend on our continued ability to attract and retain skilled and experienced scientific, clinical development and executive personnel, to identify and develop viable biologic candidates and to exploit these product candidates commercially before others are able to develop competitive products.

Government Regulation

Government authorities in the United States, at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, including any manufacturing changes, packaging, storage, recordkeeping, labeling, advertising promotion, distribution, marketing, import and export of biological products such as those we are developing. The process of obtaining required regulatory approvals and the subsequent compliance with appropriate statutes and regulations require the expenditure of substantial time and money, and there is no guarantee that we will successfully complete the steps needed to obtain regulatory approval of any of our product candidates.

U.S. Government Regulation

In the United States, our product candidates are regulated by the FDA as biological products. Biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and related regulations, and other federal, state and local statutes and regulations. Failure to comply with the

applicable U.S. regulatory requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the imposition by the FDA or an Institutional Review Board, or IRB, of a clinical hold on trials, the FDA’s refusal to approve pending applications or supplements, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.

The process required by the FDA before a biological product may be marketed in the United States generally involves the following:

•

completion of preclinical laboratory and animal tests conducted in compliance with the FDA’s good laboratory practice, or GLP, requirements to assess a product’s biological activity and to identify potential safety problems, and to characterize and document the product’s manufacturing controls and stability;

•

submission to the FDA of an investigational new drug, or IND, application, which must become effective before clinical testing in humans can begin;

•

obtaining approval of IRBs of research institutions or other clinical sites to introduce the biologic product candidate into humans in clinical trials;

•

completion of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the product for its intended indication conducted in compliance with the FDA’s good clinical practice, or GCP, requirements;

•

compliance with applicable cGMP regulations and standards and, for cell-based products, cGTP regulations;

•

submission to the FDA of a biologics license application, or BLA, for marketing approval that includes, among other things, results of preclinical testing and clinical trials;

•

FDA review of the BLA in order to determine, among other things, whether the product is safe and effective for its intended uses; and

•

satisfactory completion of an FDA inspection of the facility or facilities at which the product is manufactured, processed, packaged or held to assess compliance with cGMP and cGTP requirements, prior to any commercial sale or shipment of the biological product.

Preclinical Studies and IND Submission

Preclinical studies include laboratory evaluation of the product candidate and animal studies to assess its potential safety and efficacy. An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data and any available clinical data or literature to the FDA as part of an IND. The IND will also include the protocols for the initial clinical trials and an investigator’s brochure, and the IND must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical trials as outlined in the IND. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before clinical trials can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical trials to commence.

Clinical Trials

Clinical trials involve the administration of the product candidate to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing prior to their participation in any clinical trial. Clinical trials

are conducted under protocols detailing, among other things, the objectives of the study, and the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the study protocol and informed consent for any clinical trial before it commences at that institution. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur.

Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined, such as in the case of our completed Phase 1/2 clinical trial of ALD-301:

•

In Phase 1 trials, the product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance and biological response.

•

In Phase 2 trials, the product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance and optimal dosage and schedule.

•

In Phase 3 trials, the product candidate is administered to an expanded patient population generally at geographically dispersed clinical trial sites to further evaluate dosage, clinical efficacy and safety and to establish the overall risk-benefit ratio of the product candidate and an adequate basis for product labeling.

•

The FDA may require Phase 4 trials or other post-marketing trials if it finds that additional clinical information must be collected following market entry or it may condition approval of a product on the sponsor’s agreement to conduct additional clinical trials to further assess the product’s safety and effectiveness after approval.

Clinical trials may not be completed successfully within any specified time period, or at all. Further, the FDA, an IRB or the product candidate’s sponsor may prevent clinical trials from beginning or suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk.

Marketing Approval

Assuming successful completion of the required clinical trials, the results of product development, preclinical studies and clinical studies, descriptions of the manufacturing process and other relevant information concerning the safety, purity and potency of the biological product candidate are submitted to the FDA in the form of a BLA. In most cases, the BLA must be accompanied by a substantial user fee. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product’s continued safety, purity and potency. Under the Prescription Drug Fee Act, the FDA has committed to reviewing most standard BLAs in 10 months, although the FDA’s review process can sometimes be longer.

The FDA may request that an Advisory Committee review the BLA and make a recommendation as to whether the application should be approved and under what conditions. The Advisory Committee is a panel of experts who provide advice and recommendations when requested by the FDA on matters of importance that come before the agency. Committee recommendations are not binding on the FDA, but the agency considers them carefully when making decisions.

BLAs for a new product, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may also require sponsors of currently marketed biologics to conduct pediatric studies if the product serves a substantial number of pediatric patients and adequate pediatric

labeling could benefit such patients, the product would provide a meaningful therapeutic benefit for pediatric patients or the absence of pediatric labeling could pose a risk to pediatric patients. The FDA may, on its own initiative or at the request of the applicant, defer submission of some or all pediatric data until after approval of the product for use in adults, or grant a full or partial waiver from the pediatric data requirements.

Before approving an application, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.

The testing and approval process requires substantial time, effort and financial resources and may take many years to complete. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs in our efforts to develop our products and secure the necessary approvals, which could delay or prevent us from marketing our products. The FDA may deny an application if all applicable regulatory criteria are not satisfied or may require additional clinical data. Even if additional clinical data are submitted, the FDA may ultimately decide that the application does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret the data differently than we interpret the data. Even if the FDA approves a product, it may limit the approved therapeutic uses for the product, require that contraindications, warnings or precautions be included in the product labeling, require that additional studies be conducted following approval, or require surveillance programs to monitor the product after commercialization. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further FDA review and approval.

Orphan Drugs

Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs and biological products intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation for a biological product must be requested before submitting a BLA. In October 2008, we received orphan drug designation for ALD-101 for the indication of improving patient outcomes by decreasing time to platelet and neutrophil engraftment in patients with inherited metabolic diseases undergoing umbilical cord blood transplantation. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. However, the first applicant with FDA orphan drug designation for a particular product to receive FDA approval for the disease for which it has such designation is entitled to a seven-year exclusive marketing period in the United States for the product for that indication. During the seven-year period, the FDA may not approve any other applications to market the same product for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Therefore, if an equivalent product with orphan drug status were to obtain FDA approval before ALD-101, we would be prohibited from commercializing ALD-101 for seven years. However, orphan drug exclusivity does not prevent the FDA from approving a different drug or biological product for the same disease or condition, or the same drug or biological product for a different disease or condition. We believe that our ALDH^br cell populations are sufficiently different from potentially competing products so that a competing product with orphan drug exclusivity that is intended to improve cord blood transplants, or any other indications that our existing or new product candidates may target in the future, would not prevent us from commercializing ALD-101. Similarly, any orphan drug exclusivity that we obtain may not prevent the approval of competing products that are similar to our ALDH^br cell populations. Among the other benefits of orphan drug designation are tax credits for specified research and a waiver of the marketing application user fee.

Accelerated Approval

Under the FDA’s accelerated approval regulations, the FDA may approve a biologic product for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments, based

upon a surrogate endpoint that is reasonably likely to predict clinical benefit. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. Time to engraftment is a surrogate endpoint. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the biological product from the market on an expedited basis. All promotional materials for biologics approved under accelerated regulations are subject to prior review by the FDA.

Combination Products

The FDA has the authority to approve and regulate combination products. A combination product may include a product that includes two or more regulated components such as a biologic product and a device that are combined or produced as a single entity; two or more separate products packaged together in a single package or as a unit; or a product packaged separately that is intended to be used only with an approved drug, device or biological product to achieve the intended effect. In some cases, a combination product might fall under the jurisdiction of more than one agency center within the FDA, for example the center charged with regulating biological products or the center that regulates devices. In these cases, to determine which agency center will be assigned primary responsibility for regulating a particular combination product, the FDA looks to the product’s primary mode of action. To determine the primary mode of action, the FDA assesses the principal means by which a product achieves its most important intended therapeutic effect or action. If the product has a biological primary mode of action, it will likely be regulated by the FDA center focused on regulating biological products. The center with primary jurisdiction may also consult other FDA centers to assist with reviewing a marketing application, as appropriate. In most instances, only a single marketing application is filed with the center at the FDA that is assigned with primary jurisdiction over the application. We believe that ALD-201 may be regulated as a combination product because it requires administration through a specialized medical device, such as the MyoStar system.

Post-approval Requirements

Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including requirements relating to recordkeeping, periodic reporting, distribution, advertising and promotion, and reporting of adverse experiences with the product.

In addition, manufacturers of biological products must continue to comply with cGMP requirements after approval, which are extensive and require considerable time, resources and ongoing investment to ensure compliance. The requirements apply to all stages of the manufacturing process, including the processing, packaging, labeling, storage and shipment of the product. Manufacturers must establish validated systems to ensure that products consistently meet high standards of sterility, safety, purity, potency and identity. Changes to the manufacturing process are strictly regulated and generally require prior FDA approval before being implemented.

FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Manufacturing establishments are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP. Future FDA and state inspections may identify compliance issues at our manufacturing facilities or the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct.

The FDA may withdraw or revoke a product’s approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Further, the failure to

maintain compliance with regulatory requirements may result in administrative or judicial action, such as fines, warning letters, holds on clinical trials, product recalls or seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing, injunctions, civil penalties or criminal prosecution. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Also, new governmental requirements may be established, including those resulting from new legislation, or the FDA’s policies may change, which could significantly affect our business, including preventing or delaying regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of any adverse governmental legislation, regulation or other administrative action, or what the impact of such changes, if any, may be.

Privacy Laws

Federal and state laws govern our ability to obtain and, in some cases, to use and disclose data we need to conduct research activities. Through the Health Insurance Portability and Accountability Act of 1996, or HIPAA, Congress required the Department of Health and Human Services to issue a series of regulations establishing standards for the electronic transmission of certain health information. Among these regulations were standards for the privacy of individually identifiable health information.

HIPAA does not preempt, or override, state privacy laws that provide even more protection for individuals’ health information. These laws’ requirements could further complicate our ability to obtain necessary research data from our collaborators. In addition, certain state privacy and genetic testing laws may directly regulate our research activities, affecting the manner in which we use and disclose individuals’ health information, potentially increasing our cost of doing business, and exposing us to liability claims. In addition, patients and research collaborators may have contractual rights that further limit our ability to use and disclose individually identifiable health information. Claims that we have violated individuals’ privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.

Other Regulations

In addition to privacy law requirements and regulations enforced by the FDA, we also are subject to various local, state and federal laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including chemicals, micro-organisms and various radioactive compounds used in connection with our research and development activities. These laws include, but are not limited to, the Occupational Safety and Health Act, the Toxic Test Substances Control Act and the Resource Conservation and Recovery Act. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by state and federal regulations, we cannot assure you that accidental contamination or injury to employees and third parties from these materials will not occur. We may not have adequate insurance to cover claims arising from our use and disposal of these hazardous substances.

Foreign Regulation

In addition to regulations in the United States, we may be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of biological products. Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. The requirements governing the conduct of clinical trials and the approval process vary from country to country and the time may be longer or shorter than that required for FDA approval. In the European Union, marketing authorizations may be submitted under a centralized or decentralized procedure. The centralized procedure is mandatory for the approval of biotechnology products and many pharmaceutical products, and provides for the

grant of a single marketing authorization that is valid in all European Union member states. The decentralized procedure provides for mutual recognition of national approval decisions and is available at the request of the applicant for medicinal products that are not subject to the centralized procedure.

In addition to regulations in Europe and the United States, we will be subject to a variety of other foreign regulations governing, among other things, the conduct of clinical trials, pricing and reimbursement and commercial distribution of our products. If we fail to comply with applicable foreign regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

To date, we have not initiated any discussions with the European Medicines Agency or any other foreign regulatory authorities with respect to seeking regulatory approval for any of our product candidates in Europe or in any other country outside the United States.

Employees

As of September 30, 2009, we employed 24 individuals, 23 of whom were full-time employees. Of our employees, 19 were engaged in research and development activities and five were engaged in selling, general and administrative activities. None of our employees is represented by a labor union or covered under a collective bargaining agreement, nor have we experienced any work stoppages. We consider our employee relations to be good.

Facilities

Our corporate headquarters, which includes our manufacturing facility, are located in Durham, North Carolina, where we lease approximately 16,000 square feet of space. The lease on our office space expires in April 2013, and the lease on our manufacturing facility expires in December 2013.

Legal Proceedings

We are not currently a party to or engaged in any material legal proceedings. However, we may be subject to various claims and legal actions arising in the ordinary course of business from time to time.

MANAGEMENT

Directors and Executive Officers

The following table sets forth information concerning our directors and executive officers, including their ages as of September 30, 2009:


Name	Age	Position
W. Thomas Amick	66	Chairman of the Board of Directors, Chief Executive Officer
Edward L. Field	44	President and Chief Operating Officer
David P. Carberry	57	Chief Financial Officer
Andrew E. Balber, Ph.D.	64	Chief Scientific Officer
James M. Hinson, M.D.	58	Chief Medical Officer
Joel R. Kimbrough	51	Director
Martin J. Murphy, Ph.D.	66	Director
B. Jefferson Clark	53	Director
Garheng Kong, M.D., Ph.D.	34	Director
William E. Evans, PharmD.	59	Director
Lyle A. Hohnke, Ph.D.	66	Director

Executive Officers

W. Thomas Amick

Mr. Amick has served as our Chief Executive Officer and Chairman of our Board of Directors since March 2005. Mr. Amick was retired from March 2004 until he began serving as a consultant to Aldagen in March 2005, before becoming an employee in March 2006. Mr. Amick served in a series of positions with Johnson & Johnson and its subsidiaries and divisions from 1974 until his retirement in February 2004, including Vice President, Business Development at Johnson & Johnson Development Corporation from 2003 to February 2004, President of Ortho Biotech Europe from 2001 to 2003, President of Janssen-Ortho, Inc., from 1999 to 2000 and Vice President of the Oncology Franchise for Ortho Biotech Products from 1997 to 1999. Mr. Amick has served as a director of Discovery Laboratories, Inc., a publicly traded life sciences company, since September 2004, as the chairman of its board of directors since March 2007 and as its interim chief executive officer since August 2009. Mr. Amick received a B.A. degree in business administration from Elon College.

Edward L. Field

Mr. Field has served as our President and Chief Operating Officer since November 2004. Prior to joining Aldagen, Mr. Field was the President and Chief Executive Officer of Inologic, Inc., a private biopharmaceutical company, from 2002 to September 2004. Prior to joining Inologic, from 1999 to 2002, Mr. Field was the President of Molecumetics, Ltd., a drug discovery and development subsidiary of Tredegar Corporation, until its merger with Therics, LLC, a regenerative medicine company. Mr. Field received a Master of Business Administration degree from the University of Virginia’s Darden School of Business Administration and a Bachelor of Science degree in Economics from Duke University.

David P. Carberry

Mr. Carberry has served as our Chief Financial Officer since March 2008. Prior to joining Aldagen, Mr. Carberry served with Johnson & Johnson and its subsidiaries and divisions in a variety of financial positions from 1981 to February 2008. Most recently, Mr. Carberry served as Vice President, Finance and Chief Financial Officer of Johnson & Johnson*Merck Consumer Pharmaceuticals Co. from March 2005 to September 2006 and as Vice President, Finance and Chief Financial Officer of Johnson & Johnson Health Care Systems Inc. from 1995 to February 2005. Concurrently, Mr. Carberry acted as Vice President, Finance and Chief Financial Officer

of Independence Technology, Inc., a division of Johnson & Johnson, from September 2004 to September 2007. Mr. Carberry received a Master of Business Administration degree from Drexel University and a Bachelor of Science degree in accounting from LaSalle University. Mr. Carberry is a Certified Management Accountant.

Andrew E. Balber, Ph.D.

Dr. Balber is a co-founder of Aldagen, has been employed by us since our inception in 2000 and has served as our Chief Scientific Officer since 2007. Dr. Balber began his work with cell therapies in 1983 when, as a Duke University faculty member in immunology and Director of the Comprehensive Cancer Center Flow Cytometry Facility, he helped organize and manage a university-based, industry sponsored research consortium in immunology. Dr. Balber received a Bachelor of Science degree in biology from Haverford College and his Ph.D. degree from Rockefeller University and completed postdoctoral training in immunology and microbiology at Yale University.

James M. Hinson, Jr., M.D.

Dr. Hinson has been a consultant to our company since July 2009 and has served as our Chief Medical Officer since October 2009. Since 2000, he has been the owner and principal of Unicorn Pharma Consulting, a pharmaceutical development consulting firm. In this role, he has provided consultation to large and small pharmaceutical companies, clinical research organizations and biotechnology organizations in clinical trial construction and management, data analysis, clinical development plans and interactions with financial and regulatory authorities, including serving on data safety monitoring boards. Dr. Hinson has also previously held senior drug development positions at Ardent Pharmaceuticals, Alliance Pharmaceuticals, Rhone-Poulenc Rorer and Burroughs Wellcome. He received a Bachelor of Arts degree from the University of Missouri-Columbia and his M.D. degree from the Vanderbilt University School of Medicine. Dr. Hinson is board certified in internal medicine, pulmonary medicine and critical care medicine.

Non-management Directors

Joel R. Kimbrough

Mr. Kimbrough has served as a member of our board of directors since November 2007. Currently retired, Mr. Kimbrough served as the Senior Vice President, Chief Financial Officer and Treasurer of Accredo Health Group, Inc., a specialty pharmaceutical provider, and its predecessor companies from 1989 until its acquisition by Medco Health Solutions in August 2005. He then served as Senior Vice President of the specialty segment of Medco from August 2005 to March 2007. Mr. Kimbrough was an auditor with Ernst & Young LLP from 1980 to 1989. In addition to his directorship with us, Mr. Kimbrough is a member of the board of directors of Trust One Bank, a division of Synovus Financial Corp. Mr. Kimbrough received a Bachelor of Science degree in accounting from the University of North Alabama and is a certified public accountant.

Martin J. Murphy

Dr. Murphy has served as a member of our board of directors since May 2007. Since 1995, he has served as Founding Chairman and Chief Executive Officer of AlphaMed Consulting, Inc., a corporation that provides strategic support for academic cancer centers and cancer drug development programs for global pharmaceutical and biotechnology companies. In 1978, he founded the Hipple Cancer Research Center, now the Cancer Prevention Institute, where he served as President and Chief Executive Officer from 1985 to 1990 and was also a professor of medicine and principal investigator. Dr. Murphy is a member of the board of trustees of the American Cancer Society Foundation, a director of the Foundation for the National Institutes of Health and a charter member of C-Change, formerly the National Dialogue on Cancer. At the request of former President George H.W. Bush, Dr. Murphy has been convener of the non-profit CEO Roundtable on Cancer since its inception in 2001. He is also the executive editor of two international peer-reviewed scientific journals. Dr. Murphy received a Ph.D. degree in experimental hematology from New York University.

B. Jefferson Clark

Mr. Clark has served as a member of our board of directors since 2000. He co-founded The Aurora Funds, a venture capital firm, in 1994 and serves as its Managing General Partner. Mr. Clark currently serves on the boards of directors of several of Aurora’s private life science portfolio companies. He received a Bachelor of Science degree in Mechanical Engineering from Duke University and a Master of Business Administration degree from the Fuqua School of Business at Duke University.

Garheng Kong

Dr. Kong has served as a member of our board of directors since August 2004. He is a General Partner at Intersouth Partners, a venture capital firm, and has been associated with Intersouth since 2000. Dr. Kong received his M.D., Ph.D. in biomedical engineering and Master of Business Administration degrees from Duke University. He also holds Bachelor of Science degrees in chemical engineering and biological sciences from Stanford University. Dr. Kong served on the Duke University Medical Center Institutional Review Board from August 1999 to August 2000. Dr. Kong is also on the faculty at the Fuqua School of Business at Duke University as a Senior Scholar.

William E. Evans, PharmD

Dr. Evans has served as a member of our board of directors since August 2008. Since November 2004, Dr. Evans has served as a director and Chief Executive Officer of the St. Jude Children’s Research Hospital. Dr. Evans is also a professor at the University of Tennessee Colleges of Medicine and Pharmacy. Dr. Evans joined the St. Jude staff in 1976, served as the chair of the Department of Pharmaceutical Sciences from 1986 until 2002 and served as scientific director and executive vice president from 2002 until his promotion to Chief Executive Officer in November 2004. Dr. Evans received Bachelor of Science and PharmD degrees from the University of Tennessee.

Lyle A. Hohnke, Ph.D

Dr. Hohnke has served as a member of our board of directors since August 2008. He has been a partner of Tullis Dickerson, a healthcare-focused venture capital fund, since 1994. Dr. Hohnke holds Ph.D. and M.A. degrees from the University of Oregon and was a postdoctoral fellow at the UCLA School of Medicine. He also holds an M.B.A. degree from the Hartford Graduate Institute at Rensselaer Polytechnic Institute and a B.A. degree from Western Michigan University.

Board Composition

Our board of directors currently consists of seven members. Our board of directors has determined that all of our directors, other than Mr. Amick, are independent within the meaning of applicable NASDAQ listing standards.

Effective upon the completion of this offering, we will divide our board of directors into three classes, as follows:

•

Class I, which will consist of and , and whose term will expire at our first annual meeting of stockholders to be held after the completion of this offering;

•

Class II, which will consist of and , and whose term will expire at our second annual meeting of stockholders to be held after the completion of this offering; and

•

Class III, which will consist of , and whose term will expire at our third annual meeting of stockholders to be held after the completion of this offering.

At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will serve until the third annual meeting following their election and until their successors are duly elected and qualified. The authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This classification of the board of directors may have the effect of delaying or preventing changes in our control or management. Under our certificate of incorporation to be in effect upon the closing of this offering, our directors may be removed only for cause by the affirmative vote of the holders of 66²/3% of our voting stock.

Board Committees

Upon the completion of this offering, our board of directors will have an audit committee, a compensation committee and a nominating and corporate governance committee. At that time, each of these committees will have adopted a written charter that will be available on our corporate website. The composition and primary responsibilities of each committee are described below.

Audit Committee

Upon the completion of this offering, the members of our audit committee will be , and . will serve as chairman of the audit committee. Our board of directors has determined that each member of the audit committee meets the independence requirements of Rule 10A-3 of the Exchange Act and NASDAQ listing standards. Our board of directors has also determined that qualifies as an audit committee financial expert within the meaning of SEC regulations.

The primary purpose of the audit committee is to discharge the responsibilities of our board of directors with respect to our accounting, financial and other reporting and internal control practices and to oversee our independent registered public accounting firm. Specific responsibilities of our audit committee include:

•

evaluating the performance of our independent registered public accounting firm and determining whether to retain or terminate their services;

•

determining and pre-approving the engagement of our independent registered public accounting firm to perform audit services and any permissible non-audit services, other than immaterial aggregate amounts of non-audit services as excepted under applicable laws and rules;

•

reviewing and discussing with management and our independent registered public accounting firm the results of the annual audit and the independent registered public accounting firm’s review of our annual and quarterly financial statements and reports;

•

reviewing with management and our independent registered public accounting firm, significant issues that arise regarding accounting principles and financial statement presentation;

•

conferring with management and our independent registered public accounting firm, regarding the scope, adequacy and effectiveness of our internal control over financial reporting; and

•

establishing procedures for the receipt, retention and treatment of any complaints we receive regarding accounting, internal control or auditing matters.

Compensation Committee

Upon the completion of this offering, the members of our compensation committee will be , and . will serve as chairman of the compensation committee. Each member of the compensation committee is independent within the meaning of applicable NASDAQ listing standards, is a non-employee director as defined in Rule 16b-3 under the Exchange Act and is an outside director as that term is

defined in Section 162(m) of the Internal Revenue Code of 1986, or the Code. The purpose of our compensation committee is to discharge the responsibilities of our board of directors to oversee our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers and other senior management. Specific responsibilities of our compensation committee include:

•

determining the compensation and other terms of employment of our executive officers and reviewing and approving corporate performance goals and objectives relevant to such compensation;

•

evaluating and recommending to our board of directors the compensation plans and programs advisable for us, and evaluating and recommending the modification or termination of existing plans and programs; and

•

reviewing and approving the terms of any employment agreements, severance arrangements, change-of-control protections and any other compensatory arrangements for our executive officers.

Nominating and Corporate Governance Committee

Upon the completion of this offering, the members of our nominating and corporate governance committee will be , and . will serve as chairman of the nominating and corporate governance committee. Each member of the nominating and corporate governance committee is independent within the meaning of applicable NASDAQ listing standards. The specific responsibilities of our nominating and corporate governance committee include:

•

identifying, reviewing, evaluating and recommending for selection candidates for membership to our board of directors;

•

reviewing, evaluating and considering the recommendation for nomination of incumbent members of our board of directors for reelection to our board of directors and monitoring the size of our board of directors;

•

evaluating nominations by stockholders of candidates for election to our board of directors;

•

reviewing, discussing and reporting to our board of directors an assessment of our board’s performance; and

•

determining adherence to our corporate governance documents.

Compensation Committee Interlocks and Insider Participation

Mr. Amick, our chief executive officer, was formerly a member of our compensation committee. Mr. Amick resigned as a member of this committee during 2008. Other than Mr. Amick none of the members of the compensation committee is currently or has been at any time one of our officers or employees. None of our officers currently serve, nor have they served during the last completed fiscal year, as a member of the board of directors or compensation committee of any entity that has one or more officers serving as a member of our board of directors or compensation committee.

Non-Employee Director Compensation

The following table shows, for the fiscal year ended December 31, 2008, information with respect to the compensation of all of our non-employee directors. Prior to January 1, 2008, non-employee directors did not receive any cash compensation for attendance at board and committee meetings. Beginning in 2008, we pay Mr. Kimbrough, in his capacity as a director and chairman of our audit committee, a quarterly cash retainer of $1,000 and a fee of $3,000 per meeting attended, and we pay each of Dr. Murphy and Dr. Evans, in his capacity as a director, a quarterly cash retainer of $1,000 and a fee of $2,000 per meeting attended. Directors are also eligible for reimbursement for their reasonable expenses incurred in connection with attendance at board and committee meetings.


Name	Fees Earned or Paid in Cash		Option Awards⁽¹⁾		All Other Compensation	Total
Joel R. Kimbrough(2)	$	16,000	$	24,750	—	$	40,750
Martin J. Murphy(3)	$	12,000	$	16,383	—	$	28,383
William W. Brooke(4)		—		—	—		—
B. Jefferson Clark		—		—	—		—
Garheng Kong		—		—	—		—
William E. Evans(5)	$	6,000	$	10,821	—	$	16,821
Lyle A. Hohnke		—		—	—		—

(1)

(2)

In November 2007, our board of directors approved the grant of a stock option to Mr. Kimbrough to purchase 300,000 shares of common stock. This stock option has a grant date of January 1, 2008 and an exercise price of $0.397, which was equal to the fair market value of our common stock as determined by a retrospective valuation as of December 31, 2007. The shares subject to this option vest in three equal annual installments on each anniversary of the grant date, subject to continued service as a director of our company. This option had a grant date fair value of $75,000.

(3)

Upon joining our board of directors in May 2007, Dr. Murphy was granted a stock option to purchase 100,000 shares of our common stock at $0.20 per share. This option had a grant date fair value of $16,000 as determined in accordance with ASC 718, adjusted to disregard the effect of any estimate of forfeitures related to service-based vesting. The shares subject to this option vested as to 25% of the shares on the date of grant, and the remainder vest in three equal annual installments. In November 2007, our board of directors approved the grant of an additional stock option to Dr. Murphy to purchase 150,000 shares of common stock. This stock option has a grant date of January 1, 2008 and an exercise price of $0.397, which was equal to the fair market value of our common stock as determined by a retrospective valuation as of December 31, 2007. The shares subject to this option vest in three equal annual installments on each anniversary of the grant date, subject to continued service as a director of our company. This option had a grant date fair value of $37,500.

(4)	Mr. Brooke resigned as a member of our board of directors in May 2008.

(5)

Upon joining our board of directors in August 2008, Dr. Evans was granted a stock option to purchase 250,000 shares of our common stock at $0.626 per share, which was equal to the fair market value of our common stock as determined by our valuation as of April 15, 2008. The shares subject to this option vest in three equal annual installments on each anniversary of the grant date, subject to Dr. Evans’ continued service as a director of our company. This option had a grant date fair value of $93,500.

We expect that our board of directors will adopt a formal compensation program for non-employee directors. If adopted, this compensation program will be effective immediately upon the closing of this offering.

EXECUTIVE COMPENSATION

The following discussion and analysis of compensation arrangements of our named executive officers for our fiscal year ended December 31, 2008 should be read together with the compensation tables and related disclosures set forth below. This discussion contains forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt may differ materially from currently planned programs as summarized in this discussion.

Compensation Discussion and Analysis

Our executive compensation program is designed to help us attract talented individuals to manage and operate all aspects of our business, to reward those individuals fairly over time and to retain those individuals who continue to meet our high expectations. The goals of our executive compensation program are to align our executive officers’ compensation with our business objectives and the interests of our stockholders, to incentivize and reward our executive officers for our success and to reflect the teamwork philosophy of our executive management team. To achieve these goals, we have established executive compensation and benefit packages that are generally based on a mix of base salary, cash incentive payments and equity awards, in the proportions that our board believes are the most appropriate to incentivize and reward our executive officers for achieving our objectives. Our executive compensation program is also intended to make us competitive in the biopharmaceutical industry, where there is significant competition for talented employees, and to be fair relative to other professionals within our organization. We believe that we must provide competitive compensation packages to attract and retain the most talented and dedicated executive officers possible and to help our executive management team function as a stable unit over the longer term.

Role of Our President and Our Chief Executive Officer in Setting Executive Compensation

We initially establish executive officers’ compensation arrangements when negotiating their employment when they join our company. We generally include these initial compensation terms in an offer letter or employment agreement with the executive. Additionally, we conduct an annual review of executive compensation, as well as the mix of elements used to compensate our executive officers. In connection with each annual review cycle, Edward Field, our President, and Thomas Amick, our Chief Executive Officer, each meet with those officers who report directly to them to discuss the company’s accomplishments during the year and the individual’s performance and contributions to those accomplishments over the prior year. Based on these discussions, our President and our Chief Executive Officer then develop a set of compensation recommendations for submission to the compensation committee. In making these recommendations, our President and our Chief Executive Officer also seek input, as appropriate, from representatives of the venture capital funds who have invested in our company, including some of our outside directors, in order to ensure that their compensation recommendations are generally consistent with the compensation paid to executives of comparable companies.

Role of Our Board and Compensation Committee in Setting Executive Compensation

Our board of directors has established a compensation committee for the purpose of making recommendations to the full board regarding compensation decisions for our executive officers. The compensation committee currently consists of Mr. Kimbrough and Drs. Kong and Murphy. In carrying out its responsibilities, our compensation committee receives and evaluates the compensation recommendations made by our President and our Chief Executive Officer as described above. None of our executive officers participates in the discussions regarding his own compensation. Based on the evaluation of management’s suggestions, the compensation committee then makes formal recommendations regarding executive compensation decisions to the full board of directors. In making these recommendations, the compensation committee does not delegate any of its functions to others, and has historically not engaged a compensation consultant to advise it in making its compensation recommendations. Instead, the committee members have relied on their own experience and

observations in the marketplace in assessing and making recommendations regarding executive compensation. Our board of directors evaluates the recommendations from the compensation committee and makes final decisions regarding executive compensation.

Our compensation committee consists solely of directors who are “outside directors” for purposes of Section 162(m) and “non-employee directors” for purposes of Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

Elements of our Executive Compensation Program

General. Our executive compensation program consists of three principal components: base salary, cash bonus payments and long-term incentive compensation in the form of equity awards. Each component of our executive compensation program is designed to address specific compensation objectives. Our executive officers are also eligible to participate, on the same basis as other employees, in our 401(k) plan and our other benefit programs generally available to all employees. We have not adopted any formal guidelines for allocating total compensation among these elements. However, in order to incentivize our executive officers to focus their efforts on our corporate success, we intend to implement and maintain compensation plans that provide for a substantial portion of our executive officers’ overall compensation to consist of cash bonuses and long-term equity compensation. Additionally, pursuant to the terms of offer letters and employment agreements, some of our executive officers are entitled to receive severance payments in the event that their employment is terminated without cause.

We view each of the elements of our compensation program as related but distinct. Our decisions about each individual element generally do not affect the decisions we make about other elements. For example, we do not believe that significant compensation derived from one element of compensation, such as equity appreciation, should necessarily negate or reduce compensation from other elements, such as salary or bonus.

Base Salary. Upon joining the company, each of our executive officers either entered into an employment agreement or received an offer letter that provided for an initial base salary. These initial salaries are the product of negotiation with the executive, but we generally seek to establish salaries that we believe are commensurate with the salaries being paid to executive officers serving in similar roles at comparable biopharmaceutical companies. We do not engage in any formal benchmarking of salaries. Instead, we have historically relied on our compensation committee members’ collective experience in the marketplace for determining what they believe to be the market rate of salaries for executives of comparable companies. In determining these market salaries, the members of our compensation committee also seek input from the venture capitalists on our board of directors with regard to the general levels of salaries of similarly situated executives of their respective portfolio companies and other companies about which they have knowledge.

Shortly before the end of each calendar year, we review company and individual performance to, among other things, determine whether adjustments in base salary are necessary or appropriate. In establishing the 2008 base salaries of our executive officers, our compensation committee and board of directors took into account a number of factors, including the executive’s seniority, position, functional role and level of responsibility and individual performance during 2007. We will continue to review base salaries of our executive officers on an annual basis and make adjustments to reflect individual performance-based factors, as well as our financial status. Historically, we have not applied, nor do we intend to apply, specific formulas to determine base salary increases.

Cash Bonuses. In addition to base salaries, our executive officers are eligible to receive annual discretionary cash bonuses. The annual cash bonuses are intended to compensate our executive officers for their individual contributions to our achievement of corporate goals. Our annual cash bonus amounts are recommended by our compensation committee and approved by our board, and these bonuses are ordinarily paid in a single installment in the first quarter of each year for performance in the prior year. Each executive officer is eligible for a

100

discretionary annual cash incentive payment up to an amount equal to a specified percentage of the executive officer’s salary. The board of directors sets these target percentages at levels that, upon achievement of the target percentage, are likely to result in cash bonus payments that the board believes to be approximately the level paid to high-performing executives of comparable companies in the biopharmaceutical industry.

As described above, at the end of each year, our President and our Chief Executive Officer develop bonus recommendations for each of our executive officers, based on the company’s corporate accomplishments and the individual’s performance and contributions to those accomplishments during the year. These recommendations are subjective determinations which may vary, from time to time, depending on our overall strategic objectives and the job responsibilities of each executive officer, but relate generally to factors such as development and progression of our existing product candidates, achievement of clinical and regulatory milestones, operational goals such as the expansion of our manufacturing capabilities, and financial factors such as raising and maintaining capital. However, these recommendations may be more or less than the established target percentages for the executive officers, depending on individual and corporate performance, as well as our financial position. The compensation committee assesses the bonuses recommended by management and makes its bonus recommendations to the full board of directors. Based on its consideration of the recommendations of the compensation committee, the full board then makes a final decision regarding cash bonus payments, if any, for the year. Whether or not a cash bonus is paid for any year is solely within the discretion of the board of directors.

For 2008, based upon recommendations of the compensation committee, the board of directors established the target amounts of cash bonuses at 25% of the base salary for each of our executive officers. The compensation committee then made its bonus recommendations in December 2008, following a review of our corporate accomplishments during the year, which included:

•

Initiation of our pivotal Phase 3 clinical trial of ALD-101 with enrollment of three sites and over 10 patients;

•

Receipt of orphan drug designation for ALD-101;

•

Completion of our Phase 1/2 clinical trial of ALD-301, receipt of a positive clinical data set from this trial, and the submission of a special protocol assessment to the FDA for a potential pivotal Phase 3 clinical trial;

•

Completion of enrollment for our Phase 1 clinical trial of ALD-201;

•

Initiation of our Phase 1 clinical trial of ALD-151 with enrollment of five patients;

•

Submission of an IND for a Phase I clinical trial of ALD-601;

•

Receipt of positive preclinical data in the post-acute treatment of ischemic stroke for our ALD-401 product candidate;

•

Expansion of our manufacturing capabilities, including the construction of a cGMP facility, while meeting all of our clinical needs for the manufacture of our product candidates;

•

An equity financing transaction;

•

Filing of a registration statement for an initial public offering; and

•

Strengthening of our management team by adding a chief financial officer.

After considering our corporate accomplishments during the year, the compensation committee also made a subjective assessment of each executive officer’s individual contribution to the achievement of each of those accomplishments. In the case of Mr. Amick, the committee considered his overall responsibility in leading our company through the significant corporate developments referenced above. For Mr. Field, the committee considered his role in running our day-to-day operations, including the achievements referenced above. In the case of Mr. Carberry, the committee considered his primary responsibility, as our principal

101

financial and accounting officer, for our Series C-1 convertible preferred stock financing that closed in April 2008 and the filing of the registration statement for our proposed IPO in May 2008. For Dr. Balber, the committee considered his role in overseeing our scientific progress during 2008, particularly the preclinical development of our product candidates. In the case of Dr. Keller, the committee considered our progress in the enrollment of our ongoing clinical trials during 2008.

The committee also considered the recent economic downturn, with members observing an overall reduction in cash incentives being paid to executives of comparable private companies. As a result, the committee, in its discretion, made bonus recommendations of somewhat less than the original 25% target for each executive officer. In December 2008, the board of directors adopted the bonus recommendations of the compensation committee. The bonuses paid to Mr. Amick, Mr. Field, Mr. Carberry, Dr. Balber and Dr. Keller were equal to 20%, 16%, 14%, 15% and 10% of their 2008 base salaries, respectively.

We have not determined whether we would attempt to recover cash bonus payments paid to our executive officers if the performance objectives that led to the determination of such payments were to be restated, or found not to have been met to the extent that we originally believed.

Long-Term Equity Compensation. The salary and cash bonus payment components of our executive compensation program are intended to compensate our executive officers for short-term performance. We believe that long-term performance is best incentivized through an ownership culture that encourages performance by our executive officers through the use of stock options. Our equity benefit plans have been established to provide our employees, including our executive officers, with incentives to help align those employees’ interests with the interests of our stockholders. We believe that the use of stock options, which only provide value to the executive officer if the value of our common stock increases, offers the best approach to achieving our compensation goals and provides tax and other advantages to our executive officers relative to other forms of equity compensation. We believe that our equity benefit plans are an important retention tool for our employees.

Initial option grants to our executive officers are generally set forth in an offer letter or employment agreement. These initial option grants are the product of negotiation with the executive, but we generally seek to establish equity ownership levels that we believe are commensurate with the equity stakes held by executive officers serving in similar roles at comparable biopharmaceutical companies. In addition, as part of our annual compensation review process, we provide subsequent option grants to those executive officers determined to be performing well.

We have not formally adopted stock ownership guidelines, although through December 31, 2007 Mr. Amick had historically been awarded options that allow him to maintain an ownership of our company equal to 5% of our capital stock on a fully diluted basis. With the exception of Dr. Balber, who as a founder of our company received shares of restricted stock at our inception, which shares have since vested in full, our equity benefit plans have provided the principal method for our executive officers to acquire equity in our company. Prior to this offering, we have granted stock options exclusively through our 2000 stock option plan, which was adopted by our board of directors and approved by our stockholders to permit the grant of stock options to our employees, officers, directors, consultants, advisors and independent contractors. In 2008, each of our named executive officers, who are designated below under “—Executive Compensation—Summary Compensation Table,” were awarded stock options under our 2000 stock option plan in the amounts indicated in the section below entitled “—Executive Compensation—Stock Option Grants in 2008.” In determining the size of the stock option grants to our executive officers, the compensation committee and board of directors took into account each executive officer’s existing ownership stake in our company, as well as his position, scope of responsibility, ability to affect stockholder value, historic and recent performance, and the equity ownership levels of executive officers in similar roles of comparable companies in our industry.

In connection with this offering, our board of directors has adopted a new equity benefit plan described under “—Employee Benefit Plans” below. The 2009 equity incentive plan will replace our existing 2000 stock

102

option plan immediately following this offering and, as described below, will afford our compensation committee much greater flexibility in making a wide variety of equity awards, as it determines to be appropriate.

Severance and Change of Control Benefits. Under their employment agreements and offer letters, some of our executive officers are entitled to cash severance benefits if they are terminated without cause. In some instances, this may include reimbursement for the costs of continued health insurance premiums for a period of time after termination of employment. The terms of these arrangements are more fully described below under “—Termination of Employment and Change of Control Arrangements.”

401(k) Plan. Our employees, including our executive officers, are eligible to participate in our 401(k) plan. Our 401(k) plan is intended to qualify as a tax qualified plan under Section 401 of the Code. Our 401(k) plan provides that each participant may contribute a portion of his or her pretax compensation, up to a statutory limit, which for most employees is $16,500 in 2009, with a larger “catch up” limit for older employees. Employee contributions are held and invested by the plan’s trustee. Beginning in 2008, we began providing a 100% match on employee contributions on the first 3% of each contributing employee’s salary and a 50% match on an additional 2% of salary contributed.

Other Benefits and Perquisites. We provide medical insurance, dental insurance, vision coverage, life insurance and accidental death and dismemberment insurance benefits to all full-time employees, including our executive officers. These benefits are available to all employees, subject to applicable laws. Our executive officers generally do not receive any perquisites, except that we pay temporary living expenses for Mr. Amick in connection with his travel from his residence to our corporate headquarters. However, from time to time, we have provided relocation expenses in connection with the relocation of executive officers to the geographic area of our corporate headquarters in Durham, North Carolina. We intend to continue to provide relocation expenses in the future, as necessary, to obtain the services of qualified individuals.

Other Compensation. We intend to continue to maintain the current benefits for our executive officers, which are also available to all of our other employees; however, our compensation committee, in its discretion, may in the future revise, amend or add to the benefits of any executive officer if it deems it advisable.

Federal Tax Considerations Under Sections 162(m) and 409A

Section 162(m) of the Code limits our deduction for federal income tax purposes to not more than $1 million of compensation paid to specified executive officers in a calendar year. Compensation above $1 million may be deducted if it is performance-based compensation within the meaning of Section 162(m). Our compensation committee has not yet established a policy for determining which forms of incentive compensation awarded to our executive officers will be designed to qualify as performance-based compensation. To maintain flexibility in compensating our executive officers in a manner designed to promote our objectives, our compensation committee has not adopted a policy that requires all compensation to be deductible. However, the committee intends to evaluate the effects of the compensation limits of Section 162(m) on any compensation it proposes to grant, and the compensation committee intends to provide future compensation in a manner consistent with our best interests and those of our stockholders.

Section 409A of the Code addresses the tax treatment of nonqualified deferred compensation benefits and provides for significant taxes and penalties in the case of payment of nonqualified deferred compensation. We currently intend to structure our executive compensation programs to avoid triggering these taxes and penalties under Section 409A.

Accounting Considerations

Effective January 1, 2006, we adopted the fair value provisions of ASC 718. Under ASC 718, we are required to estimate and record an expense for each award of equity compensation, including stock options, over

103

the vesting period of the award. Our board of directors has determined to retain for the foreseeable future our stock option program as the sole component of its long-term compensation program, and, therefore, to record this expense on an ongoing basis according to ASC 718. Our compensation committee may in the future consider the grant of restricted stock or other equity-based awards to our executive officers in lieu of stock option grants, in light of the accounting impact of ASC 718 with respect to stock option grants.

Summary Compensation Table

The following table sets forth information regarding compensation earned during the years ended December 31, 2008 and 2007 by our principal executive officer, our principal financial officer, and our three other most highly compensated executive officers serving as executive officers at December 31, 2008 whose total compensation exceeded $100,000 for the year ended December 31, 2008. We refer to these persons as our named executive officers.


Name and Principal Position	Year	Salary ($)	Bonus ($)	Option Awards(1) ($)	All Other Compensation ($)		Total ($)
W. Thomas Amick	2008	280,000	55,000	107,511	34,299	(2)	476,810
Chairman of the Board of Directors and Chief Executive Officer	2007	250,000	60,000	93,971	38,378	(2)	442,349


Edward L. Field	2008	243,600	40,000	25,538	—		309,138
President and Chief Operating Officer(3)	2007	217,500	43,500	12,875	—		273,875

David P. Carberry	2008	179,166	25,000	52,205	—		256,371
Chief Financial Officer(4)	2007	—	—	—	—		—

Andrew E. Balber	2008	197,635	30,000	8,003	—		235,638
Chief Scientific Officer	2007	188,225	29,650	2,719	—		220,594

Laurence H. Keller	2008	255,000	25,000	16,239	39,429	(6)	335,668
Vice President of Medical Affairs and Former Chief Medical Officer(5)	2007	10,417	—	—	—		10,417

(1)

The assumptions we used in valuing options are described under the caption “Share-Based Compensation” in note 2 to our financial statements included in this prospectus. This column reflects compensation expense that would be recorded under ASC 718 as stock-based compensation in our financial statements for the indicated year in connection with options we granted in the indicated year and in prior years, adjusted to disregard the effects of any estimate of forfeitures related to service-based vesting, if we had adopted the modified-prospective transition method of ASC 718. As a result, unlike our financial statements for the indicated year, the amounts in the table include values associated with stock options that were granted prior to January 1, 2006 and that had not fully vested prior to the indicated year, and assume that the executive will perform the requisite service for the award to vest.

(2)	Amount represents the cost of temporary living expenses for Mr. Amick during the indicated year that we reimbursed or paid on his behalf.

(3)	Mr. Field served in the capacity of our principal financial officer during 2008 until the commencement of Mr. Carberry’s employment in March 2008.

(4)	Mr. Carberry became our Chief Financial Officer in March 2008.

(5)	Dr. Keller’s employment with us commenced in December 2007 and he ceased to be our Chief Medical Officer in October 2009.

(6)	Amount represents the cost of temporary living and relocation expenses for Dr. Keller during the year that we reimbursed or paid on his behalf, including a gross-up for taxes.

104

Stock Option Grants in 2008

All options granted to our named executive officers in 2008 were incentive stock options, to the extent permissible under the Code. The exercise price per share of each option granted to our named executive officers was equal to the fair market value of our common stock as determined by our board of directors on the date of the grant. Our common stock was not publicly traded in 2008 and accordingly, no actual closing price for the common stock on the grant date is available. In determining the fair market value of our common stock granted on the grant date, our board of directors considered many factors, including:

•

the rate of progress of our clinical trials and other research and development activities;

•

the fact that our options involved illiquid securities in a non-public company;

•

prices of preferred stock we issued to outside investors in arm’s-length transactions;

•

the rights, preferences and privileges of our preferred stock over our common stock; and

•

the likelihood that our common stock would become liquid through an initial public offering, an acquisition of us or another event.

The following table sets forth information regarding grants of plan-based awards to the named executive officers during the year ended December 31, 2008. All awards were stock options granted under our 2000 stock option plan.


	Grant date	Number of Shares Underlying Option Awards	Exercise Price of Option Awards ($/sh)		Grant Date Fair Value of Option Awards(1)
W. Thomas Amick	January 1, 2008	501,467	$	0.397	$	125,367

Edward L. Field	January 1, 2008	200,000		0.397		50,000

David P. Carberry	April 15, 2008	400,000		0.626		156,000

Andrew E. Balber	January 1, 2008	75,000		0.397		18,750

Laurence H. Keller	—	—		—		—

(1)

The assumptions we used in valuing the options we granted during 2008 are described under the caption “Share-Based Compensation” in note 2 to our financial statements included in this prospectus. This column reflects the amount we will record under ASC 718 as stock-based compensation in our financial statements in connection with these options over the entire term of the options, adjusted to disregard the effects of any estimate of forfeitures related to service-based vesting. Instead, it assumes that the executive will perform the requisite service for the award to vest.

105

Outstanding Equity Awards at End of 2008

The following table provides information about outstanding stock options held by each of our named executive officers at December 31, 2008. All of these options were granted under our 2000 stock option plan. Our named executive officers did not hold any restricted stock or other stock awards at the end of 2008. Our named executive officers did not exercise any stock options during 2008 and they did not have any stock awards that vested in 2008.


	Number of Shares Underlying Unexercised Options				Option Exercise Price		Option Expiration Date
Name	(#) Exercisable		(#) Unexercisable		Option Exercise Price		Option Expiration Date
W. Thomas Amick	212,289	(1)	—		$	0.20	March 2, 2015
	614,418		279,424	(2)		0.20	March 23, 2016
	473,927		559,942	(3)		0.20	February 27, 2017
	114,901		386,566	(7)		0.397	January 1, 2018
Edward L. Field	300,000	(4)	—			0.20	October 4, 2014
	137,520		162,480	(3)		0.20	February 27, 2017
	45,826		154,174	(7)		0.397	January 1, 2018
Andrew E. Balber	50,000	(5)	—			0.20	March 4, 2013
	34,380		40,620	(3)		0.20	February 27, 2017
	17,184		57,816	(7)		0.397	January 1, 2018
David P. Carberry	100,000		300,000	(6)		0.626	April 15, 2018
Laurence H. Keller	62,500		187,500	(8)		0.397	December 17, 2017

(1)	These options vested six months following the date of grant and are now fully vested.

(2)	These options vest in 48 equal monthly installments through March 23, 2010.

(3)	These options vested as to 25% of the shares on February 26, 2008 and vest as to an additional 1/48th of the shares per month thereafter.

(4)	These options vested over a period of three years from the date of grant and are now fully vested.

(5)	These options vested over a period of four years beginning March 4, 2003 and are now fully vested.

(6)	These options vested as to 25% of the shares on September 3, 2008 and 12.5% of the shares on March 3, 2009 and will vest as to an additional 2.084% of the shares per month thereafter.

(7)	These options vest in 48 equal installments through January 1, 2012.

(8)	These options vested as to 25% of the shares on December 17, 2008 and vest as to an additional 2.084% of the shares per month thereafter.

Termination of Employment and Change of Control Arrangements

Potential Payments Under Employment Arrangements

Edward Field. In September 2004, we entered into an offer letter with Mr. Field, pursuant to which, if we terminate his employment at any time without cause, he would be entitled to receive an amount equal to three months’ then base salary, subject to signing an acceptable release in favor of our company. In addition, Mr. Field would be entitled to receive continuation of standard health benefits payable by us for a period of three months, or a shorter period if he obtains reasonably comparable coverage from another employer. For purposes of the offer letter, termination for cause would include Mr. Field’s material breach of the terms of his employment or his failure to diligently and properly perform his duties for us, his misappropriation or unauthorized use of our property, his material failure to comply with the reasonable policies and directives of management or our board of directors, the use of illegal drugs or substances or alcohol in any manner that materially interferes with the performance of his duties, any action that is illegal or dishonest and which is detrimental to our interest, well-being and reputation, his failure to disclose any material conflict of interest in a transaction between us and a third party that is materially detrimental to our interests and well-being, or any adverse act of omission that

106

would be required to be disclosed pursuant to federal securities laws or that would limit our ability to sell securities or disqualify us from any securities law exemption otherwise available to us. Under this offer letter, if Mr. Field’s employment was terminated by us without cause on December 31, 2008, he would have been entitled to severance in the amount of $63,498 and continuation of health benefits in the amount of $2,571.

Andrew Balber. In October 2000, we entered into an offer letter with Dr. Balber, pursuant to which, if we terminate his employment at any time without cause, he would be entitled to receive an amount equal to six months’ then base salary, payable on our normal payroll dates. For purposes of the offer letter, termination for cause would include any material breach of the terms of any agreement between Dr. Balber and us or his failure to diligently and properly perform his duties for us, his material failure to comply with the reasonable policies and directives of management or our board of directors, any action that is illegal or not in good faith and which is detrimental to our interest and well-being, his failure to disclose any material conflict of interest in a transaction between us and a third party that is materially detrimental to our interests and well-being, any adverse act of omission that would be required to be disclosed pursuant to federal securities laws or that would limit our ability to sell securities or disqualify us from any securities law exemption otherwise available to us, or any violation of our corporate policies prohibiting harassment or unlawful discrimination. Under this offer letter, if Dr. Balber’s employment was terminated by us without cause on December 31, 2008, he would have been entitled to severance pay in the amount of $103,017.

None of our other named executive officers are currently entitled to payments upon termination of employment or in connection with a change of control transaction other than amounts earned during the term of employment, including salary, vested options and vacation pay.

Option Acceleration Under Equity Incentive Plans

Under our 2000 stock option plan and the 2009 equity incentive plan to be in effect following the closing of this offering, the vesting of stock options granted to our employees and officers may be accelerated by our board of directors in connection with specified change in control transactions. However, to date, the board of directors has not committed us to accelerate the vesting of any options in connection with such a transaction.

Confidential Information and Inventions Agreement

Each of our named executive officers has entered into a standard form agreement with respect to confidential information and inventions. Among other things, this agreement obligates each named executive officer to refrain from disclosing any of our confidential information received during the course of employment and, with some exceptions, to assign to us any inventions conceived or developed during the course of employment.

Employee Benefit Plans

We believe that our ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees and directors with the financial interests of our stockholders. In addition, we believe that our ability to grant options and other equity-based awards helps us to attract, retain and motivate qualified employees, and encourages them to devote their best efforts to our business and financial success. The material terms of our equity incentive plans are described below.

Stock Option Plan

Our board of directors adopted, and our stockholders approved, our stock option plan, or the 2000 stock option plan, in May 2000. As of September 30, 2009, an aggregate of 10,000,000 shares of common stock were reserved for issuance under the 2000 stock option plan. The 2000 stock option plan provides for the grant of incentive stock options and nonstatutory stock options. As of September 30, 2009, options to purchase 6,655,463

107

shares of common stock at a weighted average exercise price per share of $0.32 were outstanding under the 2000 stock option plan. As of September 30, 2009, 3,135,790 shares of common stock remained available for future issuance.

Our board of directors has the authority to construe and interpret the terms of the 2000 stock option plan and the options granted under it. After the effectiveness of the 2009 equity incentive plan described below, we will make no further stock option grants under the 2000 stock option plan, but all outstanding options will continue to be governed by their existing terms.

Transfer of Shares to 2009 Equity Incentive Plan. Following this offering, any shares of common stock that have been reserved for issuance under the 2000 stock option plan, but which are not subject to any outstanding stock option award at the time of the completion of this offering, shall no longer be available for issuance under the 2000 stock option plan, but instead shall be considered shares that are available for awards under our 2009 equity incentive plan. In addition, if any outstanding stock option award under the 2000 stock option plan is forfeited, cancelled, or terminated for any reason without such option being exercised, either in part or whole, then the shares of common stock subject to the unexercised portion of such stock option shall revert to and become available for issuance under the 2009 equity incentive plan. In the event an optionee’s service relationship with us, or one of our affiliates, terminates for cause, any outstanding options under the 2000 stock option plan are cancelled and forfeited.

Stock Options. The 2000 stock option plan provides for the grant of incentive stock options under the federal tax laws and the grant of nonstatutory stock options. Only employees may receive incentive stock options, but nonstatutory stock options may be granted to employees, non-employee directors, advisors, independent contractors and consultants. The exercise price of incentive stock options may not be less than 100% of the fair market value of our common stock on the date of grant. Shares subject to options under the 2000 stock option plan generally vest in a series of installments over a specified period of service, typically four years. In general, except as described below, the term of options granted under the 2000 stock option plan may not exceed 10 years.

Unless the terms of an optionee’s stock option agreement provide otherwise, if an optionee’s service relationship with us, or any of our affiliates, ceases for any reason other than termination for cause, disability or death, the optionee may exercise the vested portion of any options for three months after the date of such termination. If an optionee’s service relationship with us, or any of our affiliates, ceases due to disability or death or an optionee dies within a certain period following cessation of service, the optionee or a beneficiary may exercise any vested portion of an option for a period of 12 months. In no event, however, may an option be exercised beyond the expiration of its term.

Tax Limitations on Incentive Stock Options. Incentive stock options may be granted only to our employees. The aggregate fair market value, determined at the time of grant, of shares of our common stock with respect to incentive stock options that are exercisable for the first time by an optionee during any calendar year under all of our stock plans may not exceed $100,000. No incentive stock option may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and the term of the incentive stock option does not exceed five years from the date of grant.

Corporate Transactions. Unless otherwise determined by the board of directors at the time of grant, in the event of a merger, consolidation, corporate reorganization or any transaction in which all or substantially all of our assets or stock are sold, leased, transferred or otherwise disposed of, any unvested portion of a stock option granted under the 2000 stock option plan will become fully vested, unless the surviving or acquiring corporation assumes or substitutes comparable options for the outstanding options granted under the 2000 stock option plan or replaces the options with a cash incentive program that preserves the intrinsic value of the options at the time of the transaction and provides for subsequent payout over the same vesting schedules as the options being replaced.

108

2009 Equity Incentive Plan

Our board of directors and stockholders adopted the 2009 Equity Incentive Plan, or the 2009 equity incentive plan, in 2009. The 2009 equity incentive plan will become effective immediately upon the signing of the underwriting agreement for this offering. The 2009 equity incentive plan will terminate on , 2019, unless sooner terminated by our board of directors.

Stock Awards. The 2009 equity incentive plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of equity compensation, which may be granted to employees, including officers, non-employee directors, and consultants.

Initial Share Reserve; Transfer of Shares from 2000 stock option plan. Following this offering, the aggregate number of shares of our common stock that may be issued initially pursuant to stock awards under the 2009 equity incentive plan is shares, plus any shares of our common stock that were previously held in reserve under the 2000 stock option plan, but which were unused and which have been transferred to the 2009 equity incentive plan. Additionally, if any outstanding stock options granted under the 2000 stock option plan should for any reason expire or otherwise terminate, in whole or in part, without having been exercised in full, or if any shares of common stock issued under the 2000 stock option plan are reacquired by or returned to us for any reason, including the failure to satisfy a vesting contingency, the shares of common stock that are not acquired, or which are returned, will revert to and become available for issuance under the 2009 equity incentive plan.

Evergreen Share Replacement Feature. The number of shares of our common stock reserved for issuance will automatically increase on each January 1, from January 1, 20 through January 1, 20 , by the lesser of 5% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year, or shares.

Maximum Number of Shares Issued through Incentive Stock Options. The maximum number of shares that may be issued pursuant to the exercise of incentive stock options under the 2009 equity incentive plan is shares of common stock, which equals the total initial share reserve, as increased from time to time pursuant to annual “evergreen” increases, plus shares subject to awards granted under the 2000 stock option plan that may be transferred to the 2009 equity incentive plan.

Section 162(m) Limits. No person may be granted awards covering more than shares of our common stock under the 2009 equity incentive plan during any calendar year pursuant to an appreciation-only stock award. An appreciation-only stock award is a stock award whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the fair market value of our common stock on the date of grant. A stock option with an exercise price equal to the value of the stock on the date of grant is an example of an appreciation-only award. Such limitation is designed to help assure that any deductions to which we would otherwise be entitled upon the exercise of an appreciation-only stock award or upon the subsequent sale of shares purchased under such an award, will not be subject to the $1,000,000 limitation on the income tax deductibility of compensation paid per covered executive officer imposed by Section 162(m) of the Code.

Reversion of Shares. If a stock award granted under the 2009 equity incentive plan expires or otherwise terminates without being exercised in full, the shares of our common stock not acquired pursuant to the stock award again become available for subsequent issuance under the 2009 equity incentive plan. In addition, the following types of shares under the 2009 equity incentive plan may become available for the grant of new stock awards under the 2009 equity incentive plan:

•

shares that are forfeited to or repurchased by us prior to becoming fully vested;

•

shares withheld to satisfy income and employment withholding taxes;

•

shares used to pay the exercise price of an option in a net exercise arrangement;

109

•

shares tendered to us to pay the exercise price of an option; and

•

shares that are cancelled pursuant to an exchange or repricing program.

Shares issued under the 2009 equity incentive plan may be previously unissued shares or reacquired shares bought on the open market. No shares of our common stock have been issued under the 2009 equity incentive plan.

Administration. Our board of directors has delegated its authority to administer the 2009 equity incentive plan to our compensation committee. Subject to the terms of the 2009 equity incentive plan, our board of directors or an authorized committee, referred to as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted, and the terms and conditions of the stock awards, including the period of their exercisability and vesting. Subject to the limitations set forth below, the plan administrator will also determine the exercise price of options granted, the consideration to be paid for restricted stock awards, and the strike price of stock appreciation rights.

The plan administrator has the authority, under appropriate circumstances, to:

•

reduce the exercise price of any outstanding option or the strike price of any outstanding stock appreciation right;

•

cancel any outstanding option or stock appreciation right and to grant in exchange one or more of the following:

•

new options or stock appreciation rights covering the same or a different number of shares of common stock,

•

new stock awards,

•

cash, and/or

•

other valuable consideration; or

•

engage in any action that is treated as a repricing under generally accepted accounting principles.

Stock Options. Incentive and nonstatutory stock options are granted pursuant to incentive and nonstatutory stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for a stock option, within the terms and conditions of the 2009 equity incentive plan, provided that the exercise price of an incentive stock option and nonstatutory stock option cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2009 equity incentive plan vest at the rate specified by the plan administrator.

Generally, the plan administrator determines the term of stock options granted under the 2009 equity incentive plan, up to a maximum of 10 years, except in the case of specified incentive stock options, as described below. Unless the terms of an optionee’s stock option agreement provide otherwise, if an optionee’s service relationship with us, or any of our affiliates, ceases for any reason other than a termination for “cause” or a termination because of disability or death, the optionee may exercise the vested portion of any options for a period of three months following the cessation of service. If an optionee’s service relationship with us, or any of our affiliates, ceases due to disability or death or an optionee dies within a specified period following cessation of service, the optionee or a beneficiary may exercise the vested portion of any options for a period of 12 months in the event of death or disability. In the event of a termination of an optionee’s services for cause, the unexercised portion of any outstanding stock option held by the optionee will be forfeited and may not be exercised. The option term may be extended in the event that exercise of the option following termination of service is prohibited by applicable securities laws. In no event, however, may an option be exercised beyond the expiration of its term.

110

Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include cash or check, a broker-assisted cashless exercise, the tender of common stock previously owned by the optionee, a net exercise of the option, and other legal consideration approved by the plan administrator.

Unless the plan administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic relations order. An optionee may designate a beneficiary, however, who may exercise the option following the optionee’s death.

Restricted Stock Awards. Restricted stock awards are granted pursuant to restricted stock award agreements adopted by the plan administrator. Restricted stock awards may be granted in consideration for cash or check, past or future services rendered to us or our affiliates, or any other form of legal consideration. Shares of common stock acquired under a restricted stock award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the plan administrator. Rights to acquire shares under a restricted stock award may be transferred only upon such terms and conditions as set by the plan administrator.

Restricted Stock Unit Awards. A restricted stock unit is a promise by us to issue shares of our common stock, or to pay cash equal to the value of shares of our common stock, equivalent to the number of units covered by the award at the time of vesting of the units or thereafter. Restricted stock unit awards are granted pursuant to restricted stock unit award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect to shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant’s cessation of continuous service for any reason.

Stock Appreciation Rights. A stock appreciation right entitles the participant to a payment equal in value to the appreciation in the value of the underlying shares of our common stock for a predetermined number of shares over a specified period. Stock appreciation rights are granted pursuant to stock appreciation rights agreements adopted by the plan administrator. The plan administrator determines the strike price for a stock appreciation right which cannot be less than 100% of the fair market value of our common stock on the date of grant. Upon the exercise of a stock appreciation right, we will pay the participant an amount equal to the product of (a) the excess of the per share fair market value of our common stock on the date of exercise over the strike price, multiplied by (b) the number of shares of common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2009 equity incentive plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator.

The plan administrator determines the term of stock appreciation rights granted under the 2009 equity incentive plan, up to a maximum of 10 years. If a participant’s service relationship with us, or any of our affiliates, ceases, then the participant, or the participant’s beneficiary, may exercise any vested stock appreciation right for three months, or such longer or shorter period specified in the stock appreciation right agreement, after

111

the date such service relationship ends. If a participant’s service relationship is terminated for cause, any unexercised stock appreciation right will terminate immediately and may not be exercised. In no event, however, may a stock appreciation right be exercised beyond the expiration of its term.

Performance Stock Awards. The 2009 equity incentive plan permits the grant of performance stock awards that may qualify as performance-based compensation that is not subject to the $1,000,000 limitation on the income tax deductibility of compensation paid per covered executive officer imposed by Section 162(m) of the Code. To assure that the compensation attributable to one or more performance stock awards will so qualify, our compensation committee can structure one or more such awards so that stock will be issued or paid pursuant to such award only upon the achievement of certain pre-established performance goals during a designated performance period. The maximum benefit to be received by a participant in any calendar year attributable to performance stock awards may not exceed shares of our common stock.

Other Stock Awards. The plan administrator may grant other awards based in whole or in part by reference to our common stock. The plan administrator will set the number of shares under the award and all other terms and conditions of such awards.

Adjustment provisions. Transactions not involving our receipt of consideration, such as certain mergers, consolidations, reorganizations, stock dividends, or stock splits, may change the type, class and number of shares of our common stock subject to the 2009 equity incentive plan and outstanding awards. In that event, the 2009 equity incentive plan will be appropriately adjusted as to the type, class and the maximum number of shares of our common stock subject to the 2009 equity incentive plan, and outstanding awards will be adjusted as to the type, class, number of shares and price per share of common stock subject to such awards.

Corporate Transactions; Changes in Control. In the event of certain specified organizational changes, which we refer to in this prospectus as corporate transactions, including but not limited to a consolidation, merger, or similar transaction involving our company, the sale, lease or other disposition of all or substantially all of the assets of our company or the consolidated assets of our company and our subsidiaries, or a sale or disposition of at least 50% of the outstanding capital stock of our company, then our board of directors, or the board of directors of any corporation assuming our obligations, may take any one or more actions as to outstanding awards, or as to a portion of any outstanding award under the 2009 equity incentive plan, including:

•

providing that such awards will continue in existence with appropriate adjustments or modifications, if applicable;

•

providing that such awards will be assumed, or equivalent awards substituted, by the acquiring or succeeding corporation or an affiliate thereof;

•

providing that all unexercised stock options, or other awards to the extent they are unexercised or unvested, will terminate immediately prior to the consummation of such transaction unless exercised within a specified period;

•

in the event of a consolidation, merger, combination, reorganization or similar transaction under the terms of which holders of our common stock will receive a cash payment per share surrendered in the transaction, making or providing for an equivalent cash payment in exchange for the termination of such awards; or

•

providing that all or any outstanding awards will become vested and exercisable in full or part or any reacquisition or repurchase rights held by us shall immediately lapse in full or part at or immediately prior to such event.

If a corporate transaction occurs that also qualifies as a change in control under the 2009 equity incentive plan, an individual stock award may provide for accelerated vesting upon the change in control. A change in control includes a transaction or series of related transactions, in each case, where persons who were not our stockholders

112

immediately prior to acquiring our capital stock as part of such transaction become the owners of our capital stock that represents more than 50% of the combined voting power of our outstanding capital stock.

Limitation of Liability and Indemnification

Our amended and restated certificate of incorporation to be in effect upon the closing of this offering requires us to indemnify, and limit the liability of, our directors to the fullest extent permitted by Delaware law. Our amended and restated bylaws to be in effect upon the closing of this offering require us to indemnify our directors to the fullest extent not prohibited by law and permit us to indemnify our officers, employees and other agents as set forth under Delaware law. We will indemnify any such person in connection with a proceeding initiated by such person only if such indemnification is expressly required by law, the proceeding was authorized by our board of directors, the indemnification is provided by us, in our sole discretion, pursuant to the Delaware General Corporation Law or other applicable law or is otherwise expressly required by our amended and restated bylaws. Section 145 of the Delaware General Corporation Law permits indemnification of officers, directors and other agents under specified circumstances and subject to specified limitations. Delaware law also permits a corporation to not hold its directors personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability for:

•

breach of their duty of loyalty to the corporation or its stockholders;

•

acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

•

unlawful payments of dividends or unlawful stock repurchases or redemptions; and

•

any transaction from which the director derived an improper personal benefit.

These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission.

Our amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this capacity. We have obtained directors’ and officers’ liability insurance to cover certain liabilities described above.

We have entered into indemnity agreements with each of our directors that require us to indemnify such persons against any and all expenses, including attorneys’ fees, witness fees, judgments, fines, settlements and other amounts incurred, including expenses of a derivative action, in connection with any action, suit or proceeding or alternative dispute resolution mechanism, inquiry hearing or investigation, whether threatened, pending or completed, to which any such person may be made a party by reason of the fact that such person is or was a director, an officer or an employee of our company, provided that such person’s conduct did not constitute a breach of his or her duty of loyalty to us or our stockholders, and was not an act or omission not in good faith or which involved intentional misconduct or a knowing violation of laws. The indemnity agreements also set forth procedures that will apply in the event of a claim for indemnification thereunder. We believe that these provisions and agreements are necessary to attract and retain qualified persons as directors of our company.

At present, there is no pending litigation or proceeding involving a director or officer of our company for which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted by directors, executive officers or persons controlling us, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

113

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

The following is a summary of transactions, and series of related transactions, since January 1, 2006 to which we have been or will be a participant, in which the amount involved exceeded or will exceed $120,000 and in which any of our executive officers, directors or beneficial holders of more than 5% of our capital stock had or will have a direct or indirect material interest, or any immediate family member of, or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest, other than executive and director compensation arrangements, including the employment, termination of employment and change of control arrangements, which are described in the section of this prospectus entitled “Executive Compensation.”

Sales of Securities

Series C and Series C-1 Convertible Preferred Stock Financings

In December 2006 and September 2007, we issued and sold an aggregate of 24,742,979 shares of Series C convertible preferred stock at a price of $0.7278 per share for aggregate consideration of approximately $17.8 million, including the conversion of principal and accrued interest on outstanding convertible promissory notes, and net of issuance costs. In connection with this offering, in December 2006 we also exchanged all of the warrants issued in connection a prior convertible note financing for new warrants with revised terms. The new warrants are exercisable for an aggregate of 1,326,605 shares of Series C convertible preferred stock at an exercise price of $0.7278 per share and expire in December 2011.

In April 2008, we issued and sold an aggregate of 17,636,655 shares of Series C-1 convertible preferred stock at a price of $1.0411 per share for aggregate consideration of $18.4 million.

The participants in these transactions included the following entities affiliated with our directors and other holders of more than 5% of our capital stock or their affiliates. The following table presents the number of shares issued to these related parties in these financings. Each share of our Series C convertible preferred stock and Series C-1 convertible preferred stock is currently convertible into one share of our common stock.


Stockholder⁽¹⁾	Number of Shares Series C Convertible Preferred Stock Purchased (including the conversion of principal and accrued interest under convertible promissory notes)	Number of Shares of Series C Convertible Preferred Stock Underlying Warrants Received Upon Exchange of Series B Warrants	Number of Shares of Series C-1 Convertible Preferred Stock Purchased
Entities affiliated with directors:
Entities affiliated with Intersouth Partners⁽²⁾	9,990,418	617,376	5,878,695
Entities affiliated with The Aurora Funds⁽³⁾	2,306,064	308,687	1,021,358
Tullis-Dickerson Capital Focus III, L.P.⁽⁴⁾	3,435,010	—	2,401,322

Other 5% stockholders:
Entities affiliated with Harbert Venture Partners⁽⁵⁾	3,297,609	—	5,974,013
The Trelys Funds, L.P.	1,314,698	231,516	95,504
CNF Investments II, LLC	2,748,008	—	1,440,794

⁽¹⁾	See “Principal Stockholders” for more information about shares held by these stockholders.

⁽²⁾	Represents shares held by Intersouth Partners V, L.P., Intersouth Affiliates V, L.P., Intersouth Partners VI, L.P. and Intersouth Partners VII, L.P. Dr. Garheng Kong, one of our directors, is a member of the general partner of each of these entities.

114

⁽³⁾

Represents shares held by Harbinger/Aurora QP Venture Fund, L.L.C., Harbinger/Aurora Venture Fund, L.L.C. and Aurora Enrichment Fund, LLC. B. Jefferson Clark, one of our directors, is a member of the investment committee of Harbinger/Aurora Ventures, LLC, the managing member of Harbinger/Aurora QP Venture Fund, L.L.C. and Harbinger/Aurora Venture Fund, L.L.C., and a manager of Aurora Enrichment Management Company LLC, the managing member of Aurora Enrichment Fund, LLC.

⁽⁴⁾	Lyle A. Hohnke, a member of our board of directors, is a member of the investment committee of Tullis-Dickerson Partners III, LLC, the general partner of Tullis-Dickerson Capital Focus III, L.P.

⁽⁵⁾

Represents shares held by Harbert Venture Partners, L.L.C. and ALD Co-Investor, LLC. The consideration paid by Harbert Venture Partners, L.L.C. for the purchase of Series C-1 convertible preferred stock included the cancellation of approximately $20,000 in indebtedness. William W. Brooke, one of our former directors, is an executive vice president of the manager of the managing member of these entities. Mr. Brooke is also a member of the investment committee of Harbinger/Aurora Ventures, LLC, the managing member of Harbinger/Aurora QP Venture Fund, L.L.C. and Harbinger/Aurora Venture Fund, L.L.C. Mr. Brooke resigned as a member of our board of directors in May 2008.

Convertible Bridge Notes and Related Warrants

In October 2009, we issued and sold convertible promissory notes in the aggregate principal amount of $7.3 million. These notes, which we refer to as the October convertible bridge notes, are unsecured and bear interest at a rate of 8% per annum. Interest is payable only at the time the notes mature. The notes will mature and the principal and unpaid accrued interest on the notes will be automatically converted into shares of our capital stock on the earlier to occur of:

•

the closing of this offering, if it closes on or before October 22, 2010; and

•

the next equity financing we complete that raises gross proceeds of at least $20 million, including the value of any indebtedness converted as a result of that transaction.

If the notes do not automatically convert as a result of the occurrence of one of the above events, the notes will mature, and the principal and unpaid accrued interest on the notes will be voluntarily convertible at the option of the noteholders into shares of our capital stock upon:

•

the closing of this offering, if it closes after October 22, 2010;

•

a specified liquidation event, including a merger or acquisition of our company; or

•

October 22, 2010.

If the conversion of the October convertible bridge notes occurs as a result of the closing of this offering, the notes will convert into shares of common stock at a conversion price equal to the initial public offering price per share in this offering, which means that the notes will be converted into an aggregate number of shares equal to the total amount of principal and accrued interest under the notes immediately prior to the closing of the offering divided by the initial public offering price per share in this offering. If the conversion occurs as a result of a specified liquidation event or due to maturity of the notes on October 22, 2010, the notes will convert into shares of Series C-1 convertible preferred stock at a conversion price of $1.0411 per share of Series C-1 convertible preferred stock. If the conversion occurs as a result of the next equity financing, the notes will be convertible into the securities issued in that financing at a conversion price equal to the price paid per share in that financing.

In connection with the issuance of the October convertible bridge notes, we also issued to each investor who purchased the notes a warrant exercisable for shares of our capital stock. Each warrant is exercisable for a number and type of shares equal to 20% of the number of shares into which the investor’s October convertible bridge note ultimately converts, and each warrant has an exercise price of either $0.01 per share if the warrant is exercisable for common stock upon the closing of this offering, $1.0411 per share if the warrant is exercisable for Series C-1 convertible preferred stock or upon maturity on October 22, 2010, or the price per share paid by

115

investors in the next equity financing if the warrant is exercisable for the securities issued in such next equity financing. The warrants expire upon the occurrence of any of the events giving rise to conversion of the notes, including the closing of this offering. The warrants include a net exercise feature entitling the holder to elect to exercise the warrant without paying the cash purchase price and to receive a smaller number of shares equal to the net value of the warrant.

Assuming that:

•

the initial public offering price in this offering is $ per share, the midpoint of the range set forth on the cover page of this prospectus;

•

this offering is closed on , 2009; and

•

each warrant holder elects a net exercise of its warrants,

we will issue an aggregate of shares of our common stock upon the conversion of the notes and the net exercise of the related warrants immediately prior to the closing of this offering. Each $1.00 increase in the assumed initial public offering price of $ per share would decrease the aggregate number of shares issued upon the conversion of the October convertible bridge notes and upon net exercise of the related warrants by shares, and each $1.00 decrease in the assumed initial public offering price per share would increase the aggregate number of shares by the same amount. Every additional month after , 2009 that lapses before the closing of this offering would increase the aggregate number of shares issued upon the conversion of the October convertible bridge notes and upon net exercise of the related warrants by shares.

The purchasers of our October convertible bridge notes included the following entities affiliated with our directors and other holders of more than 5% of our capital stock or their affiliates. The following table presents the principal amount of the October convertible bridge notes purchased by each of these related parties and the number of shares of our common stock that we will issue to each of them upon conversion of their notes and net exercise of their related warrants immediately prior to the closing of this offering, assuming the initial public offering price in this offering is $ per share, the midpoint of the range set forth on the cover page of this prospectus, assuming that this offering is closed on , 2009 and assuming we do not make any interest payments on the October convertible bridge notes prior to their conversion.


Investor	Principal Amount of Notes Purchased		Aggregate Number of Shares of Common Stock Issuable upon Conversion of Notes and Net Exercise of Related Warrants
Directors and entities affiliated with directors:
Joel R. Kimbrough	$	250,000
Entities affiliated with Intersouth Partners	$	3,394,902
Entities affiliated with The Aurora Funds	$	250,000
Tullis-Dickerson Capital Focus III, L.P.	$	1,500,000

Other 5% stockholders:
Entities affiliated with Harbert Venture Partners	$	1,100,000
CNF Investments II, LLC	$	750,000

We believe that the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described above were comparable to terms available or the amounts that would be paid or received, as applicable, in arm’s-length transactions.

Amended and Restated Investor Rights Agreement

In connection with our preferred stock financings, we have entered into an amended and restated investor rights agreement with the purchasers of our preferred stock and warrants to purchase preferred stock, including

116

entities with which some of our directors are affiliated, and with some holders of our common stock, including some of our officers. This amended and restated investor rights agreement relates to voting rights, information rights, rights of first refusal and registration rights, among other things. This agreement will terminate upon the closing of this offering, except for the registration rights granted under the agreement, as more fully described in “Description of Capital Stock—Registration Rights.”

Related Person Transaction Policy

Prior to this offering, we have not had a formal policy regarding approval of transactions with related parties. In 2009, we adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. The policy will become effective immediately upon the execution of the underwriting agreement for this offering. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involves exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons.

Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our board of directors, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Business Conduct and Ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our board of directors, will take into account the relevant available facts and circumstances including, but not limited to:

•

the risks, costs and benefits to us;

•

the impact on a director’s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated;

•

the availability of other sources for comparable services or products; and

•

the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.

The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit committee, or other independent body of our board of directors, determines in the good faith exercise of its discretion.

All of the transactions described above were entered into prior to the adoption of the written policy, but all were approved by our board of directors considering similar factors to those described above.

117

PRINCIPAL STOCKHOLDERS

The following table sets forth the beneficial ownership of our common stock as of September 30, 2009 by:

•

each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock;

•

each of our named executive officers;

•

each of our directors; and

•

all of our executive officers and directors as a group.

The percentage of shares beneficially owned before the offering shown in the table is based upon 62,907,818 shares of common stock outstanding as of September 30, 2009, after giving effect to the conversion of all of our convertible preferred stock into 59,288,071 shares of common stock, which will occur automatically immediately prior to the closing of this offering. The number of shares outstanding as of September 30, 2009 does not give effect to the conversion of the October convertible bridge notes or the net exercise of the related warrants to purchase shares of our capital stock. The information relating to numbers and percentages of shares beneficially owned after the offering gives effect to the issuance of shares of common stock in this offering and the issuance of an aggregate of shares of our common stock upon the conversion of the outstanding principal and accrued interest on the October convertible bridge notes and upon the net exercise of the related warrants, assuming the initial public offering price in this offering is $ per share, the midpoint of the range set forth on the cover page of this prospectus, and assuming that this offering is closed on , 2009.

We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options or warrants that are either immediately exercisable or exercisable on or before November 29, 2009, which is 60 days after September 30, 2009. These shares are deemed to be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.

118

Except as otherwise noted below, the address for persons listed in the table is c/o Aldagen, Inc., 2810 Meridian Parkway, Suite 148, Durham, North Carolina 27713.


	Shares Beneficially Owned Before Offering			Shares Beneficially Owned After Offering
Name of Beneficial Owner	Number	Percentage		Number	Percentage
5% Stockholders:
Entities affiliated with Intersouth Partners⁽¹⁾ 406 Blackwell Street, Suite 200 Durham, NC 27701	26,515,547	41.6	%			%

Entities affiliated with Harbert Venture Partners⁽⁴⁾ 2100 Third Avenue North, Suite 600 Birmingham, AL 35203	9,271,622	14.7

Entities affiliated with The Aurora Funds⁽²⁾ 790 SE Cary Parkway, Suite 204 Cary, NC 27511	7,778,545	12.3

Tullis-Dickerson Capital Focus III, L.P.⁽³⁾ Two Greenwich Plaza Greenwich, CT 06830	5,836,332	9.3

CNF Investments II, LLC⁽⁶⁾ 7500 Old Georgetown Road, 15th Floor Bethesda, MD 20814	4,188,802	6.7

The Trelys Funds, L.P.⁽⁵⁾ 790 SE Cary Parkway, Suite 204 Cary, NC 27511	3,385,903	5.4		3,385,903

Named Executive Officers and Directors:
W. Thomas Amick⁽⁷⁾	1,972,246	3.0		1,972,246
Edward L. Field⁽⁷⁾	597,944	*		597,944	*
David P. Carberry⁽⁷⁾	216,688	*		216,688	*
Andrew E. Balber⁽⁸⁾	415,942	*		415,942	*
Laurence H. Keller⁽⁷⁾	119,810	*		119,810	*
Joel R. Kimbrough⁽⁷⁾	100,000	*
Martin J. Murphy⁽⁷⁾	125,000	*		125,000	*
B. Jefferson Clark⁽²⁾	7,778,545	12.3
Garheng Kong⁽¹⁾	26,515,547	41.6
William E. Evans⁽⁷⁾	83,333	*		83,333	*
Lyle A. Hohnke⁽³⁾	5,836,332	9.3
All current directors and executive officers as a group⁽⁹⁾ (11 persons)	43,641,777	64.9

*	Represents beneficial ownership of less than 1%.

⁽¹⁾

Consists of 5,003,835 shares of common stock issuable upon the conversion of shares of Series A convertible preferred stock, 4,447,853 shares of common stock issuable upon the conversion of shares of Series B convertible preferred stock, 138,995 shares of common stock issuable upon the conversion of shares of Series B convertible preferred stock issuable upon exercise of immediately exercisable warrants, 3,859,967 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock, 590,390 shares of common stock issuable upon the conversion of shares of Series C convertible

119

preferred stock issuable upon exercise of immediately exercisable warrants and 416,671 shares of common stock issuable upon the conversion of shares of Series C-1 convertible preferred stock, in each case held by Intersouth Partners V, L.P.; 228,719 shares of common stock issuable upon the conversion of shares of Series A convertible preferred stock, 203,303 shares of common stock issuable upon the conversion of shares of Series B convertible preferred stock, 6,353 shares of common stock issuable upon the conversion of shares of Series B convertible preferred stock issuable upon exercise of immediately exercisable warrants, 176,435 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock, 26,986 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock issuable upon exercise of immediately exercisable warrants and 19,046 shares of common stock issuable upon the conversion of shares of Series C-1 convertible preferred stock, in each case held by Intersouth Affiliates V, L.P.; 5,954,016 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock and 1,600,889 shares of common stock issuable upon the conversion of shares of Series C-1 convertible preferred stock, in each case held by Intersouth Partners VI, L.P.; and 3,842,089 shares of common stock issuable upon the conversion of shares of Series C-1 convertible preferred stock held by Intersouth Partners VII, L.P. Intersouth Associates V, LLC, the general partner of each of Intersouth Partners V, L.P. and Intersouth Affiliates V, L.P., Intersouth Associates VI, LLC, the general partner of Intersouth Partners VI, L.P., and Intersouth Associates VII, LLC, the general partner of Intersouth Partners VII, L.P., may be deemed to share voting and dispositive power over the shares held by each of Intersouth Partners V, L.P., Intersouth Affiliates V, L.P., Intersouth Partners VI, L.P. and Intersouth Partners VII, L.P. Dennis Dougherty and Mitch Mumma are both member managers of Intersouth Associates V, LLC, Intersouth Associates VI, LLC and Intersouth Associates VII, LLC and share voting and investment power over the shares held by each of Intersouth Partners V, L.P., Intersouth Affiliates V, L.P., Intersouth Partners VI, L.P. and Intersouth Partners VII, L.P. Dr. Garheng Kong, a member of our board of directors, is a member of each of Intersouth Associates V, LLC, Intersouth Associates VI, LLC and Intersouth Associates VII, LLC. Pursuant to powers of attorney granted by each of Intersouth Associates V, LLC, Intersouth Associates VI, LLC and Intersouth Associates VII, LLC, Dr. Kong shares voting power with respect to the securities owned by the entities for which these entities serve as general partners. Dr. Kong disclaims beneficial ownership of these shares held by Intersouth Partners V, L.P., Intersouth Affiliates V, L.P., Intersouth Partners VI, L.P. and Intersouth Partners VII, L.P.

⁽²⁾

Consists of 1,030,963 shares of common stock issuable upon the conversion of shares of Series A convertible preferred stock, 859,116 shares of common stock issuable upon the conversion of shares of Series B convertible preferred stock, 42,965 shares of common stock issuable upon the conversion of shares of Series B convertible preferred stock issuable upon exercise of immediately exercisable warrants, 809,188 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock, 60,814 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock issuable upon exercise of immediately exercisable warrants and 603,652 shares of common stock issuable upon the conversion of shares of Series C-1 convertible preferred stock, in each case held by Harbinger/Aurora QP Venture Fund, L.L.C.; 713,221 shares of common stock issuable upon the conversion of shares of Series A convertible preferred stock, 594,371 shares of common stock issuable upon the conversion of shares of Series B convertible preferred stock, 29,709 shares of common stock issuable upon the conversion of shares of Series B convertible preferred stock issuable upon exercise of immediately exercisable warrants, 559,929 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock, 42,081 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock issuable upon exercise of immediately exercisable warrants and 417,706 shares of common stock issuable upon the conversion of shares of Series C-1 convertible preferred stock, in each case held by Harbinger/Aurora Venture Fund, L.L.C.; and 872,091 shares of common stock issuable upon the conversion of shares of Series B convertible preferred stock, 936,947 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock and 205,792 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock issuable upon exercise of immediately exercisable warrants, in each case held by Aurora Enrichment Fund, LLC. Harbinger/Aurora Ventures, LLC is the managing member of Harbinger/Aurora QP Venture Fund, L.L.C.

120

and Harbinger/Aurora Venture Fund, L.L.C. and has voting and investment power with respect to all shares held by those entities, which is exercised by the investment committee comprised of M. Scott Albert, B. Jefferson Clark and William W. Brooke. Mr. Clark is also the manager of Aurora Enrichment Management Co. LLC, the managing member of Aurora Enrichment Fund, LLC. Mr. Clark is a member of our board of directors and disclaims beneficial ownership of the shares held by Harbinger/Aurora QP Venture Fund, L.L.C., Harbinger/Aurora Venture Fund, L.L.C., and Aurora Enrichment Fund, LLC.

⁽³⁾

Consists of 3,435,010 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock and 2,401,322 shares of common stock issuable upon the conversion of shares of Series C-1 convertible preferred stock. Tullis-Dickerson Partners III, L.L.C. is the general partner of Tullis-Dickerson Capital Focus III, L.P. Lyle A. Hohnke, Joan P. Neuscheler, James L. L. Tullis, Thomas P. Dickerson and Timothy M. Buono share voting and/or dispositive power over all shares held by Tullis-Dickerson Capital Focus III, L.P. Dr. Hohnke is a member of our board of directors.

⁽⁴⁾

Consists of 3,297,609 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock and 1,171,401 shares of common stock issuable upon the conversion of shares of Series C-1 convertible preferred stock, in each case held by Harbert Venture Partners, L.L.C.; and 4,802,612 shares of common stock issuable upon the conversion of shares of convertible preferred stock held by ALD Co-Investor, LLC. Harbert Venture Partners MM, LLC is the sole managing member of each of Harbert Venture Partners, L.L.C. and ALD Co-Investor, LLC, and HMC-Virginia, Inc. is the sole manager of Harbert Venture Partners MM, LLC. The managers of HMC-Virginia, Inc. are William Brooke, David Boutwell, John McCullough and Raymond Harbert, each of whom may be deemed to beneficially own the shares held of record by Harbert Venture Partners, L.L.C. and ALD Co-Investor, LLC.

⁽⁵⁾

Consists of 1,744,185 shares of common stock issuable upon the conversion of shares of Series B convertible preferred stock, 1,314,698 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock, 231,516 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock issuable upon exercise of immediately exercisable warrants and 95,504 shares of common stock issuable upon the conversion of shares of Series C-1 convertible preferred stock. Trelys Ventures, LLC is the general partner of The Trelys Funds, L.P. Adrian Wilson holds voting and investment power over all shares held by The Trelys Funds, L.P.

⁽⁶⁾

Consists of 2,748,008 shares of common stock issuable upon the conversion of shares of Series C convertible preferred stock and 1,440,794 shares of common stock issuable upon the conversion of shares of Series C-1 convertible preferred stock. Robert J. Flanagan is the Manager of CNF Investments II, LLC and as such is deemed to possess voting and investment power over the shares held by this entity.

⁽⁷⁾	Represents those shares issuable upon the exercise of options exercisable within 60 days of September 30, 2009.

⁽⁸⁾	Consists of 280,000 shares of common stock held by Dr. Balber and 135,942 shares issuable upon the exercise of options exercisable within 60 days of September 30, 2009.

⁽⁹⁾	Includes an aggregate of 4,375,438 shares of common stock issuable upon the exercise of options exercisable within 60 days of September 30, 2009 and the conversion of shares of convertible preferred stock issuable upon the exercise of immediately exercisable warrants.

121

DESCRIPTION OF CAPITAL STOCK

The following description of our capital stock and provisions of our certificate of incorporation and bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws, each to be in effect upon the completion of this offering. We have filed copies of these documents with the SEC as exhibits to our registration statement of which this prospectus forms a part. The description of the capital stock reflects changes to our capital structure that will occur upon the closing of this offering. Upon the closing of this offering and the filing of the amended and restated certificate of incorporation, our authorized capital stock will consist of shares of common stock, par value $0.001 per share, and shares of preferred stock, par value $0.001 per share, all of which preferred stock will be undesignated.

As of September 30, 2009, we had issued and outstanding:

•

3,619,747 shares of our common stock held by 13 stockholders of record;

•

6,000,000 shares of our Series A convertible preferred stock held by four stockholders of record that are convertible into an aggregate of 6,976,738 shares of our common stock;

•

8,515,000 shares of our Series B convertible preferred stock held by 12 stockholders of record that are convertible into an aggregate of 9,901,136 shares of our common stock;

•

24,742,979 shares of our Series C convertible preferred stock held by 19 stockholders of record that are convertible into shares of our common stock on a one-for-one basis; and

•

17,636,655 shares of our Series C-1 convertible preferred stock held by 19 stockholders of record that are convertible into shares of our common stock on a one-for-one basis.

As of September 30, 2009, we also had outstanding:

•

options to purchase 6,655,463 shares of our common stock at a weighted-average exercise price of $0.32 per share;

•

warrants to purchase an aggregate of 408,785 shares of our Series B convertible preferred stock at an exercise price of $1.00 per share;

•

warrants to purchase an aggregate of 1,326,605 shares of our Series C convertible preferred stock at an exercise price of $0.7278 per share;

•

warrants to purchase an aggregate of 38,421 shares of our Series C-1 convertible preferred stock at an exercise price of $1.0411 per share;

•

the October convertible bridge notes, which are convertible into shares of our common stock or preferred stock upon the occurrence of specified corporate events, as described above under “Certain Relationships and Related Party Transactions—Convertible Bridge Notes and Related Warrants”; and

•

warrants to purchase shares of our capital stock on the terms described above under “Certain Relationships and Related Party Transactions—Convertible Bridge Notes and Related Warrants”.

Upon the closing of this offering, all of the outstanding shares of our preferred stock, including 26,285 shares of our Series B convertible preferred stock we expect to issue upon the exercise of warrants prior to the closing of this offering, will automatically convert into a total of 59,288,071 shares of our common stock. In addition, upon the closing of this offering, the October convertible bridge notes will automatically convert into shares of our common stock, and the related outstanding warrants will be net exercised for shares of our common stock at an exercise price of $0.01 per share. Upon the closing of this offering and after giving effect to the automatic conversion of our preferred stock into common stock and the exercise of those warrants, warrants to purchase an aggregate of 1,809,791 shares of common stock will remain outstanding.

Common Stock

Voting Rights. Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our amended and restated certificate of

122

incorporation and amended and restated bylaws do not provide for cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose.

Dividends. Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.

Liquidation. In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.

Rights and Preferences. Holders of common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.

Fully paid and Nonassessable. All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and nonassessable.

Preferred Stock

Upon the closing of this offering, all outstanding shares of preferred stock will have been automatically converted into shares of common stock. Following this offering, our certificate of incorporation will be amended and restated to delete all references to such shares of preferred stock.

Under the amended and restated certificate of incorporation, our board of directors will have the authority, without further action by the stockholders, to issue up to shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.

Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.

Preferred Stock Warrants

Except as described in the second bullet below, in connection with the automatic conversion of all of our outstanding shares of preferred stock into common stock immediately prior to the closing of this offering, all preferred stock warrants outstanding as of the closing will automatically become exercisable for shares of common stock based on the then effective conversion ratios applicable to the respective series of convertible preferred stock.

•

We have outstanding warrants to purchase an aggregate of 382,500 shares of Series B convertible preferred stock with an exercise price of $1.00 per share. Upon the closing of this offering, these warrants will become exercisable for an aggregate of 444,765 shares of common stock at an exercise price of $0.86 per share. These warrants expire between December 2012 and December 2013.

123

•

We have additional outstanding warrants to purchase an aggregate of 26,285 shares of Series B preferred stock with an exercise price of $1.00 per share. Unless exercised, these warrants will expire upon the closing of this offering. We have assumed throughout this prospectus that the holders of these warrants will exercise these warrants for cash prior to the closing of this offering for an aggregate of 26,285 shares of Series B convertible preferred stock that will convert upon completion of this offering into 30,563 shares of common stock.

•

We have outstanding warrants to purchase an aggregate of 1,326,605 shares of Series C convertible preferred stock at an exercise price of $0.7278 per share. Upon the closing of this offering, these warrants will become exercisable for an aggregate of 1,326,605 shares of common stock at an exercise price of $0.7278 per share. These warrants expire in December 2011.

•

We have outstanding warrants to purchase an aggregate of 38,421 shares of Series C-1 convertible preferred stock at an exercise price of $1.0411 per share. Upon the closing of this offering, these warrants will become exercisable for an aggregate of 38,421 shares of common stock at an exercise price of $1.0411 per share. These warrants expire in December 2016.

These warrants have net exercise provisions under which their holders may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of our stock at the time of exercise of the warrants after deduction of the aggregate exercise price. Each of the warrants contains a provision for the adjustment of the exercise price and the number of shares issuable upon the exercise of the warrant in the event of certain stock dividends, stock splits, reorganizations, reclassifications and consolidations.

Registration Rights

Under an amended and restated investor rights agreement, following the completion of this offering, the holders of an aggregate of shares of common stock and warrants to purchase an aggregate of up to shares of common stock, or their transferees, will have the right to require us to register their shares with the SEC so that those shares may be publicly resold, or to include their shares in any registration statement we file, subject to specified exemptions, conditions and limitations.

Demand Registration Rights. At any time beginning six months after the completion of this offering, the holders of at least a majority of the shares issuable upon conversion of our Series A convertible preferred stock and Series B convertible preferred stock in the aggregate have the right to demand that we file up to a total of two registration statements and additional holders of at least a majority of the shares issuable upon conversion of our Series C convertible preferred stock and Series C-1 convertible preferred stock in the aggregate have the right to demand that we file up to a total of two additional registration statements. These registration rights are subject to specified conditions and limitations, including the right of the underwriters, if any, to limit the number of shares included in any such registration under specified circumstances.

Form S-3 Registration Rights. If we are eligible to file a registration statement on Form S-3, holders of no less than 20% of the shares having registration rights have the right to demand that we file a registration statement on Form S-3 so long as the aggregate amount of securities to be sold under the registration statement on Form S-3 is at least $1,000,000, subject to specified exceptions. We are obligated to file a maximum of three registration statements on Form S-3 in any 360-day period. These registration rights are subject to specified conditions and limitations, including the right of the underwriters, if any, to limit the number of shares included in any such registration under specified circumstances.

Piggyback Registration Rights. If we register any securities for public sale, stockholders with registration rights will have the right to include their shares in the registration statement. The underwriters of any underwritten offering will have the right to limit the number of shares having registration rights to be included in the registration statement, but not below 30% of the total number of shares included in the registration statement.

124

These registration rights are also subject to other specified conditions and limitations, including the exclusion of stockholders in registration statements relating to any employee benefit plan or any corporate reorganization or transaction under Rule 145 of the Securities Act.

Expenses of Registration. We will pay all expenses relating to demand registrations, Form S-3 registrations and piggyback registrations, other than any stock transfer taxes and underwriting discounts and commissions. However, we will not pay for the expenses of any demand registration if the request is subsequently withdrawn by the holders of the shares having registration rights, subject to specified exceptions.

Termination. The registration rights terminate on the fifth anniversary of the closing of this offering.

Delaware Anti-takeover Law and Certain Provisions of Our Amended and Restated Certificate of Incorporation and Bylaws

Delaware law. We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:

•

prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

•

the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for this purpose shares owned by persons who are directors and also officers and shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

•

on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66²/3% of the outstanding voting stock that is not owned by the interested stockholder.

Section 203 defines a business combination to include:

•

any merger or consolidation involving the corporation and the interested stockholder;

•

any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;

•

subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

•

any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and

•

the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.

Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws. Provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective

125

upon the closing of this offering, may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock.

Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:

•

permit our board of directors to issue up to shares of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in our control;

•

provide that the authorized number of directors may be changed only by resolution of the board of directors;

•

provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;

•

divide our board of directors into three classes with staggered, three-year terms;

•

require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;

•

provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and also specify requirements as to the form and content of a stockholder’s notice;

•

do not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose;

•

provide that special meetings of our stockholders may be called only by the chairman of the board, our chief executive officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and

•

provide that stockholders will be permitted to amend our amended and restated bylaws only upon receiving at least % of the votes entitled to be cast by holders of all outstanding shares then entitled to vote generally in the election of directors, voting together as a single class.

The amendment of any of these provisions would require approval by the holders of at least % of our then outstanding common stock, voting as a single class.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is StockTrans, Inc. The transfer agent and registrar’s address is 44 West Lancaster Avenue, Ardmore, PA 19003.

NASDAQ Global Market Listing

We have applied for listing of our common stock on The NASDAQ Global Market under the trading symbol “ALDH.”

126

SHARES ELIGIBLE FOR FUTURE SALE

Prior to this offering, no public market existed for our common stock. Market sales of shares of our common stock after this offering and from time to time, and the availability of shares for future sale, may reduce the market price of our common stock. Sales of substantial amounts of our common stock, or the perception that these sales could occur, could adversely affect prevailing market prices for our common stock and could impair our future ability to obtain capital, especially through an offering of equity securities.

Based on the number of shares of common stock outstanding as of , 2009, upon completion of this offering, shares of common stock will be outstanding, assuming no exercise of the underwriters’ over-allotment option and no exercise of options or warrants prior to the completion of this offering. All of the shares sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, unless held by our affiliates as that term is defined under Rule 144 under the Securities Act. The remaining shares of common stock outstanding upon the closing of this offering are restricted securities as defined under Rule 144 of the Securities Act. Restricted securities may be sold in the U.S. public market only if registered or if they qualify for an exemption from registration, including by reason of Rule 144 or 701 under the Securities Act, which rules are summarized below. These remaining shares will generally become available for sale in the public market as follows:

•

restricted shares will be eligible for immediate sale upon the completion of this offering;

•

approximately restricted shares will be eligible for sale in the public market 90 days after the date of this prospectus, subject to the volume, manner of sale and other limitations under Rule 144 and Rule 701; and

•

approximately restricted shares will be eligible for sale in the public market upon expiration of lock-up agreements 180 days after the date of this prospectus, which date may be extended in specified circumstances, subject in certain circumstances to the volume, manner of sale and other limitations under Rule 144 and Rule 701.

Additionally, of the 6,655,463 shares of common stock issuable upon exercise of options outstanding as of September 30, 2009, approximately shares will be vested and eligible for sale 180 days after the date of this prospectus. All of the shares of common stock issuable upon exercise of warrants outstanding as of September 30, 2009, will be vested and may become eligible for sale beginning 180 days after the date of this prospectus.

Rule 144

In general, under Rule 144 under the Securities Act of 1933, as in effect on the date of this prospectus, beginning 90 days after the date of this prospectus, a person who is not one of our affiliates at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock to be sold for at least six months, would be entitled to sell an unlimited number of shares of our common stock, provided current public information about us is available. In addition, under Rule 144, a person who is not one of our affiliates at any time during the three months preceding a sale, and who has beneficially owned the shares of our common stock to be sold for at least one year, would be entitled to sell an unlimited number of shares immediately upon the closing of this offering without regard to whether current public information about us is available. Beginning 90 days after the date of this prospectus, our affiliates who have beneficially owned shares of our common stock for at least six months are entitled to sell within any three-month period a number of shares that does not exceed the greater of:

•

one percent of the number of shares of our common stock then outstanding, which will equal approximately shares immediately after this offering; and

•

the average weekly trading volume of our common stock on The NASDAQ Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.

127

Sales of restricted shares under Rule 144 by our affiliates are also subject to requirements regarding the manner of sale, notice and the availability of current public information about us. Rule 144 also provides that affiliates relying on Rule 144 to sell shares of our common stock that are not restricted shares must nonetheless comply with the same restrictions applicable to restricted shares, other than the holding period requirement.

Notwithstanding the availability of Rule 144, the holders of substantially all of our restricted shares have entered into lock-up agreements as described below under “Underwriting” and their restricted shares will become eligible for sale at the expiration of the restrictions set forth in those agreements.

Rule 701

Rule 701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but without compliance with some of the restrictions of Rule 144, including the holding period requirement. Most of our employees, executive officers, directors or consultants who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares under Rule 701. However, all of the Rule 701 shares are subject to lock-up agreements as described below and under “Underwriting” and will become eligible for sale at the expiration of the restrictions set forth in those agreements.

Lock-up Agreements

We, along with our directors, executive officers and substantially all of our other stockholders, optionholders and warrantholders, have agreed with the underwriters that, for a period of 180 days following the date of this prospectus, we or they will not offer, sell, assign, transfer, pledge, contract to sell or otherwise dispose of or hedge any shares of our common stock or any securities convertible into or exchangeable for shares of common stock, subject to specified exceptions. Cowen and Company, LLC and Wells Fargo Securities, LLC may, in their sole discretion, at any time without prior notice, release all or any portion of the shares from the restrictions in any such agreement.

The 180-day restricted period described in the preceding paragraph will be extended if:

•

during the last 17 days of the 180-day restricted period we issue an earnings release or material news or a material event relating to us occurs and is publicly announced; or

•

prior to the expiration of the 180-day restricted period, we announce that we will release earnings results during the 16-day period beginning on the last day of the 180-day restricted period.

In this case, the restrictions described in the preceding paragraph will continue to apply until the expiration of the 18-day period beginning on the issuance of the release of the material news or the occurrence of the material event.

The lock-up agreements signed by our securityholders generally permit them, among other customary exceptions, to make bona fide gifts to their immediate family, to transfer securities to trusts for their or their immediate family’s benefit and, if the securityholder is a partnership, limited liability company or corporation, to transfer securities to its partners, members or stockholders. However, the recipients of these transfers must agree to be bound by the lock-up agreement for the remainder of the lock-up period.

Registration Rights

Upon the closing of this offering, the holders of an aggregate of shares of our common stock and warrants to purchase an aggregate of up to shares of our common stock will have the right to require us to

128

register their shares for resale under the Securities Act, beginning six months after the date of this prospectus. Registration of these shares for resale under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of such registration. Any sales of securities by these stockholders could adversely affect the trading price of our common stock. These registration rights are described in more detail under the caption “Description of Capital Stock—Registration Rights.”

Equity Incentive Plans

As of September 30, 2009, we had outstanding options to purchase 6,655,463 shares of our common stock, of which options to purchase 4,345,956 shares were vested. We intend to file with the SEC one or more registration statements under the Securities Act covering the shares of common stock subject to outstanding stock options granted under our 2000 stock option plan, as well as the shares of common stock reserved for issuance under our 2009 equity incentive plan. We expect to file these registration statements as soon as practicable after the closing of this offering. These registration statements will become effective automatically upon filing. Accordingly, shares registered under these registration statements will be available for sale in the open market following their effective dates, subject to the volume and other limitations under Rule 144, other than the holding period, applicable to our affiliates and the lock-up agreements described above.

129

UNDERWRITING

We and the underwriters for the offering named below have entered into an underwriting agreement with respect to the common stock being offered. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase from us the number of shares of our common stock set forth opposite its name below. Cowen and Company, LLC and Wells Fargo Securities, LLC are the representatives of the underwriters.


Underwriter		Number of Shares
Cowen and Company, LLC
Wells Fargo Securities, LLC
Needham and Company, LLC
Boenning & Scattergood, Inc.

Total

The underwriting agreement provides that the obligations of the underwriters are conditional and may be terminated at their discretion based on their assessment of the state of the financial markets. The obligations of the underwriters may also be terminated upon the occurrence of the events specified in the underwriting agreement. The underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased, other than those shares covered by the overallotment option described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be increased or the underwriting agreement may be terminated.

We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act of 1933, and to contribute to payments the underwriters may be required to make in respect thereof.

The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

Overallotment Option to Purchase Additional Shares. We have granted to the underwriters an option to purchase up to additional shares of common stock at the public offering price, less the underwriting discount. This option is exercisable for a period of 30 days. The underwriters may exercise this option solely for the purpose of covering overallotments, if any, made in connection with the sale of common stock offered hereby. To the extent that the underwriters exercise this option, the underwriters will purchase additional shares from us in approximately the same proportion as shown in the table above.

Discounts and Commissions. The following table shows the public offering price, underwriting discount and proceeds, before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares.

We estimate that the total expenses of the offering, excluding underwriting discount, will be approximately $ and are payable by us.


	Total
	Per Share	Without Overallotment	With Over Allotment
Public offering price	$	$	$
Underwriting discount
Proceeds, before expenses, to us

130

The underwriters propose to offer the shares of common stock to the public at the public offering price set forth on the cover of this prospectus. The underwriters may offer the shares of common stock to securities dealers at the public offering price less a concession not in excess of $ per share. The underwriters may allow, and the dealers may reallow, a discount not in excess of $ per share to other dealers. If all of the shares are not sold at the public offering price, the underwriters may change the offering price and other selling terms.

Discretionary Accounts. The underwriters do not intend to confirm sales of the shares to any accounts over which they have discretionary authority.

Market Information. Prior to this offering, there has been no public market for shares of our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In addition to prevailing market conditions, the factors to be considered in these negotiations will include:

•

the history of, and prospects for, our company and the industry in which we compete;

•

our past and present financial information;

•

an assessment of our management;

•

our past and present operations, and the prospects for, and timing of, our future revenues;

•

the present state of our development;

•

the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.

An active trading market for the shares may not develop. It is also possible that after the offering the shares will not trade in the public market at or above the initial public offering price.

We have applied for the listing of our common stock on The NASDAQ Global Market under the symbol “ALDH.”

Stabilization. In connection with this offering, the underwriters may engage in stabilizing transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales.

•

Stabilizing transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress.

•

Overallotment transactions involve sales by the underwriters of shares of common stock in excess of the number of shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the overallotment option. In a naked short position, the number of shares involved is greater than the number of shares in the overallotment option. The underwriters may close out any short position by exercising their overallotment option and/or purchasing shares in the open market.

•

Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise of the overallotment option. If the underwriters sell more shares than could be covered by exercise of the overallotment option and, therefore, have a naked short position,

131

the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase in the offering.

•

Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock originally sold by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on The NASDAQ Global Market, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.

Lock-Up Agreements. Pursuant to certain “lock-up” agreements, we and our executive officers, directors and our other stockholders, have agreed, subject to certain exceptions, not to offer, sell, contract to sell, announce any intention to sell, pledge or otherwise dispose of, enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of, directly or indirectly, or file with the SEC a registration statement under the Securities Act relating to, any common stock or securities convertible into or exchangeable or exercisable for any common stock without the prior written consent of Cowen and Company, LLC and Wells Fargo Securities, LLC, for a period of 180 days after the date of the pricing of the offering. The 180-day restricted period will be automatically extended if (i) during the last 17 days of the 180-day restricted period we issue an earnings release or material news or a material event relating to us occurs and is publicly announced or (ii) prior to the expiration of the 180-day restricted period, we announce that we will release earnings results or become aware that material news or a material event will occur during the 16-day period beginning on the last day of the 180-day restricted period, in either of which case the restrictions described above will continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.

This lock-up provision applies to common stock and to securities convertible into or exchangeable or exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. The exceptions permit us, among other things and subject to restrictions, to: (a) issue common stock or options pursuant to employee benefit plans, (b) issue common stock upon exercise of outstanding options or warrants, (c) issue securities in connection with the conversion of our preferred stock into common stock, or (d) file registration statements on Form S-8. The exceptions permit parties to the “lock-up” agreements, among other things and subject to restrictions, to: (a) make certain distributions to their partners or stockholders (b) enter into or modify 10b5-1 plans so long as no shares may be sold under such plans during the 180 day restricted period, (c) use the “net” exercise provisions of outstanding warrants for our common stock or (d) make certain gifts. In addition, the lock-up provision will not restrict broker-dealers from engaging in market making and similar activities conducted in the ordinary course of their business.

Each of the underwriters may arrange to sell common stock offered hereby in certain jurisdictions outside the United States, either directly or through affiliates, where they are permitted to do so. In that regard, Wells Fargo Securities, LLC may arrange to sell shares in certain jurisdictions through an affiliate, Wells Fargo Securities International Limited, or WFSIL. WFSIL is a wholly-owned indirect subsidiary of Wells Fargo & Company and an affiliate of Wells Fargo Securities, LLC. WFSIL is a U.K. incorporated investment firm regulated by the Financial Services Authority. Wells Fargo Securities is the trade name for certain corporate and investment banking services of Wells Fargo & Company and its affiliates, including Wells Fargo Securities, LLC and WFSIL.

132

United Kingdom. Each of the underwriters has represented and agreed that:

•

it has not made or will not make an offer of the shares of common stock to the public in the United Kingdom within the meaning of section 102B of the Financial Services and Markets Act 2000 (as amended) (FSMA) except to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities or otherwise in circumstances which do not require the publication by us of a prospectus pursuant to the Prospectus Rules of the Financial Services Authority (FSA);

•

it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) to persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or in circumstances in which section 21 of FSMA does not apply to us; and

•

it has complied with and will comply with all applicable provisions of FSMA with respect to anything done by it in relation to the shares of common stock in, from or otherwise involving the United Kingdom.

Switzerland. The shares of common stock will not be offered, directly or indirectly, to the public in Switzerland and this prospectus does not constitute a public offering prospectus as that term is understood pursuant to article 652a or 1156 of the Swiss Federal Code of Obligations. Neither this document nor any other offering materials relating to the shares of common stock may be distributed, published or otherwise made available in Switzerland except in a manner which will not constitute a public offer of the shares of common stock in Switzerland.

European Economic Area. In relation to each Member State of the European Economic Area (Iceland, Norway and Lichtenstein in addition to the member states of the European Union) that has implemented the Prospectus Directive (each, a Relevant Member State), each underwriter has represented and agreed that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State (the Relevant Implementation Date) it has not made and will not make an offer of the shares of common stock to the public in that Relevant Member State prior to the publication of a prospectus in relation to the shares of common stock that has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with the Prospectus Directive, except that it may, with effect from and including the Relevant Implementation Date, make an offer of the shares of common stock to the public in that Relevant Member State at any time:

•

to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in shares of common stock;

•

to any legal entity which has two or more of (1) an average of at least 250 employees during the last financial year; (2) a total balance sheet of more than €43,000,000 and (3) an annual net turnover of more than €50,000,000, as shown in its last annual or consolidated accounts;

•

to fewer than 100 natural or legal persons (other than qualified investors as defined in the Prospectus Directive) subject to obtaining the prior consent of the representatives for any such offer; or

•

in any other circumstances which do not require the publication by the issuer of a prospectus pursuant to Article 3 of the Prospectus Directive.

Each person in a Relevant Member State who receives any communication in respect of, or who acquires any shares of common stock under, the offer contemplated in this prospectus will be deemed to have represented, warranted and agreed to and with us and each underwriter that:

•

it is a qualified investor within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive; and

133

•

in the case of any shares of common stock acquired by it as a financial intermediary, as that term is used in Article 3(2) of the Prospectus Directive, (1) the shares of common stock acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant Member State other than qualified investors, as that term is defined in the Prospectus Directive, or in circumstances in which the prior consent of the representatives of the underwriters has been given to the offer or resale; or (2) where shares of common stock have been acquired by it on behalf of persons in any Relevant Member State other than qualified investors, the offer of those shares of common stock to it is not treated under the Prospectus Directive as having been made to such persons.

For the purposes of the provisions in the two immediately preceding paragraphs, the expression an “offer of the shares of common stock to the public” in relation to the shares of common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for the shares of common stock, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State, and the expression “Prospectus Directive” means Directive 2003/71/EC and includes any relevant implementing measure in each Relevant Member State.

France. This prospectus has not been prepared in the context of a public offering of shares of common stock in France (appel public à l’épargne) within the meaning of Article L.411-1 and seq. of the French Code monétaire et financier and Articles 211-1 and seq. of the Autorité des marchés financiers, or AMF, regulations and has therefore not been submitted to the AMF for prior approval or otherwise. The shares of common stock have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France and neither this prospectus nor any other offering material relating to the common stock has been distributed or caused to be distributed or will be distributed or caused to be distributed to the public in France, except only to persons licensed to provide the investment service of portfolio management for the account of third parties and/or to “qualified investors” (as defined in Article L.411-2, D.411-1 and D.411-2 of the French Code monétaire et financier) and/or to a limited circle of investors (as defined in Article L.411-2, D.411-4 of the French Code monétaire et financier) on the condition that no such prospectus nor any other offering material relating to the common stock shall be delivered by then to any person nor reproduced (in whole or in part). Such “qualified investors” are notified that they must act in that connection for their own account in accordance with the terms set out by Article L.411-2 of the French Code monétaire et financier and by Article 211-4 of the AMF regulations and may not re-transfer, directly or indirectly, the common stock in France, other than in compliance with applicable laws and regulations and in particular those relating to a public offering (which are, in particular, embodied in Articles L.411-1, L.412-1 and L.621-8 and seq. of the French Code monétaire et financier).

Italy. The offering of the shares of common stock has not been registered with the Commissione Nazionale per le Società e la Borsa, or CONSOB, in accordance with Italian securities legislation. Accordingly, the shares of common stock may not be offered or sold, and copies of this offering document or any other document relating to the shares of common stock may not be distributed in Italy except to Qualified Investors, as defined in Article 2, paragraph 2, letter e), (i), (ii) and (iii) of EU Directive 2003/71/EC or in any other circumstance where an express exemption to comply with public offering restrictions provided by Legislative Decree no. 58 of February 24, 1998, referred to as the Consolidated Financial Act, or CONSOB Regulation no. 11971 of May 14, 1999, as amended, also referred to as the Issuers’ Regulation, applies, including those provided for under Article 100 of the Finance Law and Article 33 of the Issuers Regulation, and provided, however, that any such offer or sale of the shares of common stock or distribution of copies of this prospectus or any other document relating to the shares of common stock in Italy must (1) be made in accordance with all applicable Italian laws and regulations, (2) be conducted in accordance with any relevant limitations or procedural requirements that CONSOB may impose upon the offer or sale of the shares of common stock, and (3) be made only by (a) banks, investment firms or financial companies enrolled in the special register provided for in Article 107 of Legislative Decree no. 385 of September 1, 1993, to the extent duly authorized to engage in the placement and/or underwriting of financial instruments in Italy in accordance with the Consolidated Financial Act and the relevant

134

implementing regulations; or (b) foreign banks or financial institutions (the controlling shareholding of which is owned by one or more banks located in the same EU Member State) authorized to place and distribute securities in the Republic of Italy pursuant to Articles 15, 16 and 18 of the Banking Act, in each case acting in compliance with all applicable laws and regulations.

United Arab Emirates. This document has not been reviewed, approved or licensed by the Central Bank of the United Arab Emirates (the “UAE”), Emirates Securities and Commodities Authority or any other relevant licensing authority in the UAE including any licensing authority incorporated under the laws and regulations of any of the free zones established and operating in the territory of the UAE, in particular the Dubai International Financial Services Authority (the “DFSA”), a regulatory authority of the Dubai International Financial Centre (the “DIFC”). The issue of shares of common stock does not constitute a public offer of shares of common stock in the UAE, DIFC and/or any other free zone in accordance with the Commercial Companies law, Federal Law No. 8 of 1984 (as amended), DFSA Offered Securities Rules and the Dubai International Financial Exchange Listing Rules, accordingly or otherwise.

The shares of common stock may not be offered to the public in the UAE and/or any of the free zones including, in particular, the DIFC. The shares of common stock may be offered and this document may be issued, only to a limited number of investors in the UAE or any of its free zones (including, in particular, the DIFC) who qualify as sophisticated investors under the relevant laws and regulations of the UAE or the free zone concerned. Management of the company, and the representatives represent and warrant the shares of common stock will not be offered, sold, transferred or delivered to the public in the UAE or any of its free zones, in particular the, the DIFC.

Electronic Offer, Sale and Distribution of Shares. A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representatives may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.

135

LEGAL MATTERS

The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Cooley Godward Kronish LLP, Reston, Virginia. The underwriters are being represented by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York.

EXPERTS

Ernst & Young LLP, independent registered public accounting firm, has audited our financial statements at December 31, 2007 and 2008, and for each of the three years in the period ended December 31, 2008, as set forth in their report. We have included our financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst & Young LLP’s report, given on their authority as experts in accounting and auditing.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the shares of common stock being offered by this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to Aldagen and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference.

You can read our SEC filings, including the registration statement, over the Internet at the SEC’s website at http://www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Washington, D.C. 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities.

Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for inspection and copying at the public reference room and web site of the SEC referred to above. We also maintain a website at www.aldagen.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus.

136

Index to Financial Statements


Report of Independent Registered Public Accounting Firm		F-2

Balance Sheets as of December 31, 2007 and 2008 and Balance Sheet and Pro Forma Balance Sheet as of September 30, 2009 (unaudited)		F-3

Statements of Operations for the years ended December 31, 2006, 2007 and 2008 and for the nine months ended September 30, 2008 (unaudited) and 2009 (unaudited) and for the period from March 3, 2000 (inception) through September 30, 2009 (unaudited)		F-4

Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit		F-5

Statements of Cash Flows for the years ended December 31, 2006, 2007 and 2008 and for the nine months ended September 30, 2008 (unaudited) and 2009 (unaudited) and for the period from March 3, 2000 (inception) through September 30, 2009 (unaudited)		F-9

Notes to Financial Statements		F-10

F-1

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders

Aldagen, Inc.

We have audited the accompanying balance sheets of Aldagen, Inc. (a development stage company) as of December 31, 2007 and 2008, and the related statements of operations, redeemable convertible preferred stock and stockholders’ deficit, and cash flows for each of the three years in the period ended December 31, 2008. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Aldagen, Inc. (a development stage company) at December 31, 2007 and 2008, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2008, in conformity with U.S. generally accepted accounting principles.

/s/ Ernst & Young LLP

Raleigh, North Carolina

February 9, 2009,

Except for Note 3 and Note 12, as to which the date is

October 28, 2009

F-2

ALDAGEN, INC.

(A Development Stage Company)

BALANCE SHEETS


	December 31,						September 30, 2009			Pro forma September 30, 2009
	2007			2008			September 30, 2009			Pro forma September 30, 2009
							(Unaudited)			(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	7,512,689		$	16,055,960		$	8,785,612		$	8,785,612
Accounts receivable		55,567			8,775			7,000			7,000
Other receivables		84,909			140,125			15,484			15,484
Prepaid expenses and other assets		117,216			49,941			71,431			71,431
Inventories		18,011			16,365			68,576			68,576

Total current assets		7,788,392			16,271,166			8,948,103			8,948,103
Property and equipment, net		912,424			1,381,684			1,559,810			1,559,810
Other assets		9,256			9,256			9,256			9,256

Total assets	$	8,710,072		$	17,662,106		$	10,517,169		$	10,517,169


Liabilities, redeemable convertible preferred stock and stockholders’ deficit
Current liabilities:
Accounts payable	$	122,973		$	760,059		$	284,475		$	284,475
Accrued expenses		1,157,518			903,749			470,623			470,623
Deferred rent		144,905			243,409			263,559			263,559
Capital lease obligations, current portion		15,701			15,522			14,908			14,908
Notes payable, current portion		64,882			2,190,163			2,650,257			2,650,257

Total current liabilities		1,505,979			4,112,902			3,683,822			3,683,822
Preferred stock warrant liability		772,695			870,256			1,613,737			—
Capital lease obligations, less current portion		52,067			36,545			25,221			25,221
Notes payable, less current portion		3,175,285			985,122			42,835			42,835

Total liabilities		5,506,026			6,004,825			5,365,615			3,751,878

Commitments and contingencies

Junior Preferred redeemable convertible preferred stock, $0.001 par value; 14,963,785 shares authorized, 14,515,000 shares issued and outstanding, and aggregate liquidation value of $14,515,000 at December 31, 2007 and 2008 and September 30, 2009 (no shares authorized, issued or outstanding pro forma)		9,383,371			10,421,611			11,196,036			—

Series C redeemable convertible preferred stock, $0.001 par value; 26,069,584 shares authorized at December 31, 2007 and 2008 and September 30, 2009; 24,742,979 shares issued and outstanding at December 31, 2007 and 2008 and September 30, 2009, respectively; aggregate liquidation value of $19,099,892, $20,544,475 and $21,621,991 at December 31, 2007 and 2008 and September 30, 2009, respectively (no shares authorized, issued or outstanding pro forma)		18,909,883			20,401,979			21,515,117			—

Series C-1 redeemable convertible preferred stock, $0.001 par value; 5,819,474, 17,636,655 and 17,675,076 shares authorized at December 31, 2007 and 2008 and September 30, 2009, respectively; 17,636,655 shares issued and outstanding at December 31, 2008 and September 30, 2009, respectively; aggregate liquidation value of $19,411,901 and $20,510,574 at December 31, 2008 and September 30, 2009, respectively (no shares authorized, issued or outstanding pro forma)		—			19,379,942			20,486,718			—

Stockholders’ deficit:
Common stock, $0.001 par value; 80,000,000 shares authorized; 3,619,747 shares issued and outstanding at December 31, 2007 and 2008 and September 30, 2009; 62,877,255 shares issued and outstanding pro forma		3,620			3,620			3,620			62,877
Additional paid-in capital		—			—			—			54,752,351
Deficit accumulated during the development stage		(25,092,828	)		(38,549,871	)		(48,049,937	)		(48,049,937	)

Total stockholders’ deficit		(25,089,208	)		(38,546,251	)		(48,046,317	)		6,765,291

Total liabilities, redeemable convertible preferred stock, and stockholders’ deficit	$	8,710,072		$	17,662,106		$	10,517,169		$	10,517,169

The accompanying notes are an integral part of these financial statements.

F-3

ALDAGEN, INC.

(A Development Stage Company)

STATEMENTS OF OPERATIONS


	Year Ended December 31,						Nine Months Ended September 30,				Period from March 3, 2000 (inception) through September 30, 2009
	2006		2007		2008		2008		2009
							(Unaudited)				(Unaudited)
Revenues:
Grant revenue	$	—	$	—	$	—	$	—	$	—	$	109,485
Product sales, net		105,299		210,780		178,619

ALDAGEN INC S-1/A